K
A
A
J
0
9
0
2
5
3
A
C

E
t
h
i
c
s
o
f

s
y
n
t
h
e
t
i
c
b
o
o
g
y

l

i

Ethics of 
synthetic biology

Opinion No

BRUSSELS, 17 NOVEMBER 2009

 
 
 
How to obtain EU publications

Publications for sale:

•	 via	EU	Bookshop	(http://bookshop.europa.eu);
•	
from	your	bookseller	by	quoting	the	title,	the	publisher	and/or	ISBN	number;
•	 by	contacting	one	of	our	sales	agents	directly.	You	can	obtain	their	contact	 
details	on	the	Internet	(http://bookshop.europa.eu)	or	by	sending	a	fax	 
to	+352	2929-42758.

Free publications:

•	 via	EU	Bookshop	(http://bookshop.europa.eu);
•	 at	the	European	Commission’s	representations	or	delegations.	You	can	obtain	
their	contact	details	on	the	Internet	(http://ec.europa.eu/)	or	by	sending	a	fax	 
to	+352	2929-42758.

European group
on Ethics in science
and new technologies
to the European commission

Ethics of synthetic
biology

Brussels, 17 November 2009

Opinion No

European Commission

Europe Direct is a service to help you  
find answers to your questions about the European Union

Freephone number (*):
00 800 6 7 8 9 10 11

(*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed.

A great deal of additional information  
on the European Union is available on the Internet. 
It can be accessed through the Europa server  
(http://europa.eu).

Cataloguing data can be found at the end of this publication.

Luxembourg: Publications Office of the European Union, 2010

© European Union, 2010
Reproduction is authorised provided the source is acknowledged.

ISBN 978-92-79-13829-4
doi: 10.2796/10789

Printed in Luxembourg

Printed on white chlorine-free PaPer

OPINION OF THE EUROPEAN GROUP ON ETHICS IN SCIENCE  
AND NEW TECHNOLOGIES TO THE EUROPEAN COMMISSION

Ethics of synthetic biology 

No 25 

17/11/2009

Reference: 
Rapporteurs:  Rafael Capurro, Julian Kinderlerer, Paula Martinho da Silva and Pere Puigdomenech Rosell

Request from President Barroso 

THE EUROPEAN GROUP ON ETHICS IN SCIENCE AND NEW TECHNOLOGIES (EGE),

Having regard to the Treaty establishing the European Community, and in particular Article 6 
of the common provisions concerning respect for fundamental rights,

Having regard to the EC Treaty, and in particular Article 152 on public health,

Having regard to the Charter of Fundamental Rights of the European Union of 28 September 
2000, approved by the European Council in Biarritz on 14 October 2000 and proclaimed sol-
emnly in Nice by the European Parliament, the Council and the Commission on 7 December 
2000, and in particular Article 1 (Human dignity) and Article 3 (Right to the integrity of the 
person), (1)

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council 
of 31 March 2004 laying down Community procedures for the authorisation and supervision 
of medicinal products for human and veterinary use and establishing a European Medicines 
Agency, (2)

Having regard to the Convention on the grant of European patents (European Patent Convention) 
of 5 October 1973 (text as amended by the act revising Article 63 EPC of 17 December 1991 and 
by decisions of the Administrative Council of the European Patent Organisation of 21 December 
1978, 13 December 1994, 20 October 1995, 5 December 1996, 10 December 1998 and 27 October 
2005 and comprising the provisionally applicable provisions of the act revising the EPC of 29 No-
vember 2000), (3)

Having regard to Commission Directive 2003/63/EC of 25 June 2003 amending Directive 
2001/83/EC of the European Parliament and of the Council on the Community code relating to 
medicinal products for human use, (4)

Having regard to Directive 2001/20/EC of the European Parliament and of the Council of 4 April 
2001 on the approximation of the laws, regulations and administrative provisions of the Member 
States relating to the implementation of good clinical practice in the conduct of clinical trials 
on medicinal products for human use, (5) as amended in 2003 and 2005,

Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 No-
vember 2001 on the Community code relating to medicinal products for human use, (6)

Having regard to Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, (7) 

Having regard to Council Directive 90/385/EEC of 20 June 1990 on the approximation of the 
laws of the Member States relating to active implantable medical devices, (8)

(1)  Official Journal C 364 of 18 November 2000, pp. 1–22.
(2)  OJ L 136 of 30 April 2004, pp. 1–33.
(3)  http://www.european-patent-office.org/legal/epc/e/ma1.html.
(4)  OJ L 159 of 27 June 2003, pp. 46–94.
(5)  OJ L 121 of 1 May 2001, pp. 34–44.
(6)  OJ L 311 of 28 November 2001, pp. 67–128.
(7)  OJ L 169 of 12 July 1993, pp. 1–43.
(8)  OJ L 189 of 20 July 1990, pp. 17–36.

3

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

4

Having regard to Directive 76/768/EC of the European Parliament and of the Council of 27 July 
1976 on the approximation of the laws of the Members States relating to cosmetic products, (9)

Having regard to Regulation (EC) No 1907/2006 of the European Parliament and of the Coun-
cil of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restric-
tion of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 
1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC)  
No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 
93/67/EEC, 93/105/EC and 2000/21/EC,

Having regard to Council Directive 80/68/EEC of 17 December 1979 on the protection of ground-
water against pollution caused by certain dangerous substances, (10)

Having regard to Council Directive 85/337/EEC of 27 June 1985 on the assessment of the effects 
of certain public and private projects on the environment, (11)

Having regard to the Treaty of Amsterdam of 17 June 1997, and in particular to the sustainable 
development strategy (SDS) and Article 152 thereof concerning public health,

Having regard to Council Directive 90/219/EEC of 23 April 1990 on the contained use of geneti-
cally modified micro-organisms, as amended by Directive 98/81/EC, (12)

Having regard to Council Directive 91/676/EEC of 12 December 1991 concerning the protection 
of waters against pollution caused by nitrates from agricultural sources (13) in order to reduce 
overall use of nitrates,

Having regard to Council Regulation (EEC) No 2078/92 of 30 June 1992 on agricultural produc-
tion methods compatible with the requirements of the protection of the environment and the 
maintenance of the countryside, (14)

Having regard to the United Nations Convention on Biological Diversity of 6 June 1992, ratified 
by the European Union on 25 October 1993, and to the Cartagena Protocol on Biosafety, ap-
proved by the European Community on 11 September 2003,

Having regard to Council Directive 96/61/EC of 24 September 1996 concerning integrated pol-
lution prevention and control, (15)

Having regard to the Kyoto Protocol, adopted on 11 December 1997 with the aim of reducing 
greenhouse gas emissions in order to fight global climate change (for the period 2005-2012),

Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 Febru-
ary 1998 concerning the placing of biocidal products on the market, (16)

Having regard to the Commission communication ‘Directions towards sustainable agriculture’, (17)

Having regard to the World Trade Organisation (WTO) Sanitary and Phytosanitary (SPS) Agree-
ments of 1995, in particular Article 5.1, 5.2 and 5.3 thereof on health risk assessments,

Having regard to Regulation (EC) No 258/97 of the European Parliament and of the Council of 
27 January 1997 concerning novel foods and novel food ingredients, (18)

(9)  Official Journal L 262, 27.9.1976, p. 169.
(10)  OJ L 20, 26.1.1980.
(11)  OJ L 175, 5.7.1985.
(12)  OJ L 117, 8.5.1990.
(13)  OJ L 375, 31.12.1991.
(14)  OJ L 215, 30.7.1992.
(15)  OJ L 257, 10.10.1996.
(16)  OJ L 123, 24.4.1998.
(17)  COM(1999) 22, 27.1.1999.
(18)  OJ L 42, 14.2.1997.

 
 
 
Having regard to Council Directive 98/44/EC of the European Parliament and of the Council 
of 6 July 1998 on the legal protection of biotechnological inventions, in particular Article 6 
thereof, (19)

Having regard to Directive 2001/42/EC of the European Parliament and of the Council of 
27 June 2001 on the assessment of the effects of certain plans and programmes on the envi-
ronment, (20)

Having regard to Directive 2001/18/EC of the European Parliament and of the Council of 12 March 
2001 on the deliberate release into the environment of genetically modified organisms and re-
pealing Council Directive 90/220/EEC, (21)

Having regard to Regulation (EC) No 1829/2003 of the European Parliament and of the Council 
of 22 September 2003 on genetically modified food and feed, (22)

Having regard to Regulation (EC) No 1946/2003 of the European Parliament and of the Council of 
15 July 2003 on Transboundary movements of genetically modified organisms, (23)

Having regard to Council Regulation (EC) No 1234/2007 of 22 October 2007 establishing a 
common organisation of agricultural markets and on specific provisions for certain agricultural 
products (single CMO regulation) (24) , creating a horizontal legal framework for the agricultural 
markets, 

Having regard to the Commission communication ‘2006 environment policy review’ describing 
the action taken by the EU on the environment, (25)

Having regard to the Commission communication ‘Mid-term review of the Sixth Community 
Environment Action Programme’ with reference to protection of the environment, biodiversity 
and natural resources, (26)

Having regard to the Commission communication on ‘Implementation of the Community strat-
egy for dioxins, furans and polychlorinated biphenyls’, (27)

Having regard to the Council Regulation (EC) No 1334/2000 setting up a Community regime for 
the control of exports of dual-use items and technology (28) and its amendments, 

Having regard to the Commission communication ‘Preparing for the ‘health check’ of the CAP 
reform’ on the overview of the adjustments needed in the CAP, (29)

Having regard to the Treaty of Lisbon, signed on 13 December 2007 and currently open for 
ratification,

Having regard to Article 6 of the Seventh Framework Programme of the European Community 
for research, technological development and demonstration activities (2007-2013), which states 
that ‘All the research activities carried out under the Seventh Framework Programme shall be 
carried out in compliance with fundamental ethical principles’,

Having regard to the Commission communication ‘Supporting early demonstration of sustain-
able power generation from fossil fuels’, (30) 

(19)  OJ L 213, 30.7.1998.
(20)  OJ L 197, 21.7.2001.
(21)  OJ L 106, 17.4.2001.
(22)  OJ L 268, 18.10.2003.
(23)  OJ L 287, 5.11.2003.
(24)  OJ L 299, 16.11.2007.
(25)  COM(2007) 195, 30.4.2007; OJ C 181, 3.10.2007.
(26)  COM(2007) 225, 30.4.2007; OJ C 181, 3.10.2007.
(27)  COM(2007) 396, 10.7.2007; OJ C 191, 17.8.2007.
(28)  OJ L 159/1, 30.6.2000 and for the amendments 2000R1334 — EN — 12.04.2006 — 007.001 — 1
(29)  COM(2007) 722, 20.11.2007.
(30)  COM(2008) 13, 23.1.2008.

5

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

6

Having regard to the Commission communication on a ‘Proposal for a Directive on the promo-
tion of the use of energy from renewable sources’, (31)

Having regard to the Council of Europe Convention on Human Rights and Biomedicine, signed 
on 4 April 1997 in Oviedo, (32)

Having regard to the Additional Protocols to the Council of Europe Convention on Human Rights 
and Biomedicine, in particular the Additional Protocol on Prohibition of Human Cloning and 
the Protocol on Biomedical Research,

Having regard to the Universal Declaration on the Human Genome and the Rights of Man 
adopted by UNESCO on 11 November 1997, (33) the Declaration on Human Genetic Data adopted 
by UNESCO on 16 October 2003 and the Universal Declaration on Bioethics and Human Rights 
adopted by UNESCO on 19 October 2005,

Having regard to the European Commission (2003) Reference Document on Synthetic Biol-
ogy, (34)

Having regard to the European Commission Report (2005) on Synthetic Biology, Applying engi-
neering to biology, by a NEST high-level expert group (35) and the European Commission Paper 
(2007) on Synthetic Biology: A NEST pathfinder initiative, (36)

Having regard to the hearings of experts and Commission departments by the EGE during their 
January 2009, February 2009, March 2009, April 2009 and May 2009 meetings, (37)

Having regard to EGE Opinion No 21 on ‘Ethical Aspects of Nanomedicine’, (38)

Having regard to the Roundtable organised by the EGE on 19 May 2009 in Brussels,

Having heard the EGE rapporteurs Rafael Capurro, Julian Kinderlerer, Paula Martinho da 
Silva and Pere Puigdomenech Rosell, 

Hereby adopts the following opinion.

(31)  COM(2008) 19, 23.1.2008.
(32)  http://conventions.coe.int/treaty/en/treaties/html/164.htm.
(33)  http://portal.unesco.org/shs/en/ev.php-URL_ID=2228&URL_DO=DO_TOPIC&URL_SECTION=201.html.
(34)  ftp://ftp.cordis.europa.eu/pub/nest/docs/synthetic_biology.pdf.
(35)  FTP://FTP.CORDIS.EUROPA.EU//PUB/NEST/DOCS/SYNTHETICBIOLOGY_B5_EUR21796_EN.PDF.
(36)  ftp://ftp.cordis.europa.eu/pub/nest/docs/5-nest-synthetic-080507.pdf.
(37)  See agendas on the EGE website: http://europa.eu.int/comm/european_group_ethics/index_en.htm.
(38)  http://europa.eu.int/comm/european_group_ethics/docs/avis20en.pdf.

 
 
 
TABLE OF CONTENTS

11 

Scope of the Opinion

11 

11 
12 
13 
14 

16 
16 
19 
20 
23 
24 

27 

27 
31 
33 
33 
33 
33 

34 

35 
36 
37 

1. 

Scientific Aspects

1.1.   Historical overview 

1.2.   Moving from analytical molecular biology to synthetic biology

1.3.   Towards a working definition of synthetic biology

1.3.1.  To what extent does synthetic biology differ from  

other existing disciplines?

1.4.  The conceptual basis of synthetic biology

1.4.1.  Key enabling approaches to synthetic biology

1.5.  State of art and medium- to long-term forecast

1.5.1.  Current research in synthetic biology

1.5.2.  Future uses of synthetic biology

1.6.  Research funding

2. 

Legal, Governance and Policy Aspects

2.1.  EU legislation

2.1.1.  EU biosecurity policy frame

2.2.  Global provisions

2.2.1.  WHO biosafety standards

2.2.2.  The Cartagena Protocol 

2.2.3.  World Trade Organisation (WTO) agreements and Trade- 

Related Aspects of Intellectual Property Rights (TRIPS)

2.2.4.  Convention on the Prohibition of the Development,    

Production and Stockpiling of Bacteriological 

(Biological) and Toxin Weapons and on Their Destruction

2.3.  Framework on ethics and human rights

2.4.  Governance

2.5.  Public involvement and science-society dialogue

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 

39 
39 
40 
42 
42 
43 
44 
45 

48 

48 
48 
49 
50 
51 
51 
52 
53 
53 
54 
55 
55 

87 

87 

3.   Ethical Aspects

3.1.  General ethical aspects 

3.1.1.  The EU’s fundamental ethical framework

3.1.2.  Conceptual-ethical issues

3.2.  Specific ethical issues

3.2.1.  Biosafety

3.2.2.  Biosecurity

3.2.3.   Justice

3.2.4.   Intellectual property

4.  Recommendations

4.1.  Defining terminology and scope of the Opinion

4.2.   Safety

4.2.1.   Environmental applications

4.2.2.   Energy and sustainable chemical industry

4.2.3.   Biomedicine and biopharmaceuticals production

4.3.   Biosecurity

4.4.   Governance

4.5.  

Intellectual property

4.5.1.   Patenting and common heritage

4.5.2.   Trade and global justice

4.6.  Science and society aspects

4.7.   Basic research

5.  ANNEx I

The Patent System, Biotechnology and Synthetic Biology

 
 
 
 
 
 
 
 
 
 
 
 
European group
on Ethics in science
and new technologies
to the European commission

OPINION OF THE EUROPEAN GROUP ON ETHICS IN SCIENCE 
AND NEW TECHNOLOGIES TO THE EUROPEAN COMMISSION

Ethics of synthetic 
biology

Reference: 

Request from President Barroso 

Rapporteurs:  Rafael Capurro, Julian Kinderlerer,  

Paula Martinho da Silva and Pere Puigdomenech Rosell

Opinion No25

 
SCIENTIFIC ASPECTS | 1

Scope of the opinion

1.1.  Historical overview 

On May 28, 2008 President José Manuel Barroso asked 
the EGE to issue an Opinion on the ethical, legal and 
social implications that may derive from synthetic 
biology. In his letter, the President advocated that ‘(…) 
the debate about the legitimacy of engineering new 
life forms has mainly focused on safety issues and a 
work on the ethical, legal and social implications that 
may derive from this specific use of biotechnology is 
still missing.’

The EGE is aware that synthetic biology raises philo-
sophical, anthropological, ethical, legal, social and sci-
entific issues. It is equally aware that the convergence of 
multiple technologies in synthetic biology, each based 
on different scientific paradigms, increases the com-
plexity of assessing the ethics of synthetic biology and 
its products. The EGE has, however, agreed that, apart 
from safety issues associated with synthetic biology, 
an ethical, legal, and political governance of synthetic 
biology is needed in the EU and worldwide to ensure 
that the interests of society are respected. The Group 
has therefore accepted President Barroso’s request.

1. 

Scientific Aspects

Synthetic biology is a new research field within which 
scientists and engineers seek to modify existing organ-
isms by designing and synthesising artificial genes or 
proteins, metabolic or developmental pathways and 
complete biological systems in order to understand the 
basic molecular mechanisms of biological organisms 
and to perform new and useful functions. This research 
sector is heterogeneous and results from the conver-
gence of different technological and scientific tools 
(from information technology to chemistry, engineer-
ing, biology, mathematics and computer modelling). 
Synthetic biology has two main goals: 1) to be a tool 
to improve understanding of biological systems, their 
complexity and emergent properties that derive from 
the interaction of complex pathways and 2) to use the 
organisms as factories to obtain products which may 
have a direct, clear and immediate use (pharmaceuti-
cals, bio-fuels, raw materials or biomedical tools (e.g. 
vaccines), or new bio-defence agents). This distinction 
diversifies not only the potential uses of synthetic biol-
ogy but also the goals on which current research activi-
ties are being developed across the world by private or 
public research bodies. The following paragraphs aim 
to describe the research activities currently ongoing 
and to indicate potential future uses of this research 
field. 

The desire to know and understand the world around 
us has been deeply rooted in humans since ancient 
times. The first approach to the study of life has been 
analytical (39): to break down complex systems into 
smaller and simplified ones to facilitate their observa-
tion and understanding.

During  the  early  XIX  century  a  synthetic  approach 
emerged in biology as a complementary approach to 
analysis. Using the knowledge of the time, the first syn-
thesis experiments of biological compounds were car-
ried out in the field of organic chemistry. For example in 
1828, (40) urea, a component of human urine and an im-
portant fertiliser, was first synthesised from ammonium 
salts, showing that organic compounds could be chemi-
cally synthesised from inorganic compounds. This was 
revolutionary news, as common knowledge was that, 
although organic matter could be decomposed into 
inorganic constituents (e.g. through heating or other 
treatments), the reverse would be impossible because 
inorganic matter would lack the ‘vital force’ to transform 
it into organic matter. 

As time passed and research advanced, the same pat-
tern (from analysis to synthesis) was observed not only 
in chemistry, but also in genetics. In 1953, the DNA 
structure was described by Watson and Crick. (41) For 
the first time, the double helix structure was revealed 
in DNA, which is a polymer formed from monomers 
constituted of sugar molecules (deoxyribose) linked 
to a nitrogen containing base (A=adenine, T=thymine, 
C=cytosine, G=guanine) and a phosphate group.

From the mid 1950’s onwards, molecular biology re-
search focused on the study of DNA regulation, replica-
tion and repair (the analytical period). In the early 1970’s 
the first restriction endonucleases (42) were discovered 
and purified, which allowed scientists to precisely ‘cut’ 
and ‘paste’ DNA fragments from one source to another, 
paving the way for the synthetic era of molecular biology.  

(39)  Such an approach has been used since before the time of 
Aristotle, and, in a more formal way, by Descartes, G. Galilei 
and Newton.

(40)  F. Woehler, Poggendorff’s Ann. Phys., 12, 253-256 (1828).

(41)  J.D. Watson and F.H. Crick, ‘Molecular structure of nucleic 
acids; a structure for deoxyribose nucleic acid’, Nature, 
171(4356):737-8, 25 April 1953.

(42)  For this discovery the Nobel Prize for Medicine was awarded 

in 1978 to W. Arber, D. Nathans and H. Smith.

11

1 | SCIENTIFIC ASPECTS

Technology key in shifting paradigms

In 1973, Cohen and Jalal published the fi rst paper on 
the recombinant DNA technique, through which a 
functional plasmid produced by joining diff erent DNA 
fragments was inserted into E. Coli to produce trans-
genic bacteria. (43)

nique of oligonucleotide synthesis was a landmark in 
synthetic biology. This was made possible in the early 
‘80s and the development of automatic synthesisers 
resulted in a technique accessible to most molecular 
biology laboratories.

Recombinant DNA technologies have evolved con-
stantly since they fi rst appeared in the 1970’s. Biology 
research has moved increasingly towards the study of 
molecular actors and their interaction through signal-
ling pathways and complex network dynamics. Due to 
the great advances made since the 1970’s with regard 
to molecular techniques, scientists have been able to 
address complicated issues by being able to analyse 
more and more complex molecular model systems.

Another important development for molecular biology 
occurred in 1984 with the discovery of the Polymerase 
Chain Reaction (PCR) by K. Mullis. (44) It allowed the en-
zymatic replication of DNA fragments by using a DNA 
polymerase, nucleotides (dNTPs, the building blocks of 
DNA) and the repetition of cycles (denaturing, anneal-
ing and elongation) through which a DNA template is 
amplifi ed. PCR relies on the availability of small pieces 
of DNA (oligonucleotides) that are produced by chem-
ical synthesis. The development into a routine tech-

(43)  S.N. Cohen et al., ‘Construction of biologically functional 

bacterial plasmids in vitro.’ PNAS 70, 3240-44 (1973).

1.2.  Moving from analytical molecular 
biology to synthetic biology

As W. Szybalski foresaw in 1974 ‘Up to now we are work-
ing on the descriptive phase of molecular biology. […] 
But the real challenge will start when we enter the syn-
thetic biology phase of research in our fi eld. We will 
then devise new control elements and add these new 
modules to the existing genomes or build up wholly 
new genomes. This would be a fi eld with unlimited ex-
pansion potential and hardly any limitations to build-
ing ‘new better control circuits’ and […] fi nally other 
‘synthetic’ organisms […].’

Synthetic biology was born, therefore, at least theo-
retically, in 1974, although the term synthetic biology 
can be traced back at least to 1912 when Stephane 
Leduc published his Biologie Syntetique. (45) However, 
in practice, the term was not used for a further twenty 
years, until scientists began to think about assembling 
synthetic genetic regulatory networks (circuits) in the 

(44)  K. Mullis et al., ‘Specific enzymatic amplification of DNA 
in vitro: the polymerase chain reaction’, Cold Spring Harb 
Symp, Quant Biol. (1986).

(45)  Stephane Leduc, La Biologie Synthétique, Paris 1912. Also 
see Szostak, J.W., Bartel, D.P., Luisi, P.L.(2001) Synthesizing life. 
Nature 409:387–390.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

12

 
 
 
SCIENTIFIC ASPECTS | 1

laboratory. (46) The first formal conference on synthetic 
biology was held in 2004, showing that by that time a 
scientific community grouped under the name of syn-
thetic biology was present and active.

Synthetic biology experts believe that the field should 
not be defined only by its applications and that it may 
contribute significantly to the progress of biology. For 
instance, knowledge of the minimum number of genes 
needed to support a microorganism is relevant to  
understanding the essential functions of living beings. 
They also claim that knowing whether the components 
of basic biological machinery can differ from those ex-
isting in present organisms including, for instance, the 
genetic code, may enlighten us as to the origins of life. 
All these important basic biological questions are key 
to research into what we call synthetic biology, which 
has a number of objectives in a variety of fields of ap-
plication. From a biological point of view, interactions 
between different cellular pathways in metabolic or 
developmental processes are essential for understand-
ing cell dynamics. Synthetic biology may therefore be 
a heuristic tool to improve our understanding of the 
main biological mechanisms of life.

1.3.  Towards a working definition of  

synthetic biology

It is not easy to find a working definition of synthetic 
biology. It depends on the desired outcomes, either 

on its applications (or aims) or more in general on the 
broad concept of basic research and therefore its ex-
perimental nature. It may not be possible to find an 
unequivocal definition and it could change over time 
as awareness of this discipline increases and becomes 
more widespread.

A recent (2008) description of synthetic biology reads: 
The fundamental idea behind synthetic biology is that any 
biological system can be regarded as a combination of in-
dividual functional elements — not unlike those found in 
man-made devices. These can therefore be described as 
a limited number of parts that can be combined in novel 
configurations to modify existing properties or to create 
new ones. (47) 

Another description can be found at the website of 
the EU Project ‘Towards a European Strategy for Syn-
thetic Biology’ (TESSY, 2007-2008): 

•	

Synthetic biology uses nucleic acid elements or com-
plex systems that are predefined and chemically syn-
thesised in the laboratory by a modular approach. 
This approach aims to: 1. engineer and study biologi-
cal systems that do not exist as such in nature, and  
2. use this approach for i) achieving better understand-
ing of life processes, ii) generating and assembling  
functional modular components, iii) developing novel 
applications or processes. (48)

(46)  M.B. Elowitz and S. Leibler, ‘A Synthetic Oscillatory Net-
work of Transcriptional Regulators’; Nature. 2000 Jan 20; 
403(6767):335-8.

(47)  A. Danchin, ‘Synthetic biology: discovering new worlds 
and new words’, EMBO reports; doi:10.1038/embor.2008.159 
(2008).

(48)  See http://www.tessy-europe.eu/.

13

1 | SCIENTIFIC ASPECTS

Other definitions of synthetic biology put forward so 
far include: 

•	

•	

•	

•	

•	

•	

[Synthetic biology] attempts to recreate in unnatural 
chemical systems the emergent properties of living 
systems … [the] engineering community has given 
further meaning to the title…to extract from living sys-
tems interchangeable parts that might be tested, vali-
dated as construction units, and reassembled to create 
devices that might (or might not) have analogues in 
living systems. (Benner and Sismour, 2005)

The development of well characterised biological com-
ponents that can be easily assembled into larger func-
tioning devices and systems to accomplish many par-
ticular goals. (Jay Keasling speaking at the Synthetic 
Biology 2.0 conference at Haas Business School, UC 
Berkeley) 

To advance knowledge and create products that can 
promote human welfare, synthetic biologists seek to 
create biological systems that do not occur naturally 
as well as reengineer biological systems that do occur 
naturally. (Hastings Center, USA)

[Synthetic biology is] the design and construction of new 
biological parts, devices and systems that do not exist in 
the natural world and also the redesign of existing bio-
logical systems to perform specific tasks. (Erosion, Tech-
nology and Concentration (ETC) Group, Canada)

[Synthetic biology] describes research that combines 
biology with the principles of engineering to design 
and build standardised, interchangeable biological 
DNA building-blocks. These have specific functions 
and can be joined to create engineered biological 
parts, systems and, potentially, organisms. [Synthetic 
biology] may also involve modifying naturally occur-
ring genomes… to make new systems or by using 
them in new contexts. (UK Parliamentary Office of 
Science and Technology, POST) 

[Synthetic biology] is broadly understood as the delib-
erate design of novel biological systems and organ-
isms that draws on principles elucidated by biologists, 
chemists, physicists and engineers... in essence it is 
about redesigning life. (UK Royal Society)

It therefore appears that a general consensus on a 
standard classification of synthetic biology does not 
exist. The definitions so far provided depend on the 
scientific approach taken or the applications carried 
out by biologists. From the range of descriptions of the 

technologies it is, possible to identify the core elements 
of synthetic biology that include the engineering of 
biological components and systems that do not exist in 
nature and the re-engineering of existing biological el-
ements. It centres on the intentional design of artificial 
or re-worked biological systems, rather than primary 
understanding of the biology of existing organisms in 
nature. A definition of synthetic biology should there-
fore include:

1.  The design of minimal cells/organisms (including 

minimal genomes); 

2.  The identification and use of biological ‘parts’ 

(toolkit); 

3.  The construction of totally or partially artificial bio-

logical systems. 

In addition, several experts emphasise the potential 
of synthetic genomics. Synthetic genomics may be 
defined as a field within synthetic biology that uses the 
increasing wealth of genomic information including the 
tools of oligonucleotide synthesis and of genetic modi-
fication with the aim of producing new genomes that 
will allow the fabrication of a product or a desired be-
haviour. One of the ways to achieve these goals is to use 
minimal genomes that become the basic framework 
into which a new set of genes are added to achieve 
new biological functions. It may make use of custom-
designed base pair series, though in a more expanded 
and hitherto unprecedented sense, synthetic genomics 
could use genetic codes that are not composed of the 
four base pairs of DNA currently used in life forms. 

1.3.1.  To what extent does synthetic biology differ 

from other existing disciplines?

A key issue to address in synthetic biology is its differ-
ence from other disciplines, such as those based on 
the insertion of recombinant DNA into organisms. For 
example, techniques used in synthetic genomics (e.g. 
the use of synthetic DNA within an existing cell may be 
considered to be a recombinant DNA application rather 
than synthetic biology). It nevertheless appears that 
no clear boundary can be drawn between genetic en-
gineering that is based on recombinant DNA and syn-
thetic biology: the first is the starting point and merges 
into the second without a clear cut limit. Nevertheless, 
recognition of the complexity of biological systems and 
the intention to construct an organism with radically 
new properties may be described as a feature of the 
new discipline.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

14

 
 
 
SCIENTIFIC ASPECTS | 1

of elements with synthetic raw materials and with no 
natural counterpart. (52) Some reserachers are producing 
protocells, that mimic the systems found in biology but 
differ in that the DNA contains nucleotides not found in 
already existing organisms. (53) Synthetic biology there-
fore involves the use of standardised parts and follows 
a formalised design process (Arkin and Fletcher, 2006). 
In parallel, synthetic biology involves a different level of 
sophistication and complexity of the work done in ge-
netic engineering (where one gene at a time is inserted 
into an existing biological system), contrary to synthetic 
biology, where a whole specialised metabolic unit can be 
constructed (Stone, 2006 and Breithaupt, 2006:22). 

One novelty that synthetic biology has introduced in 
the design and use of different bioengineering tech-
nological tools is the notion of intentionality. Synthetic 
biology uses biotechnology to intentionally design 
and build engineered biological systems that process 
information, manipulate chemicals, fabricate materi-
als and structures, produce energy, provide food, and 
maintain and enhance human health and our environ-
ment. In parallel, synthetic biology synchronically uses 
multiple technologies, such as chemistry, engineering, 
biology, information technology and nanotechnology. 
In that respect, synthetic biology uses technology to 
manufacture products that are designed to give rise 
to knowledge or which serve a given aim, defined by 
the application area on which they are built, from bio-
remedies to ICT, biomedicine, biofuels or biomaterials. 
What is also distinctive  in synthetic biology is recogni-
tion of the complexity of the systems that researchers 
want to reproduce, the fact that they work on not just 
molecular cloning of single genes or gene compo-
nents as in standard molecular biology, but on whole 
interacting genetic networks, genomes and ultimately 
entire organisms. In this sense, the results of systems 
biology, a discipline that studies the relations of differ-

(52)  Bhutkar A., 2005, Synthetic Biology: Navigating the Chal-
lenges Ahead, J. BIOLAW & BUS., Vol. 8, No 2, p. 19-29.

(53)  “Protocells are defined as self-assembling and self-repro-
ducing chemical systems created through human artifice 
(but not merely by manipulating a natural living organism) 
that produce the following interlocking chemical proper-
ties: (1) spatial localization of components by containment  
(2) utilization of energy and raw materials from the environ-
ment by metabolism and (3) control of the containment and 
metabolism by chemical information that can be replicated 
and can mutate.” From Mark A. Bedau, Emily C. Parke, Uwe 
Tangen, Brigitte Hantsche-Tangen (2009) Social and ethical 
checkpoints for bottom-up synthetic biology, or protocells 
Syst Synth Biol (2009) 3:65–75

15

Figure 1. a) Analysis and synthesis in organic chemistry;  
b) Analysis and synthesis in synthetic biology (49).

Balmer A. and Martin P. have underlined (50) that the word 
‘synthetic’ is ambiguous since it can mean either ‘construct-
ed’ or ‘artificial’. The former meaning is preferred by syn-
thetic biologists (BBSRC/EPSRC, 2007), but it is inevitable 
that the ‘artificial’ aspect of synthetics is to some extent 
associated with the term. In fact, attempts have been made 
to avoid the word ‘synthetic’ by naming the field ‘construc-
tive biology’ or ‘intentional biology’ (Carlson, 2006), but 
these terms have not become widely adopted.

The scientific community is still debating whether syn-
thetic biology has introduced a paradigm shift compared 
with other biotechnologies. Some have indicated that, in 
order to distinguish between synthetic biological fabri-
cations and other approaches, like transgenic organisms, 
the key difference could be that transgenic organisms 
are the result of introducing naturally occurring foreign 
or mutated DNA (genes) into the organism (51). Synthetic 
biology, in contrast, would result in the manufacturing 

(49)  http://www.nature.com/nchembio/journal/v3/n9/pdf/

nchembio0907-521.pdf.

(50)  Balmer A., Martin P., 2008, Synthetic Biology: Social and Ethi-
cal Challenges, Institute for Science and Society, University 
of Nottingham.

(51)  This could include copy DNA where codons have been mod-
ified to reflect the codon usage of the modified organism.

1 | SCIENTIFIC ASPECTS

ent metabolic or developmental pathways within an 
organism, are important to synthetic biology.

1.4. 

 The conceptual basis of synthetic biology

The conceptual basis underlying many modern ap-
proaches to biology is a reductionist view, which accepts 
that biological phenomena are expressions of chemical-
physical processes. There are numerous examples of this 
paradigm, including Monod (1967), Eigen (1975) and 
Watson (1998). According to this view, the phenotypic 
expression of genes is a physicochemical phenomenon 
and interaction with this fundamental biological matrix 
would offer us the possibility of the synthesis of life (54). 
This paradigm has dominated the development of mod-

(54)  An antagonistic approach to determinism is organismic biology 
(Ritter 1919). The central point is that an organism is a highly or-
ganised system where its biological meaning (and the meaning 
of its activity) cannot be understood as the sum of the activity 
of the parts, of its biological constituents. This means that when 
we wonder about the meaning of a living being we cannot 
explain its existence as a physicochemical phenomenon or at-
tribute a contingent value to a singular organisms’ constituent 
(for example, the brain). On the contrary, an organism is con-
sidered as a locus of integrated complexity, whose meaning 
refers to its composite nature. Eigen M. & Schuster P. (1978) The 
Hypercycle. Berlin; Eigen M. (1988) Perspektiven der Wissenschaft. 
Jenseits von Ideologien und Wunschdenken. Deutsche Verlags-
Anstalt; Jonas H. (1979) Das Prinzip Verantwortung Insel Verlag; 
Jonas H. (1987) ‘Creazione dell’uomo’ il Mulino (XXXVI) Bologna  
pp. 615-626; Monod J. (1967) Chance and Necessity N.Y. Vintage Books;  
Ritter W. E. (1919) The Unity of the Organism 2 vols. Boston.

ern biology for several decades. Many modern geneti-
cists, however, are now calling for a more complex con-
cept of the gene, based on not only its DNA sequence, 
but also its epigenetic interaction manual, which in turn 
may be defined by complex protein-DNA interaction. 
The relevance of mechanistic approaches to synthetic 
biology is particularly strong since the attempt to manu-
facture intentionally designed organisms relies on the 
assumption that their expression will be controlled by 
the synthesised DNA sequences. 

Some of the basic disciplines of modern biology such 
as biochemistry and molecular biology are based on 
a reductionist approach. The hope was that by decon-
structing the systems and understanding individual 
parts of the system in great detail it would be possible 
to reconstruct pathways, cell systems and cellular inter-
actions. This has been facilitated by the new methods 
available to scientists that permit the removal of parts 
of the organism. A number of scientists including Venter 
and colleagues have attempted to identify a minimal 
organism where the only remaining genes are those ab-
solutely essential for a functional organism. Synthetic 
biology can then use a less complicated approach than 
the total synthesis of a new organism – using the basic 
cellular structures of micro-organisms or combinations 
of existing parts in a new cellular environment.

1.4.1.  Key enabling approaches to synthetic biology

There are several key enabling technologies that are 
critical for the growth of synthetic biology. The key 

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

16

 
 
 
SCIENTIFIC ASPECTS | 1

http://www.nature.com/news/2009/090206/pdf/news.2009.86.pdf

issues include standardisation of biological parts and 
hierarchical abstraction to permit the use of those 
parts in increasingly complex synthetic systems. (55) 
Achieving this is greatly aided by basic technologies 
to read and write DNA (sequencing and synthesis), 
which are exponentially improving in price/perform-
ance (Kurzweil, 2001). Measurements under a variety 
of conditions are needed for accurate modelling and 
computer-aided-design (CAD).

(55)  Group, Bio FAB; Baker D, Church G, Collins J, Endy D, Jacobson J, 
Keasling J, Modrich P, Smolke C, Weiss R (June-2006). ‘Engi-
neering life: building a fab for biology’. Scientifi c American 
294 (6): 44–51. PMID 16711359.

Sequencing

Synthetic biologists use DNA sequencing to obtain in-
formation about naturally occurring organisms (large-
scale genome sequencing). The information obtained 
for many organisms will (eventually) permit the con-
struction of biological components and devices. Other 
goals of DNA sequencing for synthetic biology aim at 
verifying that the manufactured engineered systems 
correspond to the expected goals and to facilitate rapid 
detection and identifi cation of synthetic systems and 
organisms. Over the last twenty years, astonishing 
progress has been made in increasing the effi  ciency of 
DNA sequencing, synthesis and amplifi cation.

17

1 | SCIENTIFIC ASPECTS

Progress in DNA sequencing has been constant and ex-
traordinarily rapid. It started with the conversion from 
manual to automatic DNA sequencers that used fl uo-
rescence techniques and from sequencers that used 
electrophoresis gels to capillary sequencers. During 
the last two or three years, a new generation of DNA 
sequencers has emerged that allow the sequencing 
of gigabases (1 x 109 basepairs of DNA sequence) per 
run and new machines are in the pipeline. That means 
that the possibility of sequencing a single human in-
dividual’s genome in a single experiment for about 
10.000 USD could soon be reached. 

DNA synthesis

As of now, the manufacturing of engineered genetic 
sequences is time consuming and the cycle of design, 
fabrication, testing and redesign used in bioengineer-
ing may be accelerated by the techniques developed 
for synthetic biology because it may provide rapid 
and reliable de novo DNA synthesis and assembly of 
fragments of DNA. The acceleration of technical and 
heuristic capacity in this use of synthetic biology is 
impressive. In 2002, researchers at SUNY Stony Brook 
succeeded in synthesising the 7741 base poliovirus ge-
nome from its published sequence, producing the fi rst 
synthetic organism. (56) 

(56)  Couzin  J  (2002).  ‘Virology.  Active  poliovirus  baked 
from  scratch’.  Science  297  (5579):  174–5.  doi:10.1126/
science.297.5579.174b.

In 2003, the 5386 bp genome of the bacteriophage 
Phi X 174 was assembled in about two weeks. (57) In 
2006, the same team at the J. Craig Venter Institute con-
structed and patented a synthetic genome of a novel 
minimal bacterium, Mycoplasma laboratorium, and is 
working on getting it to function in a living cell. (58) 
In 2007, it was reported that several companies were 
offering the synthesis of genetic sequences up to 
2000 bp long, for a price of about USD 1 per base pair 
and a turnaround time of less than two weeks. (59) 

Modelling

Synthetic biology models are informative tools for 
the design of engineered biological systems to better 
predict system behaviour prior to fabrication. Because 
of the intentional nature of manufacturing synthetic 
biology products, modelling is a key factor allowing 

(57)  Smith, Hamilton O.; Clyde A. Hutchison, Cynthia Pfannkoch, 
J. Craig Venter (2003-12-23). ‘Generating a synthetic genome 
by whole genome assembly: {phi}X174 bacteriophage from 
synthetic oligonucleotides’. Proceedings of the National 
Academy of Sciences 100 (26): 15440-15445. doi:10.1073/
pnas.2237126100.

(58)  Wade, Nicholas (2007-06-29). ‘Scientists Transplant Genome 
of Bacteria’. The New York Times. ISSN 0362-4331; Gibson, 
DG;  Benders  GA,  Andrews-Pfannkoch  C,  Denisova  EA, 
Baden-Tillson H, Zaveri J, Stockwell TB, Brownley A, Thomas 
DW, Algire MA, Merryman C, Young L, Noskov VN, Glass JI, 
Venter JC, Hutchison CA 3rd, Smith HO. (2008-01-24). ‘Com-
plete chemical synthesis, assembly, and cloning of a Myco-
plasma genitalium genome’. Science 319 (5867): 1215–20.

(59)  Pollack, Andrew (2007-09-12). ‘How Do You Like Your Genes? 

Biofabs Take Orders’. The New York Times. ISSN 0362-4331.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

18

 
 
 
SCIENTIFIC ASPECTS | 1

Theoretical and experimental
comparative genomics: minimal
genome. Synthetic genome in a
genome-free cell. New genetic
and metabolic circuits.
Interchangeable parts...

Two strategies

Top-down

Peretó J and Català (2007)
“The Renaissance of Synthetic
Biology” Biol Theor2: 128-130

living
system

Fundamental concepts
(autonomy/autopoiesis, self-
replication) and their chemical
implementation

Bottom-up

Source: Modified graphic from a presentation by Andrés Moya “Synthetic Biology: Goethe’s Dream”,  
available at http://ec.europa.eu/european_group_ethics/activities/docs/ege_moya.pdf 

synthetic biologists to predict how the functions of bio-
logical systems will develop, for example how biologi-
cal molecules bind substrates and catalyse reactions, 
how DNA encodes the information needed to specify 
the cell and how multi-component integrated systems 
behave. Multiscale models of gene regulatory networks 
are being developed to focus on synthetic biology ap-
plications. Simulations have been used to predict bio-
molecular interactions in transcription, translation, 
regulation, and induction of gene regulatory networks, 
guiding the design of synthetic systems. (60) Research 
is also ongoing into improving accurate quantitative 
measurements of biological systems to elucidate how 
biological systems work and provide the basis for  
model construction and validation. Technologies which 
allow many parallel and time-dependent measure-
ments will be especially useful in synthetic biology. 

In addition, since biological systems are extremely 
complex and often involve thousands of interact-
ing components, bioinformatic methods are useful 
to elucidate interdependencies in various biological 
processes. (61) For instance, insights into the distribu-
tions of mutational effects are vital for understanding 
robustness, and thus for both the genetic engineering 
of synthetic biological systems and the genetic modi-

(60)  Y. N. Kaznessis, (2007) ‘Models for Synthetic Biology’, BMC 
Systems Biology, 2007, 1:47 doi:10.1186/1752-0509-1-47.

fication of existing systems. (62) Thanks to the use of 
‘in silico’ methodology, it may be possible to provide 
accurate predictions of the underlying networks from 
expression data generated with artificial genomes and 
explore computationally future genome-wide redesign 
experiments in synthetic biology. (63)

Cell-free approach 

For certain applications of synthetic biology, there is 
now a developing trend towards using a cell-free ap-
proach, an alternative to developing minimal cells. The 
cell-free approach uses a different strategy, where only 
biochemical extracts containing the components nec-
essary to operate the synthetic DNA circuit or a com-
plex metabolic process are employed. (64)  

1.5.  State of art and medium- to long-term 

forecast

There are two complementary approaches to syn-
thetic biology, which take opposite starting points for 

(62)  Loewe L. A framework for evolutionary systems biology. 

BMC Syst Biol. 2009 Feb 24;3:27.

(63)  Carrera J, Rodrigo G, Jaramillo A. Model-based redesign 
of global transcription regulation. Nucleic Acids Res. 2009 
Apr;37(5):e38. Epub 2009 Feb 2.

(61)  Jane Synnergren*, Björn Olsson and Jonas Gamalielsson. 
Classification of information fusion methods in systems 
biology. In Silico Biology 9, 0007 (2009).

(64)  24. Forster AC & Church GM, Molecular systems biology 2: 
45 (2006 Ref. in Synthetic Biology: scope, applications and 
implications, Royal Academy of Engineering 2009.

19

1 | SCIENTIFIC ASPECTS

research but share the same aim, namely to artificially 
reconstruct biological systems.

The first is called the ‘top-down’ approach because it 
takes as a starting point an existing organism (e.g. a 
bacterium or a virus) and ‘strips down’ redundant ge-
netic elements to get to the ‘minimal’ cell configuration 
(see C. Venter).

The second approach is called ‘bottom-up’ because 
it takes as a starting point the creation of an inven-
tory of ‘standard parts’ (e.g. MIT’s registry of biological 
parts (65)), which constitute the building blocks of the 
biological systems to be reconstituted. This approach 
is based on the idea of modularity, meaning that all 
biological systems can ultimately be decomposed into 
independent functional modules; the reconstitution 
of even complex networks can therefore be seen and 
designed as the combination of several modules ac-
cording to the properties one wants the system under 
investigation to have. (66)

 1.5.1.  Current research in synthetic biology

Pan-European research funded through the EU re-
search programme on synthetic biology address the 
following areas: 

•	

•	

To	produce	generic	capabilities	in	‘bio-inspired’	
tools and processes that will offer breakthrough  
answers to many needs of industry and the econ-
omy; (67)

To	fabricate	engineered	biological	devices	based	
on modular assemblies of genes and proteins to 
(a) detect and combat disease at a very early stage 
and (b) for tissue repair and cell regeneration pur-
poses;

(65)  See http://partsregistry.org/Main_Page.

(66)  Please note that the concept and definition of ‘module’ is 
somewhat arbitrary and can be subjective. As a general 
rule, a ‘module’ should be the smallest functional entity of 
a biological system, but it is not very clear cut in an absolute 
sense.

(67)  For example, while some pharmaceutical compounds are 
already produced bio-technologically using genetically  
engineered organisms, the capacity to design synthesis 
pathways based on pre-existing elements could greatly 
accelerate the development speed and the complexity 
achievable in this novel application.

•	

•	

•	

To	fabricate	synthetic	biology	products	to	produce	
useful materials, such as biodegradable plastics 
from cheap and renewable raw materials, or to 
convert sustainable feedstocks to fuels;

To	fabricate	synthetic	biology	products	to	give	rise	
to materials with new and improved properties. The 
ability to control biological structures at molecular 
level could also lead to devices such as machines 
and electronic circuitry on an ultra-small scale;

To	control	cell	membrane	behaviour	to	develop	in-
novative applications, such as biosensors, mainly in 
the pharma-industry.

According to the UK Parliamentary Office of Science 
and Technology - POST (68), the potential applications 
of synthetic biology research could include: 

New biological production techniques  
for existing or novel biological materials  
and chemicals, including food ingredients  
and biofuels

Engineering organisms to produce hydrocarbons 
has received considerable interest as a possible 
outcome of synthetic biology given the aspiration 
to develop new and more sustainable sources of 
energy (POST, 2008). A major focus is to examine 
the potential for using synthetic or modified or-
ganisms to generate ethanol from plant matter. 
There are many ways of engineering microorgan-
isms to produce carbon-neutral (or more environ-
mentally friendly) sources of energy. For example, 
bacteria could be engineered to synthesise hydro-
gen or ethanol by degrading cellulose, although 
further work is needed to overcome technical bar-
riers. Plants and algae could also be engineered to 
produce biodiesel (Shreeve, 2006). The University 
of California recently received 600 million USD 
from BP and the USA Department of Energy for 
bioenergy research. Several biotech companies 
are researching industrial applications to produce  
biofuels using bioengineered organisms. They 
speculate that fuels could be on the market within 
five years. Similar to genetically engineered bacte-
ria for degrading oil residues, synthetic organisms 

(68)  POSTNOTE — Synthetic Biology, January 2008, No 298  

report

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

20

 
 
 
SCIENTIFIC ASPECTS | 1

and their metabolic pathways could be engineered 
to breakdown specific environmental pollutants at 
a much lower cost than we see today. Researchers 
aim to engineer bacteria which produce isopre-
noids (naturally-occurring substances) that have 
the right characteristics to substitute for petrol. 
There are also plans to engineer microorganisms 
which produce hydrogen fuel from water, using 
sunlight as the energy source.

New bio-based manufacturing  
and chemical synthesis

The development of alternative production routes 
could also be used for the production of new bio-
based manufacturing and chemical synthesis. For 
example, Du Pont and Tate & Lyle are involved in 
making corn produce a compound used in the tex-
tile industry (POST, 2008). Plants have also been en-
gineered to produce a synthetic analogue of spider 
silk, which has qualities of extreme strength and 
elasticity (De Vriend, 2006). Along similar lines, syn-
thetic mollusc shells could lead to the production 
of material which is light but also strong (Academy 
of Medical Sciences & Royal Academy of Engineer-
ing, 2007). Bacteria have been engineered to pro-
duce spider silk by a process that is non-toxic to 
the cells. (69) Spider silk has significant industrial 
potential, being as strong as Kevlar and ten times 
more elastic. Future research now aims to scale up 
production to an industrially useful level. Micro-
organisms that produce the bulk of today’s raw 
material for the organic chemical industry have 
been envisaged. 

New and improved diagnostics,  
drugs and vaccines

The production of some drugs or vaccines may 
need important modifications of living organisms 
and therefore the approach of synthetic biology 
may be useful in this case.

Artemisinin is a naturally occurring, effective an-
ti-malarial drug. It is currently obtained through 
extraction from a plant at high cost and with low 
efficiency. A 43 million USD project at the Univer-
sity of California at Berkeley funded by the Gates 

(69)  See http://royalsociety.org/displaypagedoc.asp?id=31191,  

p. 6.

Foundation has extensively engineered new path-
ways in yeast which produce a precursor to the ac-
tive drug. This potentially high-yield method may 
mean that the drug may become cheaper, of con-
sistent quality and more widely available. 

Synthetic  biology  models  of  human  physiol-
ogy may also give rise to a number of medical  
applications, such as regulatory circuits designed 
to trigger insulin production in diabetes (ITI Life  
Sciences,  2007),  and  bacteria  or  viruses  pro-
grammed to identify malignant cancer cells and 
deliver therapeutic agents (Serrano, 2007). Viruses 
have also been engineered to interact with HIV-
infected cells, which could prevent the develop-
ment of AIDS (70) (De Vriend, 2006). Synthetic biol-
ogy uses for new vaccines have been hypothesised 
for SARS and Hepatitis C (Garfinkel et al., 2007).

European scientists are combining their expertise 
in immunology and molecular biology to develop 
a new technique for producing monoclonal anti-
bodies with the aim of creating a library of over 
one million cells, each expressing unique antibod-
ies. A novel screening technique, based on cell sig-
nalling, should enable cells that specifically bind an 
antigen to be selected and purified. 

By carefully linking certain genes and regulatory 
sequences, scientists are able to design and con-
struct ‘gene networks’ that can sense and respond 
to specific conditions or signals in the cell. A multi-
disciplinary team is working to develop one such 
network that will sense errors in p53 signalling  
(a pathway implicated in almost all cancers) and 
respond either by killing the cell or by actually  
repairing detected mutations. The technology 
could have a wide range of applications from gene 
therapy to diagnostics.

(70)  ‘One of the avenues of synthetic biology that has wide appli-
cation is the development of alternative production routes 
for useful compounds, and one of the most discussed of 
these is the construction of an artificial metabolic pathway 
in E. coli and yeast to produce a precursor (arteminisin) for 
an antimalarial drug (Martin et al. 2003, Ro et al. 2006). It has 
been suggested that an approach such as this could be 
used to produce other therapeutically useful compounds 
for cancer and HIV treatment (Voigt 2005). Polyketides are 
another important class of drugs which could potentially be 
produced using synthetic biology (Heinemann and Panke 
2006).’ Balmer A., Martin P., 2008, Synthetic Biology: Social 
and Ethical Challenges, Institute for Science and Society, 
University of Nottingham P. 10-11.

21

1 | SCIENTIFIC ASPECTS

Biosensors

designed to act as biosensors of arsenic in water. 
(73)

A team at the University of Edinburgh has designed 
and engineered bacteria as biological sensors for 
arsenic in water. A sequence of genes in the bacteria  
stimulates  them  to  produce  acid  if  arsenic  is 
present above the safe level for human consump-
tion. The resulting change in acidity can be read 
cheaply and simply using existing pH test devices. 
According to the Nuffield Council Background pa-
per on Synthetic Biology (2009), a biosensor has 
been developed which can detect early-stage uri-
nary catheter infections. (71) The biosensor consists 
of an engineered system suspended in a liquid that 
can be applied to the catheter end that is outside 
the body. The liquid contains a protein which binds 
the molecule AHL, associated with this kind of in-
fection, thus activating a second protein that glows 
green and makes the liquid fluoresce. The system 
allows doctors to detect urinary catheter infection 
within 3 hours, whereas currently, doctors can of-
ten only identify urinary catheter infection once it 
has spread and infected the patient.

Bioremediation tools to process contaminants

Bioremediation is the use of biological systems 
to treat environmental contaminants. Research-
ers are using knowledge of natural processes to 
develop micro-organisms that can accumulate 
and/or degrade substances, such as heavy met-
als and pesticides. For example, a team at Ber-
keley has engineered a strain of Pseudomonas 
to  degrade  an  organophosphate  (commonly 
used  as  a  pesticide).  Synthetic  biologists  are 
endeavouring  to  engineer  microorganisms 
that remediate some of the most potent envi-
ronmental contaminants, such as heavy met-
als, pesticides and nuclear material. A strain of 
Pseudomonas bacteria has been developed to  
degrade an organophosphate that is commonly 
used as a pesticide. (72) Bacteria have also been 

(71)  See  http://www.sciencedaily.com/releases/2007/11/ 

071107103105.htm.

Other research sectors in synthetic biology concern  
biosecurity and biodefence (military research and 
applications (warfare, bioterrorism). Synthetic biol-
ogy could be used to produce biosensors to detect 
biological weapons or to create biological weapons, 
or single cellular organisms could be designed to 
emit a signal (e.g.: fluorescence) in the presence of 
certain environmental  toxins. Examples of the dan-
gerous synthesis of pathogen viruses already exist. 
For example, in 2002 scientists synthesised the po-
lio virus, which had been previously eradicated. (74) 
In 2005, scientists synthesised the 1918 Spanish flu 
virus, (75) which prior to its extinction had caused a 
pandemic killing 20–50 million people. Military appli-
cations of biotechnology (including synthetic biology) 
could include biodefence, biowarfare, and bioweap-
ons. The latter could be designed to target special 
groups of humans and/or other living beings. (76) 

The column labelled ‘Difficulty of Synthesis’ is the con-
sensus of various virologists and molecular biologists 
who participated in our workshops and meetings. The 
judgment applies to someone with knowledge of and 
experience in virology and molecular biology and an 
equipped lab but not necessarily with advanced expe-
rience (‘difficulty’ includes obtaining the nucleic acid 
and making the nucleic acid infectious). (77) 

The military use of synthetic biology is often covered 
by secrecy clearance (78) (classified research). It should 
be noted that, according to a figure presented at the 

(73)  Aleksic J, Bizzari F, Cai Y et al. (2007) Development of a novel 
biosensor for the detection of arsenic in drinking water, Syn-
thetic Biology, IET 1: 87–90.

(74)  Cello J, Paul AV, Wimmer E (2002) Chemical synthesis of po-
liovirus cDNA: generation of infectious virus in the absence 
of natural template, Science 297: 1016–8.

(75)  Tumpey TM, Basler CF, Aquilar PV (2005) Characterisation of 
the reconstructed 1918 Spanish influenza pandemic virus 
Science 310: 77–80.

(76)  See Alexander Kelle (2007). Synthetic Biology & Biosecurity. 
Awareness in Europe, http://www.synbiosafe.eu/uploads///
pdf/Synbiosafe-Security_awareness_in-Europe_Kelle.pdf.

(77)  http://www.jcvi.org/cms/fileadmin/site/research/projects/
synthetic-genomics-report/synthetic-genomics-report.pdf. 
(page 16 of 66)

(78)  Garfinkel M., Endy D., Epstein GL., Friedman RM., 2007, Syn-

(72)  See http://pbd.lbl.gov/synthbio/aims.htm.

thetic Genomics — Options for Governance.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

22

 
 
 
SCIENTIFIC ASPECTS | 1

Virus

Variola

1918 influenza

H2N2 influenza  
(extinct 1968)

Poliovirus

Filoviruses (Ebola, Marburg)

Foot-and-mouth disease 
virus

SARS

Type: length  
of nucleic acid

Select 
Agent

Where Found

Difficulty of Synthesis

dsDNA;180kb

ssRNA, negative 
stranded; 8 segments 
~10kb total

ssRNA, negative 
stranded; 8 segments 
~20kb total

ssRNA, positive  
stranded; ~7.7kb
ssRNA, negative  
stranded; ~19kb
RNA, positive  
stranded; ~9kb

ssRNA, positive  
stranded; ~30kb

Yes

Yes

No

No

Yes

Yes

No

Locked lab

Difficult

Locked lab

Moderately difficult

Laboratories

Moderately difficult

Laboratories; widely in 
nature, Africa and Asia

During active outbreaks

Easy

Moderately difficult to 
difficult

Certain hoofed animals

Easy

2003 strain in labs

Moderately difficult to 
difficult

Synthetic Biology 2007 World Conference, the USA 
spends 23 billion USD on biosecurity issues per year 
(civil part only) and synthetic biology is part of this 
research area. (79) Other countries may use synthetic 
biology for biosecurity or biowar. According to the 
United States Office of Technology Assessment (since 
disbanded), seventeen countries were believed to 
possess biological weapons in 1995: Libya, North Ko-
rea, South Korea, Iraq, Taiwan, Syria, Israel, Iran, China, 
Egypt, Vietnam, Laos, Cuba, Bulgaria, India, South Af-
rica, and Russia.

1.5.2.   Future uses of synthetic biology 

Although the use of synthetic biology to manufacture 
new life forms of complex organisms does seem fu-
turistic, some synthetic biologists have advocated the 
possible use of this science to synthesise new biological 
organisms or to extensively modify higher forms of life, 
including mammals.

One possibility so far envisaged to modify the genome 
of complex organisms, including humans, is via the use 
of artificial chromosomes. De novo human artificial 
chromosomes have been generated in human cells fol-
lowing the introduction of bacterial artificial chromo-
somes or P1-derived artificial chromosomes containing 

(79)  USA Defense Department investment in synthetic biology 
for passive defence (by law [PL 103-160, all DoD work on 
chemical and biological defence is limited to passive de-
fensive): From the forms submitted to Congress with the 
budget (called the Congressional R-form) detailing fund-
ing, inclusion of synthetic biology is mentioned under the 
Chemical and Biological Defence’s Basic Research Program. 

large arrays of cloned or synthetic alphoid DNA repeats 
from chromosomes 5, 13/21, 14/22, 17, 18 and X. This has 
opened up the possibility of expressing large human 
transgenes in murine cells, and complement murine 
models of human genetic diseases. Human artificial 
chromosomes are therefore potentially useful vectors 
for gene therapy approaches where there is a need to 
transfer large segments of the genome. However, de-
velopment of human artificial chromosomes to trans-
fer large genomic loci into mammalian cells has been 
limited by difficulties in manipulating high-molecular 
weight DNA, as well as by the low overall frequencies of 
de novo human artificial chromosomes. (80) 

In April 2009, the creation of a self-replicating ribosome 
was announced. Although ribosomes were reconstituted 
40 years ago, this appears to be the first time it has been 
done successfully and synthetically. Ribosomes provide 
the scaffolding for synthesising proteins, making them 

The FY2009 budget request is available at http://www.dtic.
mil/descriptivesum/Y2009/CBDP/0601384BP.pdf (page 4) The 
FY2010 budget request, which is the most recent, is available at  
http://www.dtic.mil/descriptivesum/Y2010/CBDP/0601384BP.
pdf (page 3). In general, CBDP budget documents can be 
found at http://www.acq.osd.mil/cp/budget.html. Informa-
tion on the Transformational Medical Technologies Initiative 
(TMTI) is available at http://www.acq.osd.mil/cp/cbdreports/
tmti.pdf. Within DARPA’s Defence Sciences Office (DSO), the 
program most involved in synthetic biology is the ‘Protein 
Design Processes’ http://www.darpa.mil/dso/thrusts/bwd/
act/pdp/index.htm. DARPA’s budget is available at http://
www.darpa.mil/Docs/2010PBDARPAMay2009.pdf. Discus-
sion of DSO’s Biological Warfare Defence Program starts on 
page 103 of the pdf file.

(80)  See http://www.biomedcentral.com/1472-6750/5/21.

23

 
1 | SCIENTIFIC ASPECTS

a main component of all living organisms’. A main goal 
of the Harvard team has been to fabricate a so-called 
‘mirror-image protein’, a protein which is not susceptible 
to enzyme breakdown and can last longer than natural 
ones. This application of synthetic biology may have 
commercial applications to create basic molecular biol-
ogy tool kits to synthesise proteins for molecular biology 
research or for therapeutic proteins. The proteins them-
selves could be engineered to undergo ‘Darwinian evolu-
tion to evolve even better therapeutic proteins’. (81) 

Another use of synthetic biology converging with other 
new disciplines recently published in Science (82) was the 
combined use of synthetic biology and nanotechnology 
to produce genetically engineered high-power lithium 
ion batteries using multiple virus genes. Scientists have 
adopted a strategy for attaching electrochemically ac-
tive materials to conducting carbon nanotubes networks 
through biological molecular recognition. By manipulat-
ing two genes of the M13 virus, viruses were equipped 
with peptide groups with affinity for single-walled car-
bon nanotubes (SWNTs) on one end and peptides capa-
ble of nucleating amorphous iron phosphate (a-FePO4) 
fused to the viral major coat protein. The produced vi-
rus has demonstrated, according to the research team  
involved, 10 times greater affinity for SWNTs, increasing 
their power performance in terms comparable to that of 
crystalline lithium iron phosphate. The electrodes pro-
duced with this technique have shown that this envi-
ronmentally benign low temperature biological scaffold 
could facilitate the fabrication of electrodes from materi-
als that have been excluded due to their extremely low 
electronic conductivity.

1.6. 

 Research funding

To date, the embryonic stage of the research sector has 
mainly attracted investment from the public sector, but 
the vast range of applications of synthetic biology (if and 
when the science produces reliable products) is likely to 
attract private investment with the potential to open up 
new markets in the global economy. In the short term, 
application areas include materials, biofuels and indus-
trial chemistry. The production of new medicines in-
cluding synthetic viruses as vaccines could be promising 
from a scientific and socio-economic point of view. Syn-
thetic biology is at this moment a domain which largely  

depends on public funding, both at EU and interna-
tional level, but it is inevitable that private finance will 
follow developments. 

The USA dominates research activities in synthetic bi-
ology in terms of numbers of scientific publications, 
number of scientists involved, number of post-graduate 
courses for students and research funding. In line with a 
broader international discussion, for example, President 
Obama’s speech to the USA National Academy of Science 
on April 27, 2009, emphasizing the merit of knowledge 
for the good of humankind (and the subsequent deci-
sion to increase the USA budget allocated to this research  
sector). The majority of US funding comes from the 
National Institutes of Health (NIH), but other funding 
sources exist, such as from the government defence and 
energy agencies. The Massachusetts Institute of Technol-
ogy (MIT) and some other US centres have so far domi-
nated the field of synthetic biology, in particular with the 
creation of new terminology and language. Apart from 
the MIT registry of standard biological parts, the iGEM 
(‘international genetically engineered machine’) summer 
competition has been the main pillar of these activities. 

According to data from the US research body Woodrow 
Wilson International Centre (Washington DC, USA), the 
US research budget in synthetic biology is in the or-
der of 1 billion USD and 200 labs (100 universities and 
60 companies) benefit from it. The US National Science  
Foundation has funded SynBERC (Synthetic Biology Engi-
neering Research Centre) (83) , a network of USA institutions  
(especially universities) receiving 16 million USD over a 
period of five years. In addition, major investment from 
the private sector (Bill and Melinda Gates Foundation) has 
started in the USA. The Sloan Foundation supports activi-
ties on societal issues (ethics, risk perception, etc.).

With some exceptions European national agencies and 
programmes are not yet very active (84). Europe has, so 
far, been relatively slow to embrace the potential oppor-
tunities from synthetic biology, despite the substantial 
pool of expertise which could be tapped to contribute 
towards an effective EU programme. Efforts have been 
made, however, to coordinate developments at pan-
European level. In the EU Research Programme the 
budget is €30 million and 20 organisations benefit. EU 
funding for synthetic biology is mainly via the Frame-
work Programmes for Research and Technological De-

(81)  http://www.masshightech.com/stories/2009/03/30/weekly15-
George-Church-creates-building-block-for-artificial-life.html.

(82)  http://w w w.sciencemag.org/cgi/content /abstract / 

1171541?eaf.

(83)  http://www.synberc.org/institutions.html.

(84)  http://www.royalsoc.ac.uk/news.asp?id=6753.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

24

 
 
 
SCIENTIFIC ASPECTS | 1

velopment (85) (FP). For instance, FP6 funded NEST (New 
and Emerging Science and Technology), a part of which 
is dedicated to synthetic biology applications. In 2003, 
synthetic biology was identifi ed as an emerging and in-
novative research area and a NEST High-Level Expert 
Group reported on the subject. As a result, FP6 funding 
was granted to 18 synthetic biology research and policy 
projects. Five current EU-funded projects will run to the 
end of 2009 and aim to stimulate and coordinate syn-
thetic biology research in Europe. Some examples of 
EU-funded research projects include:

BIOMODULAR H2, specifi cally aims to generate build-
ing blocks to harvest solar energy for the production 
of useful chemicals. The project seeks to pave the way 
for designing a standards-based methodology using 
engineered bacteria to photosynthesise hydrogen, an 
environmentally-friendly potential replacement for 
dwindling fossil fuels. (86)

(85)  European Commission (2006), Synbiology. An Analysis of 
Synthetic Biology Research in Europe and North America, 
http://www2.spi.pt/synbiology/document/news/D11%20
-%20Final%20Report.pdf.

(86)  In BIOMODULAR H2, six European universities are collabo-

The CELLCOMPUT project proposes a highly innovative 
approach to defi ning basic cellular computation systems. 
By combining expertise in molecular cell and chemical bi-
ology, complex systems design and mathematical mod-
elling, CELLCOMPUT aims to demonstrate reliable fault-
tolerant designs based on predictable communications 
between engineered yeast cells. This solution makes it 
much easier to build complex biological circuitry, such 
as memory units and programmable structures. (87) 
The resulting biological-based computers would have 
potential in many areas, not least in developing modular 
assemblies of genes and proteins that would be able to 

rating to solve this problem by constructing an artifi cial 
photosynthetic bacterium containing suitably engineered 
chemical pathways. At the same time, they will lay the 
foundation for an engineering approach that will provide 
the next generation of synthetic biology engineers with 
a toolbox to design complex circuits of high potential, for 
even more industrial applications.

(87)  While the focus is on well-documented yeast cells and their 
cell-to-cell communication pathways, the long-term aim 
would be to build programmable biodevices using other 
cells as well. These engineered systems would have stand-
ardised functionalities and be substantially diff erent from 
naturally-existing systems.

25

1 | SCIENTIFIC ASPECTS

detect and respond to changes in the body and so com-
bat diseases at a very early stage. Similar devices could 
also be used for tissue repair and cell regeneration.

The possibility of artificial systems controlling living cells 
and influencing the genetic information processes might 
seem like science fiction to many, but the ORTHOSOME 
project is doing just that. A multidisciplinary consortium 
is building an artificial genetic system which will be able 
to be used in genetic engineering without the danger of 
contaminating natural systems. Such a system will rep-
resent a major breakthrough for synthetic biology and 
will give the EU’s pharmaceutical sector the leading edge 
against its competitors.

The COBIOS project aims to develop synthetic biology 
devices for therapy in medicine, in particular to create 
methods to treat diabetes through the innovative use 
of novel biological delivery systems. Among its objec-
tives, COBIOS intends to deliver a systematic approach 
to developing well characterised, engineered biologi-
cal devices in higher eukaryotes that will constitute re-
usable ‘building blocks’ for future engineered systems 
design. The project will also provide computer-aided 
design tools for the building and simulation of synthetic 
gene circuits, tools that will be available to the scientific 
community.

EU-funded research projects (88):

BIOMODULAR H2: Energy project promises a new biotechnology

BIONANO-SWITCH: Matching up living organisms with computers

CELLCOMPUT: Building computers in the body 

COBIOS: Solution for complex diseases 

EMERGENCE: Coordination puts synthetic biology on firm footing 

EUROBIOSYN: A sweeter way to make saccharine 

FuSyMEM: Functional synthetic membranes to mimic nature’s sense of smell 

HIBLIB: Monoclonal antibody production made quick and easy 

NANOMOT: Nature’s motors tuned for delivery on demand 

NEONUCLEI: Synthetic analogues of cell nuclei 

NETSENSOR: Genes join up to detect and defend 

ORTHOSOME: When artificial nucleic acids control microbial genetics 

PROBACTYS: Programming bacterial catalysts à la carte 

SYBHEL: Synthetic biology for human health – ethical and legal issues 

SYNBIOCOMM: Pushing the boundaries further 

SYNBIOLOGY: A European perspective on synthetic biology 

SYNBIOSAFE: Safety and ethics of synthetic life 

SYNTHCELLS: The bare necessities of life 

SYNTH-ETHICS: Ethical and regulatory challenges raised by synthetic biology

TESSY: Foundations for a European synthetic biology. 

(88)  ftp://ftp.cordis.europa.eu/pub/nest/docs/5-nest-synthetic- 

080507.pdf.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

26

 
 
 
LEGAL, GOVERNANCE AND POLICY ASPECTS | 2

2. 

Legal, Governance and Policy 
Aspects

Specific legislation on synthetic biology has not been 
introduced in European Union Member States. Most 
of the existing regulations result from transposing 
EU legislation into national legal systems. This is sup-
plemented by some global provisions, issued by the 
World Trade Organisation (WTO), and an international 
framework on ethics and human rights. The latter is 
only to a limited extent legally binding. These rules are 
described briefly below according to their legal force, 
focusing on their importance for synthetic biology, 
with special reference to definitions, procedures and 
the content of the provisions. The legislative framework 
applying to synthetic biology is strictly dependent on 
the applications of this scientific sector and include 
legal and policy provisions at different levels:

(A) European Union (EU) legislation on GMOs, bio-
medicine, bio-safety, chemicals, data protection and 
patents;

(B) Global provisions issued by the World Trade Or-
ganisation (WTO) and bio-safety standards issued by 
the World Health Organisation (WHO);

(C) International framework on ethics and human 
rights. 

At the moment virtually all approaches to synthetic 
biology involve the use of genetic modification tech-
niques. Therefore within the EU they are regulated 
through the Directives and Regulations for genetic 
modification introduced initially in 1990 and substan-
tially modified during the ensuing years.

Legislation adopted by the European Union is binding 
for the Member States, but there are differences in the 
nature of obligations. Legislation related to the plac-
ing of products on the EU market, e.g. medical devices, 
medicinal products and cosmetics, is harmonised at 
Member State level, whereas legislation on Good Clini-
cal Practice may be supplemented by national rules, as 
Community law establishes minimum provisions. Data 
protection and patent provisions are binding for the EU 
Member States. 

WTO agreements ratified by a great number of nations 
form the legal ground rules for international commerce. 
They are binding for the States that have signed and 
ratified them. 

The international framework on ethics and human 
rights is legally binding only to a limited extent. The 
Council of Europe Convention on Bioethics (1997), 
based on the Convention for the Protection of Human 
Rights and Fundamental Freedom (4.11.1950), is bind-
ing for the States that have signed and ratified it, but 
not all EU countries have done so. (89) However, Euro-
pean projects funded under the EU research framework 
programmes also have to comply with the principles 
enshrined in that Council of Europe Convention. The 
UNESCO Declarations and the EU Charter of Fundamen-
tal Rights are not legally binding, but they have moral 
authority. All three types of rules may be supplemented 
by national regulations. 

2.1. 

EU legislation

There is a wide range of EU legislation related to is-
sues relevant for synthetic biology, either existing or 
in preparation. These issues primarily concern risk as-
sessment. 

European Union legislation of specific importance for 
risk assessment and risk management  includes Direc-
tive 2001/18/EC on the deliberate release into the en-
vironment of genetically modified organisms (replac-
ing Council Directive 90/220/EC (90)) Regulation (EC)  
No 1946/2003 on transboundary movements of geneti-
cally modified organisms that implemented the pro-
visions of the Cartagena Protocol on Biosafety within 
the European Union; (91) and Council Directive 98/81/EC  
amending Directive 90/219/EEC (92) on the contained 
use of genetically modified micro-organisms. (93)

Most of the work in synthetic biology falls within the 
remit of Directive 98/81 which deals with the contained 
use of genetically modified micro-organisms. It regu-
lates the contained use of genetically modified micro-
organisms (GMM) and therefore has environmental 

(89)  As of November 2006, the Convention has been signed 
by 21 EU Member States and ratified by 13. (http://www.
coe.int/t/e/legal_affairs/legal_cooeration/bioethics/texts_
and_documents/1Treaties_COE.asp#TopOfPage.

(90)  http://europa.eu/eur-lex /pri/en/oj/dat/2001/l_106/

l_10620010417en00010038.pdf.

(91)  http://europa.eu/eur-lex /pri/en/oj/dat/2003/l_287/

l_28720031105en00010010.pdf.

(92)  http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CEL

EX:31990L0219:EN:HTML.

(93)  http://europa.eu/eur-lex /pri/en/oj/dat/1998/l_330/

l_33019981205en00130031.pdf.

27

2 | LEGAL, GOVERNANCE AND POLICY ASPECTS

and human health protection purposes as stated under 
Article 1 of the Directive. (94)

A microorganism is defined in Article 2 of the direc-
tive to be “any microbiological entity, cellular or non-
cellular, capable of replication or of transferring genetic 
material, including viruses, viroids, animal and plant 
cells in culture”. This includes cultures of cells derived 
from human tissue. The Article also defines a geneti-
cally modified microorganism as “a micro-organism in 
which the genetic material has been altered in a way 
that does not occur naturally by mating and/or natural 
Recombination”. Hence any new organism produced 
through synthetic biology will be regulated through 
this directive.

The Directive provides the regulatory framework for 
assuring the safety of organisms used in containment 
(whether physical or biological) (95). At the very least, 
any organization working with genetically modified 
organisms has to register with a Competent Author-
ity within a Member State (Article 7). If the organism 
(synthetic or otherwise) poses no conceivable risk to 
human health or the environment, no further action 
is necessary. If, however, there is a risk (even a low risk) 
of damage to human health or the environment the 
authorities must be informed of each individual ‘experi-
ment’. If the risk is moderate or high, prior assent must 
be obtained from the Competent Authorities.

Directive 98/81/EC also defines the ‘user’ as “any natural 
or legal person responsible for the contained use of 
GMMs” and ‘notification’ as “the presentation of the 
requisite information to the competent authorities of 
a Member State.”  A difference is made between first 
and subsequent uses and as regards to risk classifica-
tion category.

Moving from the laboratory to the commercial world, 
whether for the introduction into the environment  
of  an  organism  or  for  marketing  brings  Directive 

(94)  This Directive lays down common measures for the con-
tained use of genetically modified micro-organisms with a 
view to protecting human health and the environment.

(95)  “contained use” shall mean any activity in which micro-or-
ganisms are genetically modified or in which such GMMs 
are cultured, stored, transported, destroyed, disposed of or 
used in any other way, and for which specific containment 
measures are used to limit their contact with the general 
population and the environment (Article 2)

2001/18/EC (96) into play. It defines a ‘genetically modi-
fied organism’ (GMO) as an organism, with the excep-
tion of human beings, in which the genetic material 
has been altered in a way that does not occur naturally 
by mating and/or natural recombination. Within the 
terms of this definition, a genetic modification occurs at 
least through the use of one of the techniques listed in  
Annex IA of the Directive. (97) Risk assessment, market-
ing and labelling requirements are spelled out in Regu-
lations (EC) 1829/2003 and 1830/2003.

The definitions in the Directives differ significantly. 
Directive 2001/18/EC regulates the deliberate release 
into the environment of genetically modified organ-
isms and therefore has environmental and human 
health protection purposes as stated under Article 1 
of the Directive. In accordance with the precaution-
ary principle, the objective of this Directive is to ap-
proximate the laws, regulations and administrative 
provisions of the Member States and to protect human 
health and the environment when: 1) carrying out the 
deliberate release into the environment of genetically 
modified organisms for any other purposes than plac-
ing on the market within the Community, 2) placing 
on the market genetically modified organisms as or in 
products within the Community. The Directive defines 
a GMO as an ‘organism, with the exception of human 
beings, in which the genetic material has been altered 
in a way that does not occur naturally by mating and/
or natural recombination’. The techniques covered in 
the Directive include: 

(1) recombinant nucleic acid techniques involv-
ing the formation of new combinations of genetic 
material by the insertion of nucleic acid molecules 
produced by whatever means outside an organism, 
into any virus, bacterial plasmid or other vector sys-
tem and their incorporation into a host organism in 
which they do not naturally occur but in which they 
are capable of continued propagation;

(2) techniques involving the direct introduction into 
an organism of heritable material prepared outside 
the organism including micro-injection, macro- 
injection and micro-encapsulation;

(96)  Directive 2001/18/EC on the deliberate release into the  

environment of genetically modified organisms.

(97)  Regulations (EC) No 1829/2003 and 1830/2003 refer to the 
definition of GMO laid down in Directive 2001/18/EC.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

28

 
 
 
LEGAL, GOVERNANCE AND POLICY ASPECTS | 2

(3) cell fusion (including protoplast fusion) or hy-
bridisation techniques where live cells with new 
combinations of heritable genetic material are 
formed through the fusion of two or more cells 
by means of methods that do not occur naturally. 
(2001/18/EC, Annex 1A).

Deliberate release under Article 2.3 ‘means any inten-
tional introduction into the environment of a GMO or 
a combination of GMOs for which no specific contain-
ment measures are used to limit their contact with and 
to provide a high level of safety for the general popula-
tion and the environment.’

The standard authorisation procedure for deliberate 
release of GMOs for any other purpose than for placing 
on the market is laid down in Article 6 of the Directive, 
whilst placing on the market of GMOs as or in products 
is regulated by specific provisions on the notification 
procedure in Article 13. Both procedures lay down a 
number of requirements that need to be met in order 
for the competent authorities to take a decision on au-
thorisation of GMO release. Furthermore, Article 9 of 
Directive 2001/18/EC on ‘Consultation of and informa-
tion to the public’ provides for active involvement of 
the public and groups. 

In addition, the Commission has recently prepared a 
replacement Draft Directive on the contained use of 
genetically modified micro organisms (GMM) to amend 
Directive 98/81/EC. The above Directive aims to estab-
lish common measures to evaluate and reduce the 
potential risks arising in the course of all operations 
involving the contained use of GMMs and to set appro-
priate conditions of use. The Directive also seeks to lay 
down requirements for risk assessment and advocates 
that contained uses of GMMs should be classified in  
relation to the risks they present to human health 
and the environment. It states that where there is any  
uncertainty, appropriate containment and other pro-
tective measures for higher classification should be 
applied until less stringent measures are justified by 
appropriate data. Appropriate containment measures 
should be applied at the various stages of an operation 
to control emissions and the disposal of material from 
contained uses of GMMs, and to prevent accidents. 

The above EU regulatory framework addresses the bi-
osafety of synthetic biology but, as the Nuffield Coun-
cil underlines in its 2009 background paper, under 
the current regulatory framework, risk assessments 
of genetically modified organisms (GMOs) compare 
the altered organism with the natural organism on 

which it is based, considering the individual traits in-
troduced. Synthetic biology will produce organisms 
with multiple traits from potentially several different 
donor organisms. The use of an artificially expanded 
genetic information system or the insertion of multiple 
genetic traits or the synthesis of new synthetic biology 
products, while not excluded per se in the EU biosafety 
framework may not provide sufficient reliability to the 
risk assessment and analysis framework.

The application areas of synthetic biology are already 
regulated at EU level and synthetic biology products 
will have to comply with the existing regulations. In ad-
dition to the requirements identified above, there are 
further requirements depending on the use to which 
the products of synthetic biology might be put. A list of 
possible uses of synthetic biology is provided in Chap-
ter 1.5 of this Opinion, hence the regulatory framework 
that would apply to the various synthetic biology ap-
plications would include: 

•	 new medicinal products (Regulation (EC) No 726/ 
2004, Directive 2001/83/EC, Directive 2003/94/EC 
and Directive 2003/63/EC); 

•	 medical devices (Directive 93/42/EEC and 90/385/

EEC); 

•	 gene therapy, cell therapy and tissue engineering 
(Regulation (EC) No 1394/2007 amending Directive 
2001/83/EC and Regulation (EC) No 726/2004, Direc-
tive 2001/83/EC, Directive 2004/23/EC and Directive 
2002/98/EC); 

•	

clinical trials (EC 2001/20 amended in 2003 (98) and 
2005 (99));

•	

cosmetic products (Directive 1976/768/EC); 

•	 data protection (Directive on the processing of 
personal data and the protection of privacy in the 
electronic communications sector (100));

•	

chemicals (REACH rules (101));

(98)  Directive 2003/63/EC.

(99)  http://clusters.wallonie.be/servlet/Repository/Directive_ 

2005/28/EC_EN__comp.PDF? IDR=5482.

(100)  Directive 2002/58/EC, Directive 95/46/EC.

(101)  The REACH Regulation was formally adopted on 18 De-
cember 2006 by the Council of Environment Ministers fol-

29

2 | LEGAL, GOVERNANCE AND POLICY ASPECTS

•	 biological risks (Council Directive 82/894/EEC and 
Council Directive 2000/29/EC of 8 May 2000 (102)); 

open access, 3) security policy and Chemical, Biological, 
Radiological or Nuclear (CBRN) substances.   

•	

safety and health for workers exposed to biologi-
cal agents at work (Directive 2000/54/EC).

The above regulations are described and discussed 
in the EGE Opinion on Nanomedicine (103) (biomedi-
cine), the EGE Opinions on animal cloning for food  
supply (104) (food safety, IPR) and modern developments 
in agriculture technologies (105) (biosafety, IPR). There 
are however, three regulatory frameworks which will 
apply to synthetic biology products that have not been 
fully addressed in previous Opinions: 1) patenting, 2) 

lowing the vote in second reading of the European Parlia-
ment on 13 December 2006. REACH will enter into force 
on 1 June 2007. The text of the Regulation was published 
on 30 December 2006 in Official Journal of the European 
Union L 396  (Regulation (EC) No 1907/2006 of the Euro-
pean Parliament and of the Council of 18 December 2006 
concerning the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH), establishing a European 
Chemicals Agency, amending Directive 1999/45/EC and re-
pealing Council Regulation (EEC) No 793/93 and Commis-
sion Regulation (EC) No 1488/94 as well as Council Directive 
76/769/EEC and Commission Directives 91/155/EEC, 93/67/
EEC, 93/105/EC and 2000/21/EC. See: 
http://ec.europa.eu/environment/chemicals/reach/reach_
intro.htm). See also: Council Directive 96/82/EC of 9 Decem-
ber 1996 on the control of major accident hazards involving 
dangerous substances (Seveso II) aims at mitigating the con-
sequences of accidents. It focuses on safety, the formulation 
of emergency plans, and information exchange in case of 
incident. Council Directive 98/24/EC of 7 April 1998 on the 
protection of the health and safety of workers from the 
risks related to chemical agents at work lays down the re-
quirements for the protection of workers from risks to their 
safety and health arising, or likely to arise, from the effects 
of chemical agents that are present at the workplace or as 
a result of any work activity involving chemical agents. The 
Standing Committee of Experts on Precursors addresses the 
risks posed by chemical precursors. The standing commit-
tee has been meeting since the beginning of 2008.

(102)  This directive creates a compulsory notification system: 
when an outbreak occurs, Member States have to notify 
the Commission. Member States have also to notify the 
Commission when there is an interception at the customs 
on imported/exported goods, http://europa.eu/scadplus/
leg/en/lvb/f85001.htm.

(103)  http://ec.europa.eu/european_group_ethics/activities/

docs/opinion_21_nano_en.pdf.

(104)  http://ec.europa.eu/european_group_ethics/activities/

docs/opinion23_en.pdf.

(105)  http://ec.europa.eu/european_group_ethics/docs/ 

The Patent Directive, (106) deals specifically with the pro-
tection of biotechnological inventions and is designed 
to ensure effective legally harmonised protection of 
patents. In doing so it aims to encourage innovation 
and promote investment in the field of biotechnology 
and establish legal certainty. The inventor secures ex-
clusive rights to control commercial exploitation of his 
invention for 20 years and, in return, he must disclose 
a detailed description of his invention, making the new 
knowledge publicly available. This disclosure enables 
others (researchers etc.) to build on the knowledge 
gained. The patent may be a product claim, a process 
claim or both. (107) The standard criteria for patentability 
include novelty, inventive steps and industrial applica-
tion. According to Article 3, ‘biological material which 
is isolated from its natural environment or produced by 
means of a technical process may be the subject of an 
invention even if it previously occurred in nature’. The 
Directive contains provisions laying down restrictions 
based on ethical concerns, i.e. ordre public or morality 
(Article 6 (108)). The applicability of the morality clause 
to patents for some synthetic biology products may be 
controversial. The Directive above also states (Article 7) 
that the EGE ‘evaluates all ethical aspects of biotechnol-
ogy’. Article 7 is the only Article of the Directive that has 
not been implemented in the rules of European Patent 
Office or any Member State’s Patent Office.

Open Access (OA) is broadly defined as ‘free access to 
knowledge at no charge to the user.’ (109) Under open 
access policies, authors published in research publica-
tions grant free internet access to their scientific contri-
butions, as well as the possibility to use them, subject 
to proper attribution of authorship. (110) This means 

(106)  Directive 98/44/EC.

(107)  See also EGE Opinion No 16 on ‘Ethical aspects of patenting 
inventions involving human stem cells’ (http://ec.europa.eu/
european_group_ethics/docs/avis16_en.pdf).

(108)  According to the Directive on biological inventions, ‘inven-
tions shall be considered unpatentable where their com-
mercial exploitation would be contrary to ordre public or 
morality; however, exploitation shall not be deemed to be 
so contrary merely because it is prohibited by law or regula-
tion’. Directive 98/44/EC, Article 6(1).

(109)  EU handbook on open access — http://ec.europa.eu/ 
research/science-society//document_library/pdf_06/ 
open-access-handbook_en.pdf.

opinion24_en.pdf.

(110)  http://europa.eu/rapid/pressReleasesAction.do?reference

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

30

 
 
 
 
LEGAL, GOVERNANCE AND POLICY ASPECTS | 2

free, immediate, permanent and full access to texts, 
online for any user of internet Scientific and Digital 
Scholarship material, mainly research articles published 
in scientific journals . Although there is no specific leg-
islation applicable, there are at least three main inter-
national declarations on the subject: the first one, BOAI 
(Budapest Open Access Initiative) dated February 2002, 
followed by the ‘Bethesda Statement on Open Access 
Publishing’ (June 2003) and the ‘Berlin Declaration on 
Open Access knowledge in the Sciences and Humani-
ties’ (October 2003).

In an open access publication, ‘the author(s) and copy-
right holders(s) grant(s) to all users a free, irrevocable, 
worldwide, perpetual right of access to, and a license 
to copy, use, distribute, transmit and display the work 
publicly (...)’ (Bethesda Declaration). This is viewed, by 
some, as a potential way of improving access to and dis-
semination of publicly funded scientific information, in 
particular peer-reviewed scientific publications. In fact 
this approach, although not new to synthetic biology, 
has been discussed over the last few years regarding 
the sharing of scientific information. It is now empha-
sised where synthetic biology models are mostly used 
in modelling synthetic biology structures. Including in 
concept of OA and applicable to software, Open Source 
software is software that includes source code and is 
usually available at no charge, but carries a general li-
cence that may identify that which may (or may not) be 
done with the software (111).

In 2008, the European Commission launched a pilot 
project that was planned for in Commission Com-
munication  (COM(56)2007)  on  ‘scientific  informa-
tion  in  the  digital  age:  access,  dissemination  and  
preservation’ (112) in reaction to which European re-
search ministers adopted Council Conclusions inviting 
the Commission to experiment with open access in FP7. 
(113) The pilot project is to give unrestricted online access 
to EU-funded research results (covering around 20 % of 

=MEMO/08/548&format=HTML&aged=0&language=EN&
guiLanguage=en. See also the 2003 Berlin Declaration on 
Open Access to Knowledge in the Sciences and Humani-
ties, http://oa.mpg.de/openaccess-berlin/berlindeclaration.
html.

(111)  See http://creativecommons.org/licenses/by-nc-sa/2.0/uk/  

and http://www.bios.net/daisy/bios/home.html.

(112)  http://ec.europa.eu/research/science-society/document_ 

library/pdf_06/communication-022007_en.pdf.

(113)  http://ec.europa.eu/research/science-society/index.

cfm?fuseaction=public.topic&id=1680.

the €50 billion FP7 program budget) in areas such as 
health, energy, environment, social sciences and infor-
mation and communication technologies. The legal basis 
for the pilot project is the so-called special clause 39 on 
Open Access (114) adopted in August 2008 that requires a) 
deposit of an electronic copy (published version or final 
manuscript) in an institutional or subject-based reposi-
tory at moment of publication and b) best efforts to en-
sure that this electronic copy becomes available ‘open ac-
cess’ (freely and electronically available to anyone). (115)

2.1.1.  EU biosecurity policy frame

Either through an Open Access system or illegal action 
(such as biopiracy), access to DNA sequences and syn-
thetic biology models may raise biosecurity concerns. 
Concerns raised regarding safety have triggered impor-
tant legislation in the EU (116) as well as in the Council of 
Europe with the Convention on Cybercrime (Budapest, 
23.11.2001) as tools to ‘deter action directed against the 
confidentiality, integrity and availability of computer 
systems, networks and computer data as well as the mis-
use of such systems, networks and data’ at international 
level. Additionally, open access may apply to synthetic 
biology project results where information related to 
pathogenic and/or dangerous synthetic biology prod-
ucts are published.

Over the past ten to fifteen years, the threat of a terror-
ist group acquiring Chemical, Biological, Radiologi-
cal or Nuclear (CBRN) materials has led governments 
and international organisations to adopt far-reaching 
regulations (117) and programmes to defend populations 
against the associated risks. Tackling terrorist access to 
CBRN material is currently considered a key priority for 
the European Union. (118) This is acknowledged by the 

(114)  http://ec.europa.eu/research/press/2008/pdf/annex_1_

new_clauses.pdf.

(115)  http://ec.europa.eu/research/science-society/document_ 

library/pdf_06/ec-open-access-pilot-ppt_en.pdf.

(116)  Directive 2006/24/CE of the European Parliament and of 
the Council of 15 March 2006 on the retention of data gen-
erated or processed in connection with the provision of 
publicly available electronic communications services or of 
public communications networks and amending Directive 
2002/58/EC

(117)  Such as UN Security Council Resolution 1540.

(118)  The Council Conclusions of 6 December 2007 ‘addressing 
Chemical, biological, radiological and nuclear risks and on 
bio-preparedness’ provide the most recent EU-level over-
view of the ongoing activities.

31

2 | LEGAL, GOVERNANCE AND POLICY ASPECTS

European Union Counter-Terrorism Strategy adopted by 
the Council on 1 December 2005, and by the ‘EU Strat-
egy against proliferation of weapons of mass destruc-
tion and their means of delivery (WMD)’ adopted by the 
European Council on 12 December 2003. (119) In addition, 
the Council adopted specific Conclusions in 2007 that 
called for further EU level work on CBRN security. (120)

The Member States are responsible for protecting their 
citizens from CBRN threats by a host of different meas-
ures, and with the involvement of a wide range of author-
ities. The Ghent European Council of 2001 instigated the 
first steps in countering the CBRN threat at EU level, (121) 
followed by the adoption of the ‘Programme to improve 
cooperation in the European Union for preventing and 
limiting the consequences of chemical, biological, radio-
logical or nuclear terrorist threats’ in December 2002. (122) 
The Programme was superseded by the Council and 
Commission’s EU Solidarity Programme of 3 December 
2004 on the consequences of terrorist threats and at-
tacks, that extended, revised and replaced the 2002 
CBRN Programme following the attacks in Madrid on 
11 March 2004. (123) Aspects of the Solidarity Programme 
were included in the overall Strategy and Action Plan on 
Combating Terrorism established in 2005 after the Lon-
don attacks. (124) Whilst the responsibility for responding 
to CBRN incidents rests with the Member States, robust 
crisis management procedures and tools to support the 
Member States in the event of a crisis with cross-border 
implications have been developed at EU level. In order 
to prepare the current CBRN policy, in February 2008 
the Commission established a CBRN Task Force. The fi-
nal report of the Task Force was published in January 
2009 and contained 264 separate recommendations.  
On June 24 2009, (125) the Commission adopted an action 
plan defining the new EU CBRN policy. (126) The Action 

(119)  15708/03 and SN 400/03, no 68. See also infra, paragraph 7.

(120)  16589/07, of 17 December 2007.

(121)  SN 4292/01 REV 2.

(122)  14627/02.

(123)  15480/04.

(124)  14469/4/05, paras 20 and 31.

(125)  COM(2009)  273  final;  SEC(2009)  874;  SEC(2009)  790;  

SEC(2009) 791.

(126)  The EU CBRN Action Plan is not a legal instrument. There-
fore, immediate legal and budgetary consequences for the 
EU could only derive from possible future legal instruments 
implementing the Action Plan, which would be subject to 
separate prior impact assessment — including an assess-
ment of their impact on economic sectors and research 

Plan sets out three main areas of CBRN security work: 
1) Prevention — ensuring that unauthorised access to 
CBRN materials of concern is as difficult as possible; 
2) Detection — having the capability to detect CBRN 
materials in order to prevent or respond to CBRN inci-
dents; 3) Preparedness and response — being able to 
efficiently respond to incidents involving CBRN materials 
and recover from them as quickly as possible.

The most important part of current EU external rela-
tions policy related to the CBRN threat is the EU Strat-
egy against Proliferation of Weapons of Mass Destruc-
tion — also known as the EU WMD strategy, adopted 
in December 2003. This Strategy was recently updated 
and reviewed, resulting in the adoption by the Council 
of ‘New lines for action by the European Union in com-
bating the proliferation of weapons of mass destruction 
and their delivery systems’ in December 2008. (127) Is-
sues related to the threat of CBRN materials are also dis-
cussed in a significant number of international fora (128), 
and are dealt with by international organisations such 
as the International Atomic Energy Agency (IAEA), the 
Organisation for the Prevention of Chemical Weapons 
(OPCW), the BTWC Conference, Interpol and the Global 
Health Security Initiative (GHSI). In a more general sense, 
counter-terrorism efforts form part of many cooperation 
agreements in place or being negotiated between the 
EU and third countries. The Council decided in 2002 that 
a standard counter-terrorism clause should be inserted 
in all agreements with third countries. Additionally, since 
November 2003, WMD clauses have been inserted in all 
new or renewed mixed agreements now covering al-
most 100 countries. Work on CBRN issues with strategic 
partners, such as the United States, can be further de-
veloped based on the current policy package. From the 
public health perspective, the Commission will present a 
Communication on health security in 2009, outlining the 
internal and external aspects of health security.

environments and systematic and rigorous monitoring 
to ensure compatibility with the Charter of Fundamental 
Rights of the European Union.

(127)  17172/08, 17 December 2008.

(128)  Such as the Global Initiative to Counter Nuclear Terrorism 
(GICNT), and dual-use export control regimes such as the 
Nuclear Suppliers Group, the Wassenaar Arrangement, 
the Australia Group and the Missile Technology Control  
Regime.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

32

 
 
 
LEGAL, GOVERNANCE AND POLICY ASPECTS | 2

2.2.  Global provisions 

2.2.1.  WHO biosafety standards 

The World Health Organisation (WHO) published the 
first edition of the Laboratory bio-safety manual in 
1983. The manual encouraged countries to accept and 
implement basic concepts in biological safety and to 
develop national codes of practice for the safe han-
dling of pathogenic microorganisms in laboratories 
within their geographical borders. Since 1983, many 
countries have used the expert guidance provided in 
the manual to develop such codes of practice. Subse-
quent editions of the manual were published in 1993 
and in 2005. The last edition of the WHO bio-safety 
manual (129) stresses the importance of personal re-
sponsibility and addresses risk assessment, safe use 
of recombinant DNA technology and transport of in-
fectious materials. It also introduces biosecurity con-
cepts — the protection of microbiological assets from 
theft, loss or diversion, which could lead to the inap-
propriate use of these agents to harm public health. 

2.2.2.  The Cartagena Protocol

On 29 January 2000, the Conference of the Parties to 
the Convention on Biological Diversity adopted a sup-
plementary agreement to the Convention known as 
the Cartagena Protocol on Biosafety. (130) The Protocol 
seeks to protect biological diversity from the poten-
tial risks posed by living modified organisms resulting 
from modern biotechnology. It establishes an advance 
informed agreement (AIA) procedure for ensuring that 
countries are provided with the information neces-
sary to make informed decisions before agreeing to 
the import of such organisms into their territory. The 
Protocol contains a reference to the precautionary 
approach and reaffirms the precautionary language 
in Principle 15 of the Rio Declaration on Environment 
and Development. The Protocol also establishes a 
Biosafety Clearing House to facilitate the exchange 
of information on living modified organisms and to  
assist countries in the implementation of the Protocol. 
Countries shipping GMOs for intentional introduction 
into the environment will have to give prior notifica-
tion to the importing country that they are party to 
the Protocol under the Advance Informed Agreement 
(AIA) procedure if it is not intended for food, feed or 

processing and is the first such movement of that GMO 
between the countries. The notification must provide 
the information needed to enable the importing coun-
try to make informed decisions. The Protocol contains 
documentation requirements for shipments of GMOs 
and establishes a Biosafety Clearing House (BCH) to fa-
cilitate the exchange of information on GMOs and to 
assist countries in implementing the Protocol.

The Protocol is designed to protect biological diversity 
and human health from the potential risks arising from 
genetically modified organisms (GMOs) by providing 
a clear legal framework for transboundary movement. 
The Advanced Informed Agreement (AIA) procedure 
established by the Protocol will ensure that countries 
can make informed decisions on whether to import 
GMOs intended for introduction into the environment. 
To date, 153 instruments of ratification or accession 
have been deposited with the UN Secretary-General 
from the Parties to the Convention on Biological Di-
versity. The EU and all EU Member States have ratified 
the protocol. (131) (Regulation (EC) No 1946/2003 on 
transboundary movements of genetically modified or-
ganisms is the regulatory instrument that implements 
the provisions of the Cartagena Protocol on Biosafety 
within the European Union (132)). The risk assessment 
requirements of the Protocol are similar to those identi-
fied in the EU legislation identified earlier.

2.2.3.  World Trade Organisation (WTO) agreements 

and Trade-Related Aspects of Intellectual 
Property Rights (TRIPS)

The World Trade Organisation (WTO) has developed a 
multilateral system of trade to lower customs and trade 
barriers, and abolish discrimination in international trade. 
WTO agreements are the legal ground rules for interna-
tional commerce which were negotiated and signed by a 
large majority of the world’s trading nations and ratified 
by their parliaments. The General Agreement on Tariffs 
and Trade (GATT) and the Sanitary and Phytosanitary 
(SPS) agreement include measures that may be relevant 
for trading synthetic biology products.  

Most nations of the world are party to the World Trade 
Organisation. As part of their agreement to join the or-
ganisation, they have agreed and largely ratified all the 
component treaties of the General Agreements on Tar-

(129)  http://www.who.int/csr/resources/publications/biosafety/

(131)  http://www.cbd.int/biosafety/signinglist.shtml.

Biosafety7.pdf.

(132)  http://europa.eu/eur-lex /pri/en/oj/dat/2003/l_287/

(130)  http://www.cbd.int/biosafety/background.shtml.

l_28720031105en00010010.pdf.

33

2 | LEGAL, GOVERNANCE AND POLICY ASPECTS

iffs and Trade (GATT). The last successful round of trade 
negotiations culminated in all ratifying Member States 
endorsing all agreements in the WTO package under the 
‘single undertaking’. No opting out of individual treaties 
(over 17 in total) was allowed as they were to be ratified all 
at once. One of these is the TRIPS Agreement (Agreement 
on Trade-Related Aspects of Intellectual Property Rights). 
TRIPS provides for each country to institute a minimum 
set of laws protecting intellectual property, so that where 
inventors so wish, they may protect that which they have 
created or invented in any jurisdiction. Countries may not 
discriminate between domestic and international ‘crea-
tions’. (133)

A business has a competitive advantage if it develops, 
maintains and exploits its assets appropriately. These must 
include its intellectual property where it has an advantage 
over its competitors if it has information which it has not 
shared (secrecy) or where it has asserted rights that permit 
it to assure that others cannot use or copy without permis-
sion. A relatively new concept is that the portfolio of intel-
lectual property constitutes a currency that is negotiable 
for use in commercial or research interactions with others. 
Patents may then be used as such, without the intention 
to use them in advancing technology.  

The Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) agreement also contains a provision 
(Article 25(2)) allowing Member States to exclude from 
patentability inventions that are contrary to ordre public 
or morality or in order to protect human, plant or ani-
mal life, or in order to avoid serious detriment to the 
environment. (134)

(133)  TRIPS Article 27.1 provides that ‘…patents shall be available 
and patent rights enjoyable without discrimination as to 
the place of invention, the field of technology and whether 
products are imported or locally produced.’.

(134)  In the Patent Directive (98/44/EC) there are two major exclu-
sions from patentability: ‘ordre public’ and ‘morality’. Where 
the commercial exploitation or publication of the invention 
would be contrary to morality or affect ordre public, patent-
ability is excluded (not immoral experimentation leading 
to the invention). The TRIPS agreement permits exclusion 
on these grounds. There have been few exclusions on the 
grounds of morality, although Article 6(2) of the Patent 
Directive provides examples (stressing that these are non-
exhaustive) of possible ‘immoral’ inventions which shall 
be unpatentable: (a) processes for cloning human beings;  
(b) processes for modifying the germ line genetic identity of 
human beings; (c) uses of human embryos for industrial or 
commercial purposes; and (d) processes for modifying the 
genetic identity of animals which are likely to cause them 
suffering without any substantial medical benefit to man or 
animal, and also animals resulting from such processes.

In most jurisdiction, patents may only be granted if 
they meet specific criteria. They must be new, involve 
an inventive step and be susceptible of industrial ap-
plication and can be for processes, products or both.

1. 

2. 

3. 

‘An invention shall be considered to be new if it 
does not form part of the state of the art’ (135), which 
includes that which has been communicated to the 
‘public’ by oral or written means.

‘An invention shall be considered as involving an in-
ventive step if, having regard to the state of the art, 
it is not obvious to a person skilled in the art.’ (136) 

‘An invention shall be considered as susceptible of 
industrial application if it can be made or used in 
any kind of industry, including agriculture.’ (137)

2.2.4.  Convention on the Prohibition of the Develop-
ment, Production and Stockpiling of Bacterio-
logical (Biological) and Toxin Weapons and on 
Their Destruction  (138)

The Convention on the Prohibition of the Develop-
ment, Production and Stockpiling of Bacteriological 
(Biological) and Toxin Weapons and on Their Destruc-
tion — more commonly known as the Biological and 
Toxin Weapons Convention (BTWC) — was simultane-
ously opened for signature in Moscow, Washington 
and London on 10 April 1972 and entered into force 
on 26 March 1975. The Convention bans the develop-
ment, production, stockpiling, acquisition and reten-
tion of microbial or other biological agents or toxins, 
in types and in quantities that have no justification for 
prophylactic, protective or other peaceful purposes. It 
also bans weapons, equipment or means of delivery 
designed to use such agents or toxins for hostile pur-
poses or in armed conflict. The actual use of biological 
weapons is prohibited by the 1925 Geneva Protocol 
and Article VIII of the BTWC recognises that nothing 
contained in the Convention shall be construed as a 
derogation from the obligations contained in the Ge-
neva Protocol. As of November 2001, 162 states had 
signed the BTWC and 144 of these had ratified it. 

(135)  European Patent Convention, Article 54.

(136)  European Patent Convention, Article 56.

(137)  European Patent Convention Article 57.

(138)  http://www.opbw.org/.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

34

 
 
 
LEGAL, GOVERNANCE AND POLICY ASPECTS | 2

Article I defines the scope of the BTWC’s prohibition 
(the general purpose criterion). This includes all mi-
crobial and other biological agents or toxins and their 
means of delivery. Subsequent Review Conferences 
have reaffirmed that the general purpose criterion 
encompasses all future scientific and technological 
developments relevant to the Convention. The ob-
jects themselves (biological agents or toxins) are not 
prohibited, only their purpose. Permitted purposes are 
defined as prophylactic, protective and other peaceful 
purposes. The objects may not be retained in quanti-
ties that have no justification or which are inconsistent 
with the permitted purposes. Article IV requires States 
Parties to take any necessary national measures (e.g. 
passing national laws) to prohibit and prevent the mis-
use of biological agents, toxins, weapons, equipment 
and means of delivery within their territories. Only a 
small number of signatory states have implemented 
this provision. 155 countries have signed the BTWC, 
including all 27 EU Member States. However, the BWC 
includes no verification and enforcement mechanisms 
for preventing states from applying synthetic genom-
ics in this way, and many would argue that effective 
measures for that purpose are not feasible. The BTWC 
does not cover research for defensive measures and 
dual use considerations.

2.3. 

International Framework on ethics and 
human rights 

The Council of Europe Convention on Human Rights 
and Biomedicine (the Oviedo Convention) is legally 
binding for those States that have signed and ratified 
it (139). Other relevant documents (such as the UNESCO 
Declaration and the EU Charter of Fundamental Rights) 
are not legally binding, but have moral authority.

(a) In 1997 the Council of Europe adopted the Oviedo 
Convention — Convention on Human Rights and Bio-
medicine. Its main purpose is to protect individuals 
against exploitation arising from treatment or research. 
The articles on the purpose and object of the Conven-
tion state that the Parties ‘shall protect the dignity and 

(139)  Whilst the EU is party to the convention, many member 
states neither signed nor ratified and are therefore not Party 
to the Convention. These include Austria, Belgium, Germany, 
Malta, Ireland, and the United Kingdom. Finland, France, Ita-
ly, Latvia, Luxembourg and the Netherlands have signed but 
not ratified the Convention and others have indicated reser-
vations and declarations.  See http://www.jcvi.org/cms/file-
admin/site/research/projects/synthetic-genomics-report/
synthetic-genomics-report.pdf for detailed information.

identity of all human beings and guarantee everyone, 
without discrimination, respect for their integrity and 
other rights and fundamental freedoms with regard to 
the application of biology and medicine’. The Conven-
tion also concerns equitable access to health care, pro-
fessional standards, protection of genetic heritage and 
scientific research. The Convention is supplemented by 
a number of protocols. (140)

(b) The Universal Declaration on the Human Genome and 
Human Rights, adopted by the UNESCO General Confer-
ence in 1997 and subsequently endorsed by the United 
Nations General Assembly in 1998, deals with the human 
genome and human rights. Since the Declaration was 
drafted in 1997 it does not refer explicitly to synthetic bi-
ology, but modifications concerning DNA may fall within 
its scope. It states, among other things, that the ‘human 
genome underlies the fundamental unity of all members 
of the human family as well as the recognition of their in-
herent dignity and diversity’. The Declaration asserts that 
‘dignity makes it imperative not to reduce individuals to 
their genetic characteristics and to respect their unique-
ness and diversity’. Moreover, the Declaration prohibits 
financial gain from the human genome in its natural state, 
and affirms that the benefits of advances in the technolo-
gies should be made available to all, and that freedom of 
research is ‘necessary for the progress of knowledge’. 

The UNESCO Universal Declaration on Bioethics and Hu-
man Rights (adopted on 19 October 2005) also contains 
specific provisions on ethical issues related to medicine, 
life sciences and associated technologies and advocates 
several ethical principles, including human dignity, con-
sent, autonomy and responsibility, privacy, equity and 
justice, solidarity and benefit sharing. (141) The Declara-
tion is not legally binding, but is a reference point for the 
protection of human rights and ethics.

(c) The most recent version of the World Medical Asso-
ciation (WMA) Declaration of Helsinki, Ethical Principles 
for Medical Research Involving Human Subjects (142), was 
adopted by the 18th WMA General Assembly in Seoul in 
October 2008. The WMA Declarations of Geneva, Helsin-
ki and Tokyo clarify the duties and responsibilities of the 
medical profession to preserve and safeguard the health 

(140)  http://www.coe.int/t/e/legal_affairs/legal_cooperation/ 
bioethics/texts_and_documents/1Treaties_COE.asp#TopOfPage.

(141)  ht t p: //p o r t al .un e s co. o rg /shs /en / f il e _ d ow nl o a d . 
php/46133e1f4691e4c6e57566763d474a4dBioethics 
Declaration_EN.pdf.

(142)  http://www.wma.net/e/policy/b3.htm.

35

2 | LEGAL, GOVERNANCE AND POLICY ASPECTS

of the patient and to be dedicated to the service of hu-
manity. The Declaration advocates ethical principles for 
medical care. In its constitutive articles, the Declaration 
states that it is the duty of the physician to promote 
and safeguard the health of patients, including those 
involved in medical research. Concerning potential mili-
tary uses of medicine, the WMA adopted in October 1998 
(text amended by the WMA General Assembly, Seoul, Ko-
rea, October 2008) a Statement on Nuclear Weapons. (143) 
The WMA condemned the development, testing, pro-
duction, stockpiling, transfer, deployment, threat and 
use of nuclear weapons; asked all governments to refrain 
from the development, testing, production, stockpiling, 
transfer, deployment, threat and use of nuclear weapons 
and to work in good faith towards the elimination of 
nuclear weapons; and all National Medical Associations 
to join the WMA in supporting the Declaration and to 
urge their respective governments to work towards the 
elimination of nuclear weapons. All these principles, al-
though they address nuclear weapons, may also apply 
to other weapons, such as biological weapons.

(d) The European Charter of Fundamental Rights (144)  
emphasises that the Union is founded on the indivis-
ible and universal values of human dignity, freedom,  
equality and solidarity and on the principles of democ-
racy and the rule of law. It contributes to the preserva-
tion of these common values while respecting the di-
versity of the cultures and traditions of the peoples of 
Europe, as well as the national identities of the Member 
States and the organisation of their public authorities. 
The Charter formulates a common set of basic shared 
values at EU level. (145) Respect for human dignity, a ban 
on human reproductive cloning, respect for people’s 
autonomy, non-commercialisation of biological com-
ponents derived from the human body, prohibition of 
eugenic practices, protection of people’s privacy and the 
freedom of science are examples of values enshrined in 
the Charter, which was adopted at the Summit of Nice in 
2001 and is an integral part of the  Lisbon Treaty.

(143)  http://www.wma.net/e/policy/n7.htm.

(144)  Approved on 28 September 2000 and proclaimed by the 
European Parliament, the Council and the Commission on 
7 December 2000.

(145)  For example Article 1 (respect for human dignity), Article 3 
(ban on human reproductive cloning, respect for people’s 
autonomy, non-commercialisation of biological compo-
nents derived from the human body, prohibition of eugenic 
practices), Article 8 (data protection issues), Article 13 (free-
dom of science).

2.4.  Governance

Governance is an overarching concept including legal, 
political and ethical considerations. Since synthetic 
biology may result in major changes of traditional  
biology, governance needs to be reflected on all these 
levels, finally entering the legal sphere.

Governance of synthetic biology is being debated at 
EU and international level. Key issues relating to the 
governance of synthetic biology include, inter alia:  
1) definition of the actors to regulate synthetic biology 
as well as the governing principles to be promoted; 2) 
definition of the applications area of the identified gov-
ernance model (national, regional or international gov-
ernance); 3) definition of boundaries between synthetic 
biology and other technological fields that often interact 
in synthetic biology trials (nanotechnology; ICT; biotech-
nology; chemistry etc.); 4) definition of synthetic biology 
governance reflecting the complex heterogeneity of this 
technological sector; 5) definition of a governance of syn-
thetic biology in absence of specific target legislation (or 
regulation) on this technology sector; 6) definition of in-
terrelation between different regulatory systems (from 
protection of worker to environmental protection, from 
medical and pharmaceutical products to bio-security) 
that may conflict with one another; 7) definition of a gov-
ernance model where participative democratic processes 
are implemented etc.  This indicative list shows that a 
governance model in synthetic biology, like other emerg-
ing technologies, is difficult to define.  

The Group is aware that governance models should ad-
dress several dimensions of synthetic biology policy and 
activities, such as: political level (monitoring research 
and safety issues); ethical level: (monitoring ethical crite-
ria be properly implemented in each synthetic biology 
research sector); legal level (EU legislation and interna-
tional legislation or regulation including clarification of 
grey areas); professional level (self-regulation and codes 
of conduct); scientific level (justification of expected 
scientific results, priority setting, resource allocation); 
institutional level (risks  assessment; and implementing 
measures for risk management); societal level (public 
goods, citizens rights and liberties). The above compo-
nents are interconnected and the prevalence of one of 
them may distort the proper approach to synthetic biol-
ogy carried out in the EU and internationally.

Several models of governance of emerging technolo-
gies have been proposed, including synthetic biology. 
Governance models proposed by the Industry Associa-
tion for Synthetic Biology contemplate actions covering 

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

36

 
 
 
LEGAL, GOVERNANCE AND POLICY ASPECTS | 2

production, distribution and registration of potentially 
dangerous DNA sequences. Similar requests were indi-
cated in a report delineating options for governance 
that was authored by members of the J. Craig Venter 
Institute (146). 

The above soft law models are however confronted 
with the question of whether these regulatory at-
tempts should be sort a kind of self regulation for the 
actors of synthetic biology research (and then opening 
issues related to the legitimacy, credibility and public 
trust of the codes prepared by the scientific commu-
nity to be implemented by the scientific community 
itself (147)) or whether the addressees of such codes 
should be public authorities having power to imple-
ment and monitor them. Additional questions relate 
to the role the public should play in the policy design 
of governance of synthetic biology, with subsequent 
issues related to market opening and social desirabil-
ity of synthetic biology products. An editorial in Na-
ture asserted: ‘Self-governance need not and should 
not be exclusive – it does not preclude other forms of  
governance, any more than the possession of con-
science makes redundant the strictures of law.‘ (148) 

2.5.  Public involvement and science-society 

dialogue

Information, transparency and participation go hand in 
hand. Together, they create the sphere of trust that pro-

(146)  See: http://www.irgc.org/Synthetic-biology-genomics.html; 
Michele S. Garfinkel, Drew Endy, Gerald L. Epstein, and Robert M. 
Friedman, ‘Synthetic Genomics: Options for Governance,’ J. Craig 
Venter Institute, Center for Strategic and International Studies, and 
Massachusetts Institute of Technology, October 2007. Report avail-
able at www.jcvi.org.http://www.allacademic.com/one/www/re-
search/index.php?cmd=www_search&offset=0&limit=5&multi_
s earch _ s earch _ m o d e = p ub li c ati o n & mul ti _ s earch _ 
publication_fulltext_mod=fulltext&textfieldsubmit=true&sear
ch_module=multi_search&search=Search&search_field=title_
idx&fulltext_search=%3Cb%3EBioBricks+or+BioConflicts%3F
+Building+Public+Trust+in+European+Governance+of+Synt
hetic+Biology%3C%2Fb%3E&PHPSESSID=77e51dd113d65622-
bec5470855c62d05; http://www.jcvi.org/cms/fileadmin/site/
research/projects/synthetic-genomics-report/synthetic-ge-
nomics-report.pdf

(147)  A paper, detailing areas and ways in which oversight could be 
implemented by the scientific community, was dismissed as ‘in-
adequate’ by civil society organisations, who also raised concerns 
over scientists being allowed to act as ‘judge and jury’. See http://
www.etcgroup.org/upload/publication/pdf_file/602,, p46

(148)  Nature Editorial (2006) Policing ourselves Nature 441: 383.

vides the space for new technologies to be developed 
as part of a societal endeavour – and not against it.  

Research on the way the general public perceives risks 
of in particular new and emerging technologies show 
that certain risks will be perceived as more risky than 
others. Some risks might attract more than others the 
attention of the media and create headlines. Important 
factors include numbers and geographical distance: 
risks related to events and persons closer to us get 
more attention. Ethic and cultural factors also play an 
important role in the perception of risk. (149) This has a 
bearing on the perception of the risks of different pos-
sible applications of synthetic biology. The differences 
in risk perception between different ethnic groups and 
cultures have also been object of research.

In 2008 a first representative national survey (150) on 
public perception of synthetic biology was conducted 
in the USA showing that just over 30% of interview-
ees had already heard at all about synthetic biology. 
Notwithstanding this fact, 70% of respondents were 
ready to give their description on what they believed 
synthetic biology was and 66% expressed their opinion 
on the risk-benefit trade-off of the technology. In the 
EU, as the debate on GMOs has showed, proper involve-
ment of society in discussing synthetic biology appears 
to be of significant importance, according to the 2006 
Rathenau Institute paper (151). In different regions of the 
world, however, public discussions and consequently 
opinions are formed by various factors (152), with media 

(149)  See P. Slovic: The Perception of Risk. Earthscan 2000, and 
MacGregor, D.G., Finucane,M.L., & Gonzalez-Caban, A. (2008). 
The effects of risk perception and adaptation on health and 
safety interventions. In Martin, W.E., Raish, C. & Kent, B. (Eds.), 
Wildfire Risk: Human Perceptions and Management Implications 
(pp. 142-155). Washington, DC: Resources for the Future.

(150)  Hart Research Associates (2008), Awareness of and attitudes 
toward nanotechnology and synthetic biology. Available 
at: http://www.synbioproject.org/process/assets/files/6019/
hart_final_re8706b.pdf  

(151)  ‘Social and ethical issues will play an important role in the 
public and political acceptance of the technology’, De 
Vriend, Huib. Constructing Life. Early social reflections on the 
emerging field of synthetic biology. The Hague: Rathenau 
Institute; Working Document 97. Available at http://www.
rathenauinstituut.com/files/WED97%20Constructing%20
Life%202006.pdf 

(152)  There are two broad models for science communication:  
1) the deficit model and 2) the contextual or dialogue model. 
The deficit model is based on an educational objective with 
the underlying assumption being that people are relatively 
uninformed about science, and that providing information 

37

2 | LEGAL, GOVERNANCE AND POLICY ASPECTS

Source: Wodrow Wilson International Center for Scholars

playing an important role in making information avail-
able to and subsequently (co)shaping opinions of wide 
audiences. 

The media coverage of synthetic biology addresses 
the question of public legitimacy and support for syn-
thetic biology (153), with articles on synthetic biology 
regularly appearing in the press and popular science 
magazines (154). A 2008 study (155) analysed how synthetic 

on scientific facts and benefits by independent scientists 
will lead to more positive attitudes towards science. Its crit-
ics argue that it is an approach based on one-way traffic of 
information from the ‘informed’ scientists to the public. The 
emphasis of contextual model is on dialogue and two-way 
streams of information exchange. It can be conceptualised 
along two broad ideas, namely 1) the notion of scientific 
literacy, according to which knowledge and understanding 
are key to public support and 2) the importance of social 
context for public support, with trust issues being seen as 
more important for public support than the knowledge of 
scientific facts. Contextual model provides a means to set 
science in a social context which seems to be especially 
relevant for the field of biotechnology. For further infor-
mation see Osseweijer, Patricia: A Short History of Talking 
Biotech. Fifteen years of iterative research in institutionalis-
ing scientists’ engagement in public communication. Vrije 
Universiteit Amsterdam, 2006.

(153)  Joachim Boldt, Oliver Müller, Giovanni Maio, Synthetische 

Biologie, op.cit., pp. 104-107

(154)  COGEM  Report  CGM/080925-01,  pp.  25.  Available  at:  
http://www.cogem.net/ContentFiles/CGM080925-01- 
Biological%20machines1.pdf. See also http://ec.europa.eu/
european_group_ethics/docs/avis20_en.pdf 

(155)  See Eleonore Pauwels, Ioan Ifrim: Trends in American and 
European Press Coverage of Synthetic Biology. November 

biology had been introduced in the media looking at 
press coverage of synthetic biology in the USA and the 
EU between 2003 and 2008. In the US press 51% of arti-
cles focused on the potential benefits of synthetic biol-
ogy while in the EU press only 26% of articles addressed 
these. The EU press focused on biosafety and biosecurity 
issues as well as ethics and creation of life whilst in the 
USA the press focused primarily on biosecurity.

Public opinion has already been shaped regarding 
some of the governance issues, e.g. firm opposition 
to the so-called soft law for synthetic biology was ex-
pressed in the response of civil society to the declara-
tion on governance adopted by Second International 
Meeting on Synthetic Biology in 2006 (156). In parallel, 
the 2008 survey (157) on public perception of synthetic 
biology has showed that there is no public support for 
self-regulation of the industry in the synthetic biology 
field. The balance between potential risks and benefits 
seems to be the basis for public confidence in synthetic 
biology.

2008. Available at: http://www.synbioproject.org/process/
assets/files/5999/synbio1final.pdf

(156)  Synthetic Biology: scope, applications and implications. The 
Royal Academy of Engineering, 2009, pp. 45. Available at: 
http://www.raeng.org.uk/news/publications/list/reports/
Synthetic_biology.pdf 

(157)  Hart Research Associates (2008), Awareness of and attitudes 
toward nanotechnology and synthetic biology. Available 
at: http://www.synbioproject.org/process/assets/files/6019/
hart_final_re8706b.pdf 

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

38

 
 
 
ETHICAL ASPECTS | 3

3. 

Ethical Aspects

3.1.  General ethical aspects

Synthetic biology provides tools: (1) to improve our un-
derstanding of biological systems, their complexity and 
emergent properties that derive from the interaction of 
complex pathways (e.g. the minimal genome project) 
and methods; (2) to produce bio-products for different 
scientific, medical or market purposes (bio-remedies, 
bio-fuels, raw materials or biomedical tools (vaccines 
for example), or new bio-defence agents). 

The ethics of synthetic biology is part of an ongoing 
larger debate on the ethics of emerging technologies 
and biotechnologies. Issues addressed by the EGE in 
its recent Opinions on Nanomedicine (158) and ICT im-
plants into the human body (159) are therefore relevant 
to this Opinion.

3.1.1.  The EU’s fundamental ethical framework

As for other new technologies, the responsible develop-
ment of synthetic biology must be based on fundamental 
ethical principles that have been enshrined in the con-
ventions and declarations listed in the legal part (UN, 
UNESCO, Council of Europe and the Charter of Funda-
mental Rights). A consistent ethical framework is needed 
to undertake a thorough ethical analysis.

The Lisbon Treaty (160) states that ‘Human dignity is in-
violable. It must be respected and protected’ (Article II-61), 
goes on to explain that ‘The dignity of the human person 
is not only a fundamental right in itself but constitutes the 
real basis of fundamental rights’ (Declaration concerning 
the explanations relating to the Charter of Fundamental 
Rights). This explanation does not strictly define human 
dignity and so various writers have attempted to fill this 
gap. One such attempt (161) suggests that human dignity 
be defined as follows: ‘the exalted moral status which 
every being of human origin uniquely possesses. Human 
dignity is a given reality, intrinsic to human substance, and 
not contingent upon any functional capacities which vary in 

(158)  http://ec.europa.eu/european_group_ethics/activities/

docs/opinion_21_nano_en.pdf.

(159)  http://ec.europa.eu/european_group_ethics/docs/avis20_

en.pdf.

(160)  Official Journal of the European Union, Volume 47, C 310, 

pages. 1–482, 16 December 2004.

(161)  William Cheshire, Ethics and Medicine, Volume 18:2, 2002.

degree. (…) The possession of human dignity carries certain 
immutable moral obligations. These include, concerning the 
treatment of all other human beings, the duty to preserve life, 
liberty, and the security of persons, and concerning animals 
and nature, responsibilities of stewardship.’ This provides 
the basis for the following ethical principles, which are of 
direct relevance to this Opinion, where the general prin-
ciple of human dignity is the core of the ethics framework 
for synthetic biology. 

Bioethicists have often stated that the concept of dignity 
is vague and open to several interpretations. For example, 
as well as serving as a fundamental value, the principle of 
human dignity may be interpreted as a restrictive principle 
that protects human beings — who are principally vulner-
able to violent acts by others — against actions or prac-
tices that run the risk of treating human beings as mere 
‘objects’ of the interests of others to whose values they 
do not subscribe. D. Beyleveld and R. Brownsword define 
dignity ‘as a particular practical attitude to be cultivated in 
the face of human finitude and vulnerability (and, concomi-
tantly, the natural and social adversity that characterizes the 
human condition)’. (162) Dignity can be understood as an 
enabling principle that guarantees individual freedom 
of action and autonomy in decision-making. The Kan-
tian understanding of human dignity emphasises moral 
responsibility. A different view emphasises the need for 
individuals to consider the general effects their actions 
have on others, including other human beings, animals 
and the environment. Dignity is the basis for more specific 
principles, rights and obligations, and is closely connected 
to the principle of justice and solidarity. 

As far as the debate on the ethics of synthetic biology is 
concerned, the difficulty stems from the overlap of several 
methodologies in ethics, depending on the main appli-
cation fields. Although guiding principles have been es-
tablished for quite some time in the biomedical field and 
can be used as a starting point for the ethical analysis of 
synthetic biology biomedicine, the same does not apply 
to environmental ethics, agriculture, or biotechnology in 
general. Furthermore, synthetic biology raises fundamen-
tal questions:

1.  a conceptual analysis of life and nature ;

2.  an analysis of procedural principles that aim to se-
cure the freedom and autonomy of citizens with re-

(162)  Deryck Beyleveld and Roger Brownsword, Human Dignity 
in Bioethics and Biolaw, Introduction, p.2, Oxford University 
Press, Oxford-New York, 2001.

39

3 | ETHICAL ASPECTS

gard to the development of synthetic biology, such 
as transparency and access to information, demo-
cratic participation in fundamental issues of science 
and research and the principle of accountability and 
responsibility;

used to address the ethics of synthetic biology therefore 
needs to be ethically analysed in order to provide critical 
answers to questions concerning the difference between 
life and non-life  (167) or between the natural and the ar-
tificial.

3.  an analysis of substantial principles, depending on 

the different fields and applications. 

3.1.2.  Conceptual-ethical issues

The debate on synthetic biology addresses issues con-
cerning or related to the ethical legitimacy of manufac-
turing living organisms. Some have advocated the ethical  
legitimacy of fabricating life (163) while critics have ex-
pressed serious concerns about the radical nature of this 
intervention.  

In 1999, a group of bioethicists studied Venter’s goal to 
fabricate a minimal genome organism. (164) They argued 
that the prospect of constructing minimal and new ge-
nomes did not violate fundamental moral precepts or 
boundaries, but did raise questions about the possible 
consequences of synthesising new free-living organisms 
in relation to the concept of life and our relation to it. 
(165) 

The concept of life has many interpretations according to 
the theoretical context in which it is used. Thought must 
be given to the terminology used to discuss ethical as-
pects of synthetic biology and its products, for instance, 
‘artificial cells,’ or ‘living machines’. (166) The terminology 

(163)  John Harris, ‘Who’s Afraid of a Synthetic Human?’ The Times, 
May 17, 2008. Colin Nickerson, ‘A Quest to Create Life Out of 
Synthetics,’ Boston Globe, April 2, 2008. Erik Parens, ‘Making 
Cells Like Computers,’ Boston Globe, February 18, 2008. Na-
talie Angier, ‘Pursuing Synthetic Life, Dazzled by Reality,’ New 
York Times, February 5, 2008.

(164)  Cho MK, Magnus D, Caplan AL et al. (1999) Ethical considerations 
in synthesising a minimal genome, Science, 286: 2087–90.

(165)  The Roman Catholic Church has asserted that ‘the human 
person does not commit an illicit act when, out of respect 
for the order, beauty and usefulness of individual living be-
ings and their function in the ecosystem, he intervenes by 
modifying some of their characteristics or properties’. How-
ever, the Roman Catholic Church has also made a strong 
appeal for responsibility in this endeavour. See http://www.
vatican.va/roman_curia/pontifical_councils/justpeace/
documents/rc_pc_justpeace_doc_20060526_compendio-
dott-soc_en.html, Article 473.

(166)  See Joachim Boldt, Oliver Müller, Giovanni Maio: Synthetische 
Biologie. Eine ethisch-philosophische Analyse. Eidgenössische 
Ethikkommission für die Biotechnologie im Ausserhumanbereich 

‘Life’ is the condition which distinguishes active organisms 
from inorganic matter, including the capacity for growth, 
functional activity and continual change preceding death. 
(168) A living organism can be seen as having a number of 
capacities that differentiate it from inorganic matter, such 
as metabolism, homeostasis, capacity to grow, reproduce 
and, through natural selection, adapt to its environment 
over successive generations. The concept of ‘life’ has also 
been addressed by several non-biological disciplines. 

The distinction between life in a biological sense and its 
use in a social context is particularly relevant. (169) Some 
languages, such as Greek, have two words for this distinc-
tion, namely zoe and bios. Zoe applies to life processes 
common to all living beings, while bios refers to human 

EKAH, Bern 2009. See also Nagel T. (1973) Mortal questions 
Cambridge University. Press; Nozick R (1981) Philosophical 
Explanations, Oxford University Press; Olson E. (1997) The Hu-
man Animal Personal Identity Without Psychology, Oxford 
University Press; Parfit D. (1984) Reasons and persons, Oxford 
University Press; Williams B. (1973) Problems of the self, Cam-
bridge University Press; Wilson J. (1999) Biological Individual-
ity Cambridge University Press; Salvi. M (2002) Rationalising 
individuality : the notion of individuality in biology, philoso-
phy, (bio)ethics. Maastricht University Press, 300

(167)  See Arjun Bhutkar: Synthetic Biology: Navigating the Challenges 
ahead. Journal of Biolaw & Business, Vol. 8, No2, 2005: ‘One of 
the main ethical concerns is drawing a distinction between 
an engineered machine and a living organism. Building a 
synthetic biological system from scratch or a [sic] construct-
ing a minimal genome raises the question of the difference 
between life and nonlife.’ (p. 26) (http://www.synbiosafe.eu/
uploads/pdf/Bhutkar_Synthetic%20Biology_Navigating%20
the%20Challenges%20Ahead.pdf).

(168)  The American Heritage Dictionary of the English Language, 
4th edition, published by Houghton Mifflin Company, via  
Answers.com: ‘The property or quality that distinguishes living 
organisms from dead organisms and inanimate matter, mani-
fested in functions such as metabolism, growth, reproduc-
tion, and response to stimuli or adaptation to the environment 
originating from within the organism.’ ‘The characteristic state 
or condition of a living organism.’

(169)  For a thorough analysis of life concepts, see for instance: Hans 
Werner Ingensiep: Lebensbegriffe — der Vergangenheit, der Ge-
genwart, der Zukunft. In: H.W. Ingensiep and Anne Eusterschulte 
(Eds.): Philosophie der natürlichen Mitwelt. Festschrift für Klaus 
Michael Meyer-Abich. Würzburg 2002, pp. 103-119. See also:  
Sarah Franklin: Life. In: Warren Thomas Reich (Ed.): Encyclopedia 
of Bioethics. Revised Ed. Vol. 3, New York 1995, pp. 1345-1352.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

40

 
 
 
ETHICAL ASPECTS | 3

life in its social and cultural dimension. (170)  This distinc-
tion is echoed today in the two semantic perspectives 
we can address human life: firstly, as bodies-as-objects 
(having a body that is linked to all living beings), and sec-
ondly, as embodied beings (being a body, linked to the 
individual and irreducible experience of a self). (171) In the 
light of this, some bioethicists have advocated that from 
an ethical point of view, the human body should not be 
reduced to the concept of life proper to biosciences and 
biotechnology since it is also an expression of our social 
and cultural life deserving particular care and respect, 
which are at the core of the concept of human dignity. 
Some authors give zoe primacy over bios. (172) But this 
conceptual distinction does not necessarily advocate a 
hierarchy. From an ethical point of view, it is crucial to see 
that morality (accountability and responsibility) is con-
nected to humans’ specific capacity to decide upon the 
course of their actions. 

The first reports on synthetic biology raise the question 
whether synthetic biology opens up radically new ways 
of fabricating life, and as a side-effect will change how we 
conceive of ourselves: 

The production and/or modification of simple living or-
ganisms and their potential use to fabricate more com-

(170)  See P. Hadot, H. Hübner, J. Vennebusch, R. Piepmeier, U. Dierse, 
K. Rothe, R. Toellner: Art. Leben. In J. Ritter and K. Gründer 
(Eds.): Historisches Wörterbuch der Philosophie, Darmstadt 1980, 
Vol. 5, pp. 52-103. See Martin G. Weiß (Ed.): Bios und Zoe. Die 
menschliche Natur im Zeitalter ihrer technischen Reproduzier-
barkeit Frankfurt am Main 2009. See also Nicole C. Karafyllis 
(Ed.): Biofakte. Versuch über den Menschen zwischen Artefakt und 
Lebewesen, Paderborn 2003. The concept of ‘biofact’ is am-
biguous if one makes a difference between zoe and bios. Prod-
ucts of synthetic biology are (until now) zoofacts. For a thor-
ough analysis of life concepts, see for instance: Hans Werner 
Ingensiep: Lebensbegriffe — der Vergangenheit, der Gegenwart, 
der Zukunft. In: H.W. Ingensiep and Anne Eusterschulte (Eds.): 
Philosophie der natürlichen Mitwelt. Festschrift für Klaus Michael 
Meyer-Abich, Würzburg 2002, pp. 103-119. See also: Sarah Frank-
lin: Life. In: Warren Thomas Reich (Ed.): Encyclopedia of Bioethics. 
Revised Ed. Vol. 3, New York 1995, pp. 1345-1352 and Andreas 
Brenner: Leben. Eine philosophische Untersuchung. Beiträge zur 
Ethik und Biotechnologie, 3, Eidgenössische Ethikkommission für 
die Biotechnologie (Hrsg.), Bern 2007.

(171)  See Matthias Gutmann: Biologie und Lebenswelt. In: Ulrich 
Krohs, Georg Toepfer (Eds.): Philosophie der Biologie, Frankfurt 
am Main 2006, pp. 400-417. See also Simon Springmann, As-
mus Trautsch (Hrsg./Eds.): Was ist Leben? Festgabe für Volker 
Gerhardt zum 65. Geburtstag. Berlin  2009

(172)  See Martin G. Weiß (Ed.): Bios und Zoe. Die menschliche Natur im 
Zeitalter ihrer technischen Reproduzierbarkeit. Frankfurt am Main 
2009.

plex ones raises the questions as to how far we want to 
assign a mere instrumental value of such organisms and 
our relation to the biosphere itself. (173) In this regard, the 
ethics of synthetic biology, addressed within the frame-
work of ecological ethics, raises questions of uncertainty, 
potentiality, and complexity. (174)

There are many different approaches to environmental 
ethics, mostly grouped as ‘anthropocentric’, ‘biocentric’, 
and ‘ecocentric’. The EGE described the ethical debate on 
eco-centric theories in its Opinion on Modern develop-
ments in agriculture technology (175). It is important to 
underline that such theories have advocated the intrinsic 
value of the biosphere or the ethical dimension of nature. 
(176) Eco-centric environmental ethics questions the tradi-
tional ethics of rights and obligations, and asks instead in 
what kind of world we may wish to live in. Taken as such, 
ecological ethics advocates the change of traditional, if 
not modern values and goals at individual, national and 
global levels, and integrate the protection of the envi-
ronment in a new view towards human beings, life, and 
nature. 

Eco-centric  theories  apply  to  the  use  of  synthetic  
biology to manufacture or modify life forms, as well as 
ecological considerations for synthetic biology in envi-
ronmental protection. The relevance of such arguments 
should be considered in relation to uses of synthetic bi-
ology, although some theories of eco-centric ethics may 
intrinsically oppose synthetic biology when interacting 
with existing life forms or when (in a futuristic and hypo-
thetical sense) synthesising complex organisms. 

Anthropocentric theories, on the contrary, justify making 
instrumental use of nature for human purposes, although 
it is underlined that there are limits to human activities 
affecting the environment because they may damage the 
well-being of human beings now and in the future, since 

(173)  See Richard Maxwell, Toby Miller: Ecological Ethics and Me-
dia Technology. International Journal of Communication, 2 
(2008), 331-353. (http://ijoc.org/ojs/index.php/ijoc/article/
viewFile/320/151).

(174)  See Margaret Sommerville: Creating the ethics of synthetic biol-

ogy, Ottawa Citizen, June 14, 2007.
http://www2.canada.com/ottawacitizen/news/opinion/story.
html?id=936d1e43-3dc3-48a2-bee5-b3164f6f4517.

(175)  http://ec.europa.eu/european_group_ethics/docs/ 

opinion24_en.pdf

(176)  Rachel Carson, ‘Silent Spring’ (1963), which brought together 
a number of essays published earlier in the New Yorker maga-
zine giving details of how pesticides, such as DDT, aldrin and 
dieldrin, concentrated along the food chain.

41

 
3 | ETHICAL ASPECTS

our well-being is essentially dependent on a sustainable 
environment. (177) Anthropocentric ethics argues strongly 
that humans ought to be at the centre of our attention 
and that it is right for them to be so. Anthropocentric 
approaches to synthetic biology focus much more on 
consequential considerations and issues related to po-
tential consequences from the use of synthetic biology 
for human beings (risk assessment and management and 
hazard considerations (178)). Where do we draw the line 
between what is certain, what could be certain and what 
remains, at least for the time being, uncertain? 

3.2.  Specific ethical issues

Specific ethical issues raised by synthetic biology 
concern its potential applications in the fields of bio-
medicine, biopharmaceuticals, chemicals, environment 
and energy and the production of smart materials and 
biomaterials, particularly but not exclusively from the 
viewpoint of bio-safety and biosecurity.  (179) In addi-
tion, there have been discussions on aspects of risk 
governance, justice, public perception, intellectual 
property and co-modification. Synthetic biology raises 
issues of the governance of human practices related 
to scientific, technological, economic, political and 
cultural agents, no less than issues of security and or-
ganisational forms. (180)  

3.2.1.  Biosafety

Unexpected interactions between synthetic micro-
organisms and the environment or other organisms 
produce risks to the environment and public health. 

(177)  See Bookchin, M. 1990. The Philosophy of Social Ecology, Mon-
treal: Black Rose Books.; Norton, B., Hutchins, M., Stevens, E. and 
Maple, T. L. (eds) 1995. Ethics on the Ark, Washington: Smithso-
nian Institution Press.; Passmore, J. 1974. Man’s Responsibility for 
Nature, London: Duckworth, 2nd ed., 1980

(178)  See Antoine Danchin: Nature and Artifice, 2009. In: http://www.

normalesup.org/~adanchin/causeries/Nature.html.

(179)  See Andrew Balmer & Paul Martin: Synthetic Biology. Social and 
Ethical Challenges, May 2008. http://www.bbsrc.ac.uk/publica-
tions/corporate/synthetic_biology.pdf .

(180)  See Markus Schmidt, Helge Togersen, Agomoni Ganguli-Mitra, 
Alexander Kelle, Anna Deplazes, Nikola Biller-Andorno: SYN-
BIOSAFE e-conference: online community discussion on the 
societal aspects of synthetic biology. In Systems and Synthetic 
Biology (2008) September 16. Online at: http://www.zora.uzh.
ch/3947/2/Schmidt_m_torg.V.pdf. 
Paul Rabinow & Gaymon Bennett: From Bio-Ethics to Human 
Practice. Working Paper # 11, 2007 http://anthropos-lab.net/
wp/publications/2007/08/workingpaperno11.pdf.

The risks have to be addressed in order to use syn-
thetic biology responsibly. Synthetic microorganisms 
released into the environment could initiate proc-
esses of horizontal gene transfer and affect biotic bal-
ances, or evolve beyond their functionality and elicit 
unprecedented side-effects on the environment and 
other organisms. (181) Synthetic biology products must 
therefore address bio-safety issues when they have 
consequences for ecology and human health. 

In the EU, the protection of human health is a key condi-
tion for the marketing of products resulting from syn-
thetic biology, as with any other technology. Risk assess-
ment procedures and methods have been established 
to safeguard this principle and include precaution, but 
long-term health-related risks associated with the eco-
logical effects of synthetic biology are hard to predict. 

As identified in the EGE Opinion on nanomedicine, 
which addresses analogous issues on the potential 
health impact of nano-pollutants, risk assessments 
used for synthetic biology are designed not only as 
a technical tool for the safe governance of synthetic 
biology in order to protect human dignity and the au-
tonomy of persons directly (medical applications) or 
indirectly (exposure to synthetic biology products if 
released into the environment). 

Similar considerations apply to environmental protec-
tion, where the precautionary principle plays a key role 
in EU policy design. The Nuffield Council on Bioethics’ 
follow-up discussion paper, The Use of Genetically Modi-
fied Crops in Developing Countries, (182) stressed the pos-
sible interpretation of the precautionary principle and 
its application in the governance of biotechnology. 

The precautionary principle requires:

a)  that there are serious and irreversible risks,

b)  a shift of the burden of proof from those poten-
tially exposed to the hazards of a new technology 
to those who want to introduce it.  (183)

(181)  Nuffield Council background paper (2009).

(182)  See http://www.nuffieldbioethics.org/fileLibrary/pdf/GM_

Crops_Discussion_Paper_2004.pdf.

(183)  The Commission Communication of February 2000 states that: 
‘The precautionary principle is not defined in the Treaty, which 
prescribes it only once — to protect the environment. But 
in practice, its scope is much wider, and specifically where 
preliminary objective scientific evaluation indicates that there 

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

42

 
 
 
 
ETHICAL ASPECTS | 3

According to the European Commission, the precaution-
ary principle is a dynamic tool to follow developments 
in a sector and continuously verify that the conditions 
for the acceptability of a given innovation are fulfilled — 
thereby improving governance. The precautionary prin-
ciple does not, however, require refraining from action, 
as this may also involve risks, namely the risk of major 
environmental threats due to global pollution. For syn-
thetically produced organisms, the precautionary prin-
ciple is an important part of sound ethical debate and 
of legal, regulatory and political decisions. 

An additional concern has to do with the dangers of 
potentially harmful organisms being inadvertently re-
leased during the experimental phase. Existing regu-
lations in Europe contemplate these possibilities and 
different levels of confinement are defined, including 
a register for activities posing no risk for human health 
or the environment. In some cases these regulations 
may seem to contradict the freedom to use any avail-
able knowledge or tool for research or even recreation 
e.g. “bio-hackers”. Freedom of research cannot be in-
voked if serious or irreversible risks to human health 
or the environment may occur. Existing regulations do 
not consider exceptions for such activities. In order to 
address some of the concerns regarding the safety of 
synthetic organisms (including protocells) suggestions 
have been made to assure that they are contained.  This 
includes the traditional physical containment and disa-
bling of the organisms in some way so as to ensure they 
cannot survive if accidentally or incidentally introduced 
into the environment.

3.2.2.  Biosecurity

Ethical issues arise particularly from dangers of using 
synthetic lethal and virulent pathogens for terrorist  
attacks, bio-war, or maleficent uses (‘garage terrorism’, 
‘bio-hacking’), particularly if knowledge and skills on how 
to produce such pathogens are freely available. (184) Ap-
plications of synthetic biology for such purposes include 
the production of biological weapons, such as new and/

are reasonable grounds for concern that the potentially dan-
gerous effects on the environment, human, animal or plant 
health may be inconsistent with the high level of protection 
chosen for the Community’ (Communication Summary, para-
graph 3). http://ec.europa.eu/dgs/health_consumer/library/
pub/pub07_en.pdf.

(184)  See the Report on the workshop Technical solutions for bio-
security in synthetic biology held on April 03rd, 2008 in Munich, 
Dr Hubert Bernauer et al., IASB (Industry Association Biology) 
http://ia-sb.eu.

or modified pathogenic viruses or bacteria (185) as well 
as synthetic organisms engineered to produce toxins. 
The literature on bio-war and the use of bioengineering 
for bio-defense, bio-offence and terrorism shows the 
potential of this technology, which may be amplified by 
synthetic biology. (186)  

This applies to the potential risks associated with the use 
of dangerous bio-material produced in governmental 
bio-defence laboratories as well as by terrorists. Given 
the present state of knowledge, the design and produc-
tion of entirely novel pathogens for terrorist and/or ma-
leficent uses may seem unlikely. There are technological 
difficulties and resources involved in producing existing 
and novel pathogens, and developing them into weap-
ons. But states can mobilise resources and dangerous 
material can be obtained easily over the Internet or in 
other ways. (187) The ability to carry out DNA synthesis is 

(185)  The list of diseases considered for weaponisation, or known to 
be weaponised include anthrax, ebola, Marburg virus, plague, 
cholera, tularemia, brucellosis, Q fever, machupo, Coccidio-
ides mycosis, Glanders, Melioidosis, Shigella, Rocky Mountain 
spotted fever, typhus, Psittacosis, yellow fever, Japanese B en-
cephalitis, Rift Valley fever and smallpox (in addition naturally-
occurring toxins that can be used as weapons include ricin, 
SEB, botulism toxin, saxitoxin and many mycotoxins).

(186)  See: Alibek, K. and S. Handelman. Biohazard: The Chilling True 
Story of the Largest Covert Biological Weapons Program in the 
World – Told from Inside by the Man Who Ran it. Delta (2000) 
ISBN 0-385-33496-6; Crosby, Alfred W., Ecological Imperialism: 
The Biological Expansion of Europe, 900-1900 (New York, 1986); 
Endicott, Stephen and Edward Hagerman, The United States and 
Biological Warfare: Secrets from the Early Cold War and Korea, Indi-
ana University Press (1998). ISBN 0253334721; Keith, Jim (1999), 
Biowarfare In America, Illuminet Press, ISBN 1-881532-21-6; Man-
gold, Tom and Goldberg, Jeff (1999), Plague Wars: a true story 
of biological warfare, Macmillan, London, ISBN 0-333-71614-0; 
Orent, Wendy (2004), Plague, The Mysterious Past and Terrifying 
Future of the World’s Most Dangerous Disease, Simon & Schuster, 
Inc., New York, NY, ISBN 0-7432-3685-8: Preston, Richard (2002), 
The Demon in the Freezer, New York: Random House; Woods, Lt 
Col Jon B. (ed.), USAMRIID’s Medical Management of Biological 
Casualties Handbook, 6th edition, U.S. Army Medical Institute 
of Infectious Diseases, Fort Detrick, Maryland (April 2005).

(187)  According to the Nuffield Council paper on synthetic biology 
(2009) ‘In 2006, a journalist for the Guardian newspaper dem-
onstrated a lack of DNA supply regulation by ordering DNA 
sequences of the small pox virus and having them delivered 
to his home (See http://www.guardian.co.uk/science/2006/
jun/14/weaponstechnology.uk). The same journalist investi-
gated three UK sequencing companies and found that one 
did not screen either customers or the sequences ordered. 
The second screened only customers, and the third screened 
customers and had carried out a pilot study on screening se-
quence orders. In addition, it has been suggested that the 
actual publishing of how the polio virus was synthesised, and 

43

3 | ETHICAL ASPECTS

no longer confined to an elite group of scientists, as was 
the case for the first several decades of research using 
recombinant DNA. Now, anyone with a laptop computer 
can access public DNA sequence databases via the Inter-
net, access free DNA design software, and place an order 
for synthesised DNA for delivery. Therefore there are valid 
reasons for taking the bio-security of synthetic biology 
seriously. (188) Given this inherent dual-use risk, design-
ing ways to impede the malicious use of the technology, 
while at the same time not impeding, or even promoting, 
beneficial uses poses a number of ethical challenges. 

Concerns over bio-terrorism have also prompted in-
creased debate about whether or not ‘dual-use’ life sci-
ence discoveries with implications for developing bio-
weapons should be subject to a publishing ban. Much 
of this debate has focused on two particular studies: the 
genetic engineering of vaccine-resistant mousepox and 
the artificial synthesis of the polio virus. Proponents of 
a ban complain that publishing studies like these alerts 
would-be bio-terrorists to possibilities and provides them 
with explicit instructions for producing biological weap-
ons. On the other hand, publishing such studies can yield 
benefits for medicine or bio-defence. Issues related to the 
freedom of science and censorship emerge, including the 
process of censorship decision-making applicable to the 

the sequence and synthesis of the Spanish flu virus, could 
provide bioterrorists with the necessary information to engi-
neer their own pathogenic organisms. Coupled with this is the 
availability of DNA synthesisers, which can be purchased from 
registered manufacturers or increasingly on second-hand auc-
tion sites such as eBay.

(188)  Alexander Kelle: Synthetic Biology & Biosecurity in Europe. 
2009. M. Schmidt, A. Ganguli-Mitra, A. Kelle, H. deVriend (Eds.): 
Synthetic Biology. The Technoscience and its Societal Conse-
quences, Springer 2009. See also: Synthetics: the Ethics of Syn-
thetic Biology. In: IDEA League Summer School, August 2007, 
The Netherlands. http://www.ethicsandtechnology.eu/im-
ages/uploads/Ethics_of_synthetic_biology.pdf; H. deVriend: 
Constructing Life; Early social reflections on the emerging 
field of synthetic biology, The Hague. Rathenau Institute. 
Working Document 97 (2006); S. Miller and M. Selgelid: Ethi-
cal and philosophical consideration of the Dual-use dilemma 
in the biological sciences. Centre for Applied Philosophy and 
Public Ethics, Australian National University and Charles Sturt 
University, Canberra, Australia (2006). Committee on Research 
Standards and Practices to Prevent the Destructive Application 
of Biotechnology, Biotechnology Research in an Age of Bioter-
rorism, National Academies Press, 2004. National Science Ad-
visory Board for Biosecurity, ‘Addressing Biosecurity Concerns 
Related to the Synthesis of Select Agents,’ December 2006. 
Report available at www.biosecurityboard.gov. Jonathan B. 
Tucker and Raymond A. Zilinskas, ‘The Promise and Perils of 
Synthetic Biology,’ The New Atlantis, Spring 2006.

publishing of scientific results that may have a use for 
virulent pathogenic product production. 

Due to the cost and analytical sophistication needed for 
synthesis, there are relatively few companies that synthe-
sise long sequences of DNA. There have been suggestions 
that these companies screen all sequences for toxicity or 
infectivity before processing an order. That implies that 
databases of toxic or infective DNA sequences are avail-
able. These databases would of necessity fall within the 
ambit of the Database Directive (189). Regulation should 
ensure that all necessary information is readily available 
to these companies to permit the required searches. If the 
copyright protection provided for databases restricts ac-
cess to the information necessary Article 6(2)(c) or Article 
9(c) should be invoked to ensure that these companies 
are able to track possible dangerous sequences before 
synthesis. There is software available from CRAIC (190) 
termed ’BlackWatch’ for the purpose of tracking DNA se-
quence synthesis which may be hazardous. The software 
is open-source (for the first generation). A new genera-
tion of the software is being developed in USA (191), able 
to address the 15 million orders a month worldwide that 
are expected by 2012 (192). There are many questions that 
need to be addressed so as to ensure that the system 
works, including; 1) Support for the development and 
maintenance of open source software; 2) Assistance for 
companies (particularly SMEs) to ensure involvement 
and compliance; 3) Mechanisms for reduction of cost to 
small companies involved in synthesising DNA; 4) Mecha-
nisms for reporting to Competent Authorities where it is 
likely that the companies will not synthesise a particular 
sequence; 5) Mechanisms for ensuring privacy and iden-
tifying the chain of responsibility for placing particular 
sequences in the database(s) and identifying them as 
potentially harmful.

3.2.3.  Justice 

The EGE Opinion on ethics of agriculture technologies 
analysed the principle of justice. (193) It stated that cur-

(189)  Directive 96/9/EC of the European Parliament and of the Coun-
cil of 11 March 1996 on the legal protection of databases

(190)  https://biotech.craic.com/blackwatch/introduction.html

(191)  Bernauer, Hubert. ‘Technical solutions for biosecurity in syn-
thetic biology’ (2008). http://www.synbiosafe.eu/uploads/pdf/
iasb_report_biosecurity_syntheticbiology.pdf.

(192)  ‘DOTS - DNA Order Tracking System.’ http://www.mitre.org/

news/digest/advanced_research/02_09/genes.html

(193)  http://ec.europa.eu/european_group_ethics/docs/ 

opinion24_en.pdf.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

44

 
 
 
ETHICAL ASPECTS | 3

rent discussions on the concept of justice emerged 
from the philosophical debate on the relationship be-
tween the State and citizens, particularly distributive 
justice (J. Rawls (194) and its critics) but also concerns 
the role of the State in protecting and advancing hu-
man rights. The principle of justice is therefore key to 
the ethics of synthetic biology. The global justice dis-
course affects issues of technology divide and common 
heritage, the question of inter-generational justice, (195)  
with implications for preserving the environment and 
natural resources for future generations (e.g., human 
intervention in the environment and biotic balances, 
intentional or unintentional release into the environ-
ment of synthetic products, bio-remedies, synthetic 
biology biofuels). The relationship between citizens’ 
fundamental rights concerning the state of nature and 
the concept of a social contract affecting the actions 
of leaders against the desires of citizens (bio-security, 
bio-war, restriction in open access etc.) also needs to 
be addressed. 

3.2.4.  Intellectual Property 

Synthetic biology provides a new set of tools for using 
biology, either for the purpose of pure research with 
an intention to understand the manner in which living 
systems have developed, including their interactions, 
or for producing new processes or products. An argu-
ment has developed as to whether all or some of the 

(194)  Rawls develops what he claims are principles of justice by us-
ing an entirely and deliberately artificial device which he calls 
the ‘original position’, in which everyone decides principles of 
justice from behind a ‘veil of ignorance’. Rawls claims that all 
those in the original position would adopt a maximin strategy 
which would maximise the position of the least well-off. Rawls 
claims that parties in the original position would adopt two 
such principles, which would then govern the assignment of 
rights and duties and regulate the distribution of social and 
economic advantages across society (Rawls, 1971).

(195)  See Rawls (1971 and 1991), D. Parfit (1987), Partridge (1981) 
and Miller and Kumar (2007). See also Dobson, Andrew (ed.), 
‘Fairness and Futurity. Essays on Environmental Sustainability’, 
Oxford University Press (1999); E. Agius, ‘Towards a Relational 
Theory of Intergenerational Ethics’, in Bijdragen 50 (1989) 293-
313; Miller, Jon and Rahul Kumar (eds.), ‘Reparations. Interdis-
ciplinary Inquiries’ (2007), Oxford University Press; Partridge, 
Ernest (ed.), ‘Responsibilities to Future Generations. Environmen-
tal Ethics’, New York: Prometheus Books (1981); Ryberg, Jes-
per and Torbjön Tännsjö (eds.), ‘The Repugnant Conclusion’, 
Essays on Population Ethics, Dordrecht, Boston and London; 
Sikora, R.I. (2004) and Brian Barry (ed.), ‘Obligations to Future 
Generations’, Philadelphia: Temple University Press (1978). See 
http://plato.stanford.edu/entries/justice-intergenerational/ 
#Bib.

fruits of synthetic biology should be patentable, for the 
commercial benefit of those who have ‘invented’ the 
processes or products.

Many argue that patenting is an essential part of the 
protection of scientific endeavour. A recent paper on 
‘Inventing Biological Organisms: A Reader of Selected 
Articles’ states the case succinctly: ‘The ability to pat-
ent biological inventions is central to protecting sci-
entists’ work… What can be patented, for how long, 
and the extent of global protection are critical issues. 
However, patenting biological organisms, particularly 
human genes and other human parts, is controversial. 
Economists question whether patenting is the quickest 
and best way to diffuse new knowledge throughout 
the marketplace. Some bioethicists question whether 
genetic information is the common heritage of man-
kind, making gene patenting inappropriate’. (196) Previ-
ous EGE publications deal in detail with the debate on 
gene patenting. (197) The concern has shifted to the role 
of the patent system as technology moves towards a 
‘knowledge economy’. It has always been assumed that 
there is an important balance to be struck between pri-
vate and public interests in the manner in which the 
patent system is designed — limited rights for a limited 
time. This balance has shifted towards the private inter-
est, particularly when examined from the perspective 
of the developing world. (198)

The debate on the ethics of IPR is focusing on the 
question of which inventions should be able to be 
patented, and hence available directly for commercial 
exploitation, and which should not (if any). It has been 
argued that some discoveries or inventions should be 
considered as the common heritage of mankind. Fol-
lowing this line of reasoning, several experts on the 
ethics of patenting biological inventions have advo-
cated that some discoveries or inventions should never  

(196)  California Research Bureau (1998) http://www.library.ca.gov/

crb/98/reader/reader01.pdf.

(197)  A very detailed examination of the patent system, including an 
introduction to patent law in Europe and in the United States 
and an examination of many cases that involve patenting life 
forms, was produced for the EGE by Geertrui van Overwalle in 
2002: EGE (2002) Study on the patenting of inventions related to 
human stem cell research. Luxembourg Office for Official Pub-
lications of the European Communities. ISBN 92-894-1987-3.

(198)  Walker, Simon. 2001. The TRIPS Agreement, Sustainable Devel-
opment and the Public Interest: Discussion Paper. IUCN, Gland, 
Switzerland and Cambridge, UK and CIEL, Geneva, Switzerland 
ISBN 2-8317-0604-1.

45

3 | ETHICAL ASPECTS

result in commercialisation for profit. (199) These include  
processes the use of which offend human dignity, such 
as the production of chimeras from germ cells, totipo-
tent cells from plants and animals, process for cloning 
human beings and modified germ-line cells. 

This would imply that ‘inventions’ in biology in general 
and in synthetic biology in particular can be catego-
rised as follows:

a.  That which is common to all humankind, and should 
not be patentable or directly exploited for commer-
cial gain;

b.  That which, for a variety of reasons, should be 
placed in the public domain for all to use and ex-
ploit (the ‘commons’). It may be that the process 
or product is so expensive to produce or require 
a vast range of expertise not available to any one 
organisation, or that the placing of the information 
in the public domain enables open standards that 
allow for the effective commercialisation and use 
of a number of products that use the technology 
or product;

c.  That which may, at the inventor’s discretion, be 
protected through an intellectual property rights 
system to encourage innovation.

The first category should include the human genome 
and large projects such as the hap-map project (200) that 
address discoveries in the human genome. This would 
include artificial chromosomes introduced into human 
cells and would be justified under Article 53(a) of the 
European Patent Convention (inventions for which 
commercial exploitation would be contrary to moral-
ity). The International Treaty on Plant Genetic Resources 
attempts to return some of that which was removed 

(199)  Bovenberg JA (2006) ‘Mining The Common Heritage of our Dna: 
Lessons learned from Grotius and Pardo’ Duke Law & Technology 
Review 8; Miller, A.R. and Davis, M.H., 2000. Intellectual property: 
patents, trademarks, and copyright in a nutshell. West Group, St. 
Paul; Juengst, E.T., 1998. Should we treat the human germ-line 
as a global human resource? In: Agius, E. and Busuttil, S. (eds.) 
Germ-line intervention and our responsibilities to future genera-
tions. Dordrecht, pp. 85-102.

(200) See the HapMap website at http://www.hapmap.org/hap-
mappopulations.html.en. The HapMap is a catalogue of  
common genetic variants that occur in human beings. It de-
scribes what these variants are, where they occur in our DNA, 
and how they are distributed among people within popula-
tions and among populations in different parts of the world.

from the common heritage of mankind in the CBD to 
some crops (64) to permit free access to their genetic 
resources, arguing that ‘[n]o country is self-sufficient in 
plant genetic resources; all depend on genetic diversity 
in crops from other countries and regions. International 
cooperation and open exchange of genetic resources 
are therefore essential for food security’.

The second category covers pre-competitive inven-
tions, where the cost would be too great for a single 
organisation to bear. It should take into account the 
link between private and public interest. Where the 
range of information is so great as to make it impossi-
ble for a single organisation to develop and use during 
the lifetime of a patent, the basic information should 
be placed in the public domain or made available at 
minimum cost to others to use. This would ensure that 
information is not withheld in a way that restricts inno-
vation. As synthetic biology may involve the develop-
ment of building blocks which could be assembled into 
a living organism, open standards should be developed 
to permit interaction between systems developed by 
the engineers. 

The third category advocates that inventors should be 
mindful of the choices that they may be in a position to 
make. They could choose to patent the invention, or to 
place some or all of the information in the public domain, 
or use some form of open licence. Importantly, where a 
choice is made to patent, it should be remembered that, 
although the rules on patents are almost universal, the 
patents themselves are national, and an inventor may 
choose the jurisdictions in which protection is sought. 
It may be that, in order to encourage innovation in de-
veloping countries, inventors should be encouraged to 
choose not to patent their inventions in these countries. 
As the information regarding the invention (process or 
product) is disclosed in a patent application, an inven-
tor may choose to use some sort of licence in countries 
where patent protection is not sought. 

All these categories are relevant to the debate on IPR 
and synthetic biology products. It is clear that there 
is no general consensus on the ethics of patenting 
biological inventions. The patenting system (GATT) is 
interpreted differently in different countries; currently 
there are differences between the USA and the EU pat-
ent regime with regard to public morality, technical 
reproducibility and patents’ utility. This also concerns 
issues related to the link between innovation and IPR. 
The debate has also been enriched by discussions con-
cerning the patentability of the human genome and 
what should be eligible for patenting when common 

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

46

 
 
 
heritage considerations are concerned. Many inter-
national organisations hold that the human genome 
(and by extension other genomes) are ‘the common 
heritage of mankind’. These include the Human Ge-
nome Organisation (HUGO) Ethics Committee (2000), 
(201) the Council on Responsible Genetics (CRG 2000), 
(202) the International Federation of Gynaecology and 
Obstetrics (1997), (203) UNESCO (1997), and the Council 
of Europe (204) (2001).

(201)  Human Genome Organisation Ethics Committee, 2000.  

Genetic benefit sharing. Science, 290 (5489), 49.

(202) CRG, 2000. The genetic bill of rights. Council for Responsible 
Genetics CRG, Cambridge. [http://www.gene-watch.org/ 
programs/bill-of-rights/bill-of-rights-text.html].

(203) International Federation of Gynaecology and Obstetrics, 1997. 

Patenting human genes. http://www.figo.org/].

(204) The Parliamentary Assembly of the Council of Europe (Council 
of Europe 2001) asserted that it was ‘of the opinion that the 
results of this grandiose research effort — in which the United 
States has the lead over Europe — must be made available to 
all, genetic information being a common human heritage, as 
set out in Article 1 of the Universal Declaration on the Human 
Genome and Human Rights, adopted at UNESCO in Paris on 
11 November 1997. The Assembly in particular refers in this 
context to the Council of Europe Convention for the Protec-
tion of Human Rights and Dignity of the Human Being with 
regard to the Application of Biology and Medicine — Conven-
tion on Human Rights and Biomedicine (ETS No 164) as well 
as its own Recommendations 1425 (1999) on biotechnology 
and intellectual property and 1468 (2000) on biotechnolo-
gies’, as well as that of UNESCO in its Universal Declaration 
on the Human Genome and Human Rights (1997). UNESCO’s 
Declaration states that, ‘The human genome underlies that 
fundamental unity of all members of the human family...in 
a symbolic sense, it (the human genome) is the heritage of 
humanity (...) The human genome in its natural state shall not 
give rise to financial gain.’

ETHICAL ASPECTS | 3

47

4 | RECOMMENDATIONS

4. 

Recommendations

4.1.  Defining terminology and scope of the 

Opinion

As already described in the first chapter of the Opinion, 
synthetic biology is a new research field that results 
from the convergence of different technological and 
scientific disciplines and allows a better understanding 
of biological systems, their complexity and emergent 
properties that derive from the interaction of com-
plex pathways. At the same time it allows the produc-
tion of bio-products which may have a direct use in 
a variety of sectors such as bio-remedies, bio-fuels,  
raw-materials or biomedical tools –vaccines for exam-
ple–, or new bio-defence agents. The Group recognises 
that it is difficult to draw sharp lines between already 
established practices in biological research and the new 
approach of synthetic biology. Nevertheless, there is a 
gradual transition from modification to fabrication of 
biological systems, from engineering of simple to com-
plex systems, and from adaptation of natural biological 
systems to engineering (or designing) of partially or 
totally artificial biological systems. 

An internationally agreed definition of this research 
sector does not exist yet and this may create confusion 
with regard to scientific and regulatory frames to apply 
to different uses of synthetic biology. An internationally 
recognised definition of synthetic biology is therefore 
needed in particular if the research and applications of 
synthetic biology are to be regulated.

The Group´s understanding of synthetic biology (205), 
nevertheless, includes at least: 1) the design of minimal 
cells or organisms (206) (including minimal genomes), 
2) the identification and use of biological ‘parts’ (the 
toolkit); 3) the construction of totally or partially artifi-
cial biological systems.

Specific concerns address its potential applications 
in the fields of biomedicine, biopharmaceuticals, 
chemical industry, environment and energy, produc-
tion of smart materials and biomaterials particularly 
but not exclusively from the viewpoint of safety and 
security. (207) Beyond this, the debate is about aspects 

(205) See chapter 1.3 of the Opinion.

(206) The term organism is here intended to include acellular, unicel-
lular or multi-cellular biological entities that may be enhanced 
or modified. 

(207) See Andrew Balmer & Paul Martin: Synthetic Biology. Social 

of justice, governance, science and society dialogue, 
intellectual property and philosophical discussions 
about life (208) (See Chapters 3.1 and 3.2). As for other 
new technologies, synthetic biology must respect 
the international frame on ethics and human rights 
(see Chapter 2.3 of this Opinion) and in particular the 
respect of human dignity, which is conceived as not 
only a fundamental right in itself but ‘the real basis of 
fundamental rights’ (209). 

Other ethics principles that have to also be taken 
into account include, inter alia, the principle of safety; 
the principle of sustainability, the principle of justice, 
the principle of precaution, the principle of freedom  
of research as well as by the principle of proportional-
ity (210).

4.2.  Safety

In dealing with the ethical questions raised by synthetic 
biology a basic requirement is that both research and 
applications do not produce any specific harm to hu-
man health but also to the environment. In this respect 
safety is a pre-requisite to any use of synthetic biol-
ogy. Many of the safety issues relevant to synthetic 
biology were already considered three decades ago 
at the meeting on recombinant DNA at the Asilomar 
Conference Centre in Pacific Grove, California, which 
opened a debate on the ethics of the newly emerging 
technologies based on DNA, focusing in particular on 
the safety of transmitting genes from one organism to 
another organism via a vector such as a virus or a plas-
mid. At present, legislation on bio-safety exists in the 
EU, including legislation to protect human and animal 

and Ethical Challenges. May 2008. http://www.bbsrc.ac.uk/
publications/corporate/synthetic_biology.pdf   

(208) See Markus Schmidt, Helge Togersen, Agomoni Ganguli-Mitra, 
Alexander Kelle, Anna Deplazes, Nikola Biller-Andorno: SYN-
BIOSAFE e-conference: online community discussion on the 
societal aspects of synthetic biology. In: Systems and Synthetic 
Biology (2008) September 16. Online: http://www.zora.uzh.
ch/3947/2/Schmidt_m_torg.V.pdf 
Paul Rabinow & Gaymon Bennett: From Bio-Ethics to Human 
Practice. Working Paper # 11, 2007 http://anthropos-lab.net/
wp/publications/2007/08/workingpaperno11.pdf 

(209) Declaration concerning the explanations relating to the Char-

ter of Fundamental Rights

(210)  According to which (1) the goal or objective of the research 
must be important: (2) the methods used must be necessary 
to achieve the goals; and (3) there are no other less controver-
sial or risky methods that could be used to achieve the same 
goal.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

48

 
 
 
 
RECOMMENDATIONS | 4

health and environment, or people exposed to biologi-
cal agents and other hazardous agents. The question is 
whether the above mentioned frame responds entirely 
to the specific features of synthetic biology. 

When addressed from a safety viewpoint synthetic 
biology opens a number of concerns, such as, inter 
alia: how to assess the safety of organisms that have a 
genome derived using recombinant DNA techniques 
and that allow the production of systems combining 
elements from multiple sources. How to evaluate such 
constructions for biological safety in organisms that 
may contain genes or proteins that have never existed 
together in a biological organism or that contain newly 
designed biological functions that do not exist in na-
ture remains unclear. 

A further concern relates to unknown risks to the envi-
ronment and public health, determined by unexpected 
interactions between synthetic microorganisms and 
the environment or other organisms in it. Horizontal 
gene transfer and its potential impact to the balance 
of the ecosystems, or the interaction of synthetic mi-
croorganisms with naturally-occurring substances or 
unforeseen evolution of synthetic biology agents are 
all risks that may derive from the non contained use of 
synthetic biology agents or from inadvertent presence 
of the organisms in the environment. 

Biosafety concerns regarding synthetic biology also af-
fect risk assessment methods existing in the EU in rela-
tion to biology. The assessment methods for GMOs are 
based on a comparison of the altered organism with 
the natural organisms on which they are based, consid-
ering each individual trait introduced (211). Synthetic bi-
ology will produce organisms with multiple traits from 
multiple organisms, and therefore it may be difficult to 
predict their properties. 

The biosafety of synthetic biology products is heavily 
debated between scientists and decision makers. Some 
scientists have even proposed that in absence of clear 
biosafety data all synthetic biology research protocols 
should take place in Biological Safety Level -P3 or P4 
-laboratories with clear implications for the develop-
ment of this scientific sector. 

The Group is of the opinion that bio-safety consid-
erations are pre-requisites for the promotion and  

(211)  See risk assessment methods as discussed in the EGE Opinion 

on ethics of nanomedicine.

implementation of an EU synthetic biology research 
program, both nationally and internationally.

Recommendation No 1: The Group recommends that 
any use of synthetic biology should be conditional on 
specific safety issues identified in this Opinion. There-
fore the Group asks:

1)   The Commission to initiate a study on current 
risk assessment procedures in the EU. The study 
should (a) make a survey of relevant bio-safety 
procedures, (b) identify possible gaps in the cur-
rent bio-safety regulation to effectively assess or-
ganisms and novel products developed through 
synthetic biology; (c) indicate the mechanism to 
fill the identified gaps. 

2)  The identified risk assessment procedure should 
then be carried out by the competent Authorities 
within the EU (e.g. EC, EMEA and EFSA) and Na-
tional Authorities.

3)  This should be conditional for financing of synthet-
ic biology research and the marketing of synthetic 
biology products in the EU. 

Recommendation No 2: The Group proposes that, 
when the above biosafety rules are defined, the Com-
mission starts an international debate with relevant 
counterparts to facilitate a standardised approach to 
bio-safety of synthetic biology for public and private 
funded trials. Instruments for the monitoring of the im-
plementation of such provisions should be conceived 
as integral part of the bio-safety rules (including £li-
ability issues). 

Recommendation No 3: The Group advocates that a 
Code of Conduct for research on synthetic microor-
ganisms should be prepared by the Commission. The 
Code should, for example, assure that synthetic biol-
ogy organisms are manufactured in a way that they 
cannot autonomously survive if accidental release into 
the environment would take place.

4.2.1.  Environmental applications 

The Group is aware that synthetic biology has potential 
environmental applications. The Group acknowledges 
current synthetic biology research, for instance, to re-
duce environmental contaminants (bioremediation), 
such as heavy metals, pesticides and radioactive mate-

49

4 | RECOMMENDATIONS

rial. The Group is aware of current research to produce 
synthetic biology agents able to degrade  pesticides to 
reduce their environmental impact (212) or to produce 
biosensors for polluted water (213). The Group states that 
the goal of increasing environment protection and pro-
ducing new detection tools is positive and may increase 
human welfare and environment protection. Specific 
concerns arise, however, from a bio-safety point of view 
when environmental applications of synthetic biology 
are envisaged and therefore adequate assessment of 
safety and environmental impact should be carried out 
before any environmental release is approved.

In the area of environmental applications, the fabrica-
tion of antipollution biological systems or organisms 
must be analyzed with respect to the protection of 
workers and citizens, freedom of consumers, and re-
sponsibility, including the responsibility for animals, 
plants, and the environment in general.        214

Recommendation No 4: The Group recommends that 
before an organism, fabricated or modified via syn-
thetic biology, is released into the environment, eco-
logical long term impact assessment studies must be 
carried out. Data resulting from such studies should 
then be evaluated taking into account the precaution-
ary principle (214) and the measures foreseen in the EU 
legislation (Directive on the deliberate release into 
the environment of genetically modified organisms). 
In the absence of a favourable assessment the release 
of organisms fabricated or modified should not be 
authorised. 

4.2.2.  Energy and sustainable chemical industry 

The Group is aware that synthetic biology could con-
tribute to the development of a sustainable chemical 
industry in particular the production of synthetic biol-
ogy microorganisms aimed to substitute agents and 
methods currently used by organic chemical industry 
for its production of raw materials. 

(212)  See http://pbd.lbl.gov/synthbio/aims.htm

(213)  Arsenic contamination of drinking water is a problem in de-
veloping parts of the world, such as Bangladesh. See: Aleksic 
J, Bizzari F, Cai Y et al. (2007) Development of a novel biosensor 
for the detection of arsenic in drinking water Synthetic Biology, 
IET 1: 87–90. 

(214)  2001/18/EC, 98/81/EC and regulatory freame in chapter 2.1 of 

the Opinion.

As far use of synthetic biology for energy purposes the 
Group is also aware that synthetic biology research is 
currently aimed at engineering bacteria to produce or-
ganic compounds (215) aimed to substitute petrol as well 
as research seeking to engineer bacteria to produce the 
fuel hydrogen from different sources (216). 

The Group acknowledges that these possibilities are 
made more significant by dwindling fossil fuel reserves, 
which currently provide the raw materials and by the 
impact on climate of the combustion of fossil fuels. The 
Group is however concerned about possible safety im-
plications and therefore proposes the following:

Recommendation No 5: The Group proposes that the 
use of synthetic biology for alternative energy supply in 
EU Member States would be complementary to the EU 
renewable energy plan, and that international research 
trials (e.g. EU-USA) be promoted and co-financed to fa-
vour an integrated international approach.

Recommendation No 6: The Group recommends that 
competent authorities properly monitor the authorisa-
tion procedures for the production of synthetic biolo-
gy-derived chemicals and materials, if not identical to 
equivalent substances, by taking into consideration 
(a) risk assessment factors and (b) safety of workers 
exposed to synthetic biology chemical agents and (c) 
environment protection. 

As far use of synthetic biology for chemical products 
and novel materials, are concerned the Group is aware 
that chemical products not intended for food or feed 
derived from genetically modified organisms do not re-
quire specific labelling identifying them as genetically 
modified. The Group is aware that virtually all synthetic 
biology products that contain or are organisms or that 
are derived from such organisms in food or feed, must 
be labelled as being genetically modified. The Group 
is however concerned about possible uses of synthetic 
biology in the cosmetic and textile industry.  

(215)  Such as fatty acids which are optimal for use as biodiesel or 

other energy rich compounds.

(216)  See also: LS9 (www.ls9.com), Amyris (www.amyris.com), OPX 
Biotecnologies (www.opxbiotechnologies.com), Solazyme 
(www.solazyme.com), Gevo (www.gevo.com)  

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

50

 
 
 
RECOMMENDATIONS | 4

Recommendation No 7: The Group asserts that the 
protection of consumers´ rights is a key factor to con-
sider in EU market and stresses that labelling of spe-
cific synthetic biology products, such as cosmetics and 
textiles, should be explored. 

4.2.3.  Biomedicine and biopharmaceuticals production 

Synthetic biology has potential in medical applications 
such as to improve and develop biosensors, drugs, 
therapies, devices and cells with new properties that 
may be used to improve human health or therapeutic 
methods. Applications of synthetic biology are expect-
ed in drug production, development of new vaccines, 
medical devices such as biosensors, diagnostics, virus 
synthesis for genetic therapies, and potential uses in 
cancer therapy. 

The Group is aware that medical uses of synthetic biol-
ogy at the moment are at a basic research stage and 
that clinical applications of new drugs and methods are 
still far from being available to patients. 

As described in chapter two of this Opinion, the Group 
argues that medical applications of synthetic biology 
must not contravene the fundamental rights and eth-
ics framework outlined earlier and be conditional on 
strict biosafety provisions. For currently envisaged 
products the existing regulatory framework is gener-
ally adequate to regulate the use of synthetic biology 
and must be implemented.    (217)

Recommendation  No  8:  The  Group  recommends 
that further to the application of scientific and legal 
frameworks, specific ethics considerations have also 
to be addressed by the competent Authorities (such 
as EMEA(217)) when drugs and medical products will 
result from synthetic biology protocols. Data on medi-
cal applications of synthetic biology carried out in EU 
MS or resulting from EU funding should be collected by 
relevant bodies in the countries where such trials take 
place and made available internationally.

(217)  As required by EU legislation Synthetic biology medical 
products will be assessed from a safety viewpoint. The rel-
evant MS and EU (EMEA) Authorities should be sure that 
safety considerations expressed in this Opinion are taken 
prior authorisation procedures of both clinical and research 
trials and marketing procedures.

4.3.  Biosecurity, prevention of bioterrorism 

and dual uses

The EGE is aware of the possible use or misuse of 
synthetic biology in relation to biosecurity as well as 
of current research in this specific sector carried out 
in the EU and USA. Synthetic biology may permit the 
development of new tools that could be useful for 
military purposes ranging from biomaterials to bio-
weapons. Ethical analysis must assess the balance 
between security and the need for transparency:

•	

•	

•	

the	 production	 and	 potential	 use	 of	 synthetic	
biology materials or systems in national security 
policies, including the production of bioweapons. 
These uses must be within current national and 
international regulatory frameworks.  Transparency 
and release of information may impact on misuse 
for terrorist purposes – but open societies must 
find ways to deal with the difficult balance between 
citizens’ right to information on the one hand, and 
the need to protect their security.

the	 production	 and	 potential	 use	 of	 synthetic	
biology materials or systems for terrorist purposes, 
above all the production of biological systems that 
can have a massive destructive potential. Misuse of 
any kind of synthetic biology knowledge needs to 
be addressed. 

the	 production	 of	 synthetic	 organisms	 outside	
recognised institutions. Since synthetic biology 
materials and procedures are publicly available, 
biohacking  is  another  scenario  that  requires 
governance with respect to security. 

The EGE is also aware of the recent EC Communication 
adopted on June 24, 2009 (218), defining the new EU 
Chemical, Biological, Radiological or Nuclear (CBRN) 
policy. The Group considers this initiative valuable but 
not yet sufficient for an ethically sound and democratic 
approach to bio-security in the EU and beyond. The 
Group welcomes the embedding of ethics into the 
curricula of biosecurity scientists, including specific 
actions  to  better  clarify  the  ethical  dimension  of 
synthetic biology uses for bio security. 

In synthetic biology applications, however, information 
about the fabrication of synthetic viruses, for example, 

(218)  COM(2009)  273  final;  SEC(2009)  874;  SEC(2009)  790;  

SEC(2009) 791

51

4 | RECOMMENDATIONS

may lead to a new wave of bio-terrorism. There has 
not been much discussion about how this could be 
handled. Soldiers’ and civilians’ health must be secured, 
transparency maintained as far as possible, and research 
permitted only under strict monitoring. As described 
in chapter three of this Opinion, the Group argues 
that security and military applications of synthetic 
biology must not contravene the fundamental rights 
and ethics frameworks outlined in the opinion. The 
task of preventing terrorist and/or malicious uses of 
synthetic biology raises the moral dilemma of dual 
use for researchers as well as for democratic states. 
Some intended and unintended dual purposes can be 
foreseen but others not. One way of dealing with the 
dual use dilemma is through control mechanisms such 
as licensing and registering the tools used by synthetic 
biology. 

Examples  of  actions  that  may  be  used  to  prevent 
unacceptable  military  or  terrorist    actions  include: 
1) a centralised database be developed at least at EU 
level,  or  preferably  at  international  level  where  all 
DNA synthesisers would be registered by competent  
authorities; 2) departments or research groups dealing 
with biosecurity and biodefence use of synthetic biology 
should be licensed in the above registry; 3) criteria for the 
publication of data on highly pathogenic viruses or toxic 
agents be defined at Member State and EU level. (219)

Moreover, ethical issues that arise because of the 
potential for dual use should be dealt with at the 
educational level. Fostering individual and institutional 
responsibility through ethics discussion on synthetic 
biology is a key issue.

Recommendation No 9: The Group recommends that 
the Convention on the Prohibition of the Develop-
ment, Production and Stockpiling of Bacteriological 
(Biological) and Toxin Weapons and on Their Destruc-
tion should incorporate provisions on the limitation or 
prohibition of research in synthetic biology. 

Recommendation No 10: The Group asks the Com-
mission to define, in consultation with the EGE, a  

(219)  Regulations are in place for genetically modified organisms 
which would include those fabricated using synthetic biology 
techniques in Europe that require registration and/or approval 
of the facilities where these organisms can be grown and 
studied. See also p.40 of this Opinion and Art. 7 of EC/98/81.

comprehensive security and ethics framework for syn-
thetic biology. 

Recommendation No 11: The Group recommends that 
the European Commission 1) ensure that databases are 
available to all who use them; 2) Provides the legal sys-
tems for companies to report to Competent Authorities 
when asked to synthesise suspicious sequences whilst 
ensuring privacy; 3) Identifies the chain of responsibil-
ity for placing particular sequences in the database(s) 
and identifying them as potentially harmful. 

4.4.  Governance

The Group also advocates that if a technology is 
considered for use in the EU, its effects should be 
carefully studied and evaluated through an impact 
assessment that includes both the risks and bene-
fits of the new technologies and the risks and ben-
efits of the technologies replaced. This assessment 
should be in the context of the integrated approach 
to synthetic biology where environmental and social 
implications are taken into account. In addition to 
technical risk governance, a broader approach must 
be developed that is better able than present instru-
ments to adjust to possible changes, in the environ-
ment, in societies, in market economics or in national 
policies. The ethics of synthetic biology should deal 
with a case-by-case study of the benefits and perils 
of this technology for specific ecological settings as 
well as with potential risks and benefits for the whole 
biosphere. (220) 

A responsible use of synthetic biology would imply 
using governance tools in order to encourage scien-
tific advances and uses of research which may ben-
efit human health; help save energy and reduce the 
negative effects of climate change and at the same 
time to safeguard it from misuse; i.e. bioterrorism and 
protect biosafety and bioesecurity. This is not an easy 

(220) See Markus Schmidt, Helge Togersen, Agomoni Ganguli-
Mitra, Alexander Kelle, Anna Deplazes, Nikola Biller-Andorno: 
SYNBIOSAFE e-conference: online community discussion on 
the societal aspects of synthetic biology. In: Systems and 
Synthetic Biology (2008) September 16. Online: http://www.
zora.uzh.ch/3947/2/Schmidt_m_torg.V.pdf 
Paul Rabinow & Gaymon Bennett: From Bio-Ethics to Human 
Practice. Working Paper # 11, 2007 http://anthropos-lab.net/
wp/publications/2007/08/workingpaperno11.pdf 

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

52

 
 
 
 
RECOMMENDATIONS | 4

task and poses a number of dilemmas for the EU to 
engage in.

a)  General dilemmas; How can governance tools

–  encourage beneficial use and prevent misuse; 

when dual use is possible? 

–  encourage transparency without creating risks 

of misuses? 

–  secure against misuse without introducing un-

wanted censorship on publication etc. ?

b)  Specific governance challenges: How can the EU 

use Governance tools to 

•	

•	

•	

Take	into	account	that	synthetic	biology	includes	
a great number of areas with very different levels 
and intensity of regulations and identified possible 
gaps in securing biosafety and bioesecurity?

Identify	areas	where	soft-law	will	provide	sufficient	
protection and areas where hard law is deemed 
necessarily (see recommendation 2 on biosafety 
rules and recommendation 9 on the Convention 
on biological weapons)?

Encourage	professional	responsibilities	for	individ-
ual researches and institutions (including scientists 
who are not necessarily used to work with living 
organisms and the specific problems this entails) 
and to supplement the Code of conduct proposed 
in recommendations No 3?

•	 Play	a	role	in	the	need	for	global	governance	on	

synthetic biology?  

The  Group  expresses  its  concerns  on  the  existing 
fragmented regulatory framework, which may not be 
sufficient to properly regulate current and emerging 
aspects of synthetic biology. It also stresses the need 
to explore a proper model of synthetic biology gov-
ernance (soft law, codes of conducts etc.), also taking 
into consideration potential risks of delocalisation of 
research trials in countries where regulation may be 
less stringent than the one proposed in the EU. (221)

(221)  See Unesco MOST Ethical guidelines for international com-

parative social science research.

Recommendation No 13: The Group urges the Com-
mission to propose a robust governance framework 
for synthetic biology and put it in place in the EU. 
The Commission should review the legislation ap-
plicable to synthetic biology and assess its relevance 
to address the issues raised by synthetic biology. The 
above framework should address relevant stakehold-
ers (scientists, industries, military agents, and political 
and administrative agents) and clearly indicate their 
responsibilities. 

Recommendation No 14: The relevant science com-
munities should be encouraged to establish ethical, 
preferably global, guidelines which may act as sign-
posts and lead science institutions and individual re-
searchers to assess the impact of their work including 
the consequences of misuse (221).

Recommendation No 15: EGE Proposes that the EU 
takes up the question of governance of synthetic bi-
ology in relevant global fora.

4.5. 

Intellectual property

4.5.1.   Patenting and common heritage

The questions raised by the patenting of biological 
methods and materials have been a subject of heated 
debate for some time and it is now being discussed in 
different disciplines. The function of patents to stimu-
late research and its applications and to promote public 
disclosure of the basis of applications may be jeopard-
ized by the massive number of applications of patents 
related to genetic material and biological methods. At 
the same time the appropriation of elements of bio-
logical organisms by specific industrial actors has also 
raised a number of ethical questions. Article 7 of the Pat-
ent Directive in relation to Biotechnological Inventions 
states ‘The Commission’s European Group on Ethics in 
Science and New Technologies evaluates all ethical as-
pects of biotechnology.’ This is the only Article of the 
Directive that has not been implemented in the rules 
implementing the Directive of the EPO or the patent of-
fices of the Member States.  It is difficult to implement as 
it specifies no action and is not addressed in any of the 
other Articles. There have often been complaints from 
Patent Offices that the morality clauses in European 
Patent Law are difficult to interpret (or even that they 
should be addressed by other legislation).  The Group 
proposes that where there is a general issue raised by a 
particular patent application in the field of biotechnol-

53

4 | RECOMMENDATIONS

ogy (including nanotechnology and synthetic biology) 
that the relevant Patent Offices ask the EGE for advice in 
the general area identified in the application.

As far as the patenting and common heritage issue 
is concerned, the Group acknowledges the complex-
ity of the topic, as already indicated in Annex I of this 
Opinion. The Group stresses that general ethical issues 
involved in patent applications have to be addressed 
properly in the patent allocation system. 

Recommendation No 16: The EGE proposes that de-
bates on the most appropriate ways to ensure the 
public access to the results of synthetic biology is 
launched. These debates should include also what 
can be object of patent and what should be available 
through open access.

Recommendation No 17: The EU Patent Directive 
(98/44/EC) defines the EGE as the Body to assess eth-
ics implications related to patents. The Group urges 
the European Patent Office and the National Patent 
Offices to take account of Article 7 of the Patent Direc-
tive and refer contentious ethical issues of a general 
relevance to the EGE for consideration. This is particu-
larly important if a class of inventions that ought not 
to be directly exploited commercially (222) has to be 
defined.

4.5.2.   Trade and global justice (222)

The Group is aware of the global dimension of synthetic 
biology and its applications and considers economic 
development and growth of social welfare as a posi-
tive goal of the EU. Synthetic biology may contribute to 
the socio-economic prosperity of the EU and beyond. 
The Group welcomes this possibility; insofar principles 
of the EU Charter of fundamental rights and main EU 
fundamental values are not negatively affected by this 

(222) EC/98/44, Article 6.2 provides an indicative list of exclusion 
from patentability, namely ‘(a) processes for cloning human 
beings; (b) processes for modifying the germ line genetic 
identity of human beings; (c) uses of human embryos for 
industrial or commercial purposes; (d) processes for modify-
ing the genetic identity of animals which are likely to cause 
them suffering without any substantial medical benefit to 
man or animal, and also animals resulting from such proc-
esses.’ The Directive, Art 7, also states that ‘The Commission’s 
European Group on Ethics in Science and New Technologies 
evaluates all ethical aspects of biotechnology.’

technological sector and the trade of its products. The 
EGE therefore has concerns about the possible risks of 
a technology divide within the EU and between devel-
oped and less developed countries.

The EGE recommends the embedding of the EU funda-
mental values into the global trade of synthetic biology 
products. As in previous Opinions (such as Opinion 23 (223)  
and Opinion 24 (224)), the Group underlines the need of 
introducing ethics considerations in the global trade and 
World Trade Organisations policy actions. 

Actions to avoid a greater technological divide should 
then be taken.  If trials involving synthetic biology prod-
ucts are being conducted in developing and emerging 
countries the same ethical standards as are required 
within the EU must be implemented (225). UN Millen-
nium goals should be implemented.   (226)

Recommendation No 18: The EGE recommends that 
when synthetic biology is discussed at international 
level, including the WTO, the ethical issues associ-
ated to the technology should be addressed (226). This 
should be taken into account in the Doha round ne-
gotiations.

Recommendation No 19: The EGE urges that EU Bi-
osafety standards for synthetic biology products as 
identified in recommendations N°1, 2 and 5 of this 
Opinion are adopted as minimal standards for EU 
import-export of synthetic biology products.  

Recommendation No 20: The Group recommends 
specific EU actions to avoid new gaps between EU 
and developing and emerging countries, or within EU 
Members States, and to put into effect the recommen-
dations expressed in this Opinion. Such actions should 
be introduced in bilateral and multilateral science pro-
grammes of the EU and in the EU policies concerning 
developing and emerging countries.

(223) http://ec.europa.eu/european_group_ethics/activities/

docs/opinion23_en.pdf

(224) http://ec.europa.eu/european_group_ethics/docs/

opinion24_en.pdf

(225) http://ec.europa.eu/european_group_ethics/docs/avis17_

en.pdf

(226) See Chapters 2.2.b and 2.2.c of this Opinion.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

54

 
 
 
RECOMMENDATIONS | 10

4.6. 

Science and society dialogue

As elaborated in Chapter 3 of this Opinion, the eth-
ics of synthetic biology is complex and the identified  
conceptual questions need an effective science and so-
ciety dialogue. 

The perception of synthetic biology is influenced by social, 
cultural and ethical considerations about manipulating 
life, economic implications for developed and develop-
ing regions, issues related to ownership and intellectual  
property, concerns about environmental degradation 
and potential military uses, and so on. Traditional and 
interactive media play an important role in shaping peo-
ple’s views on new and emerging technologies, including 
synthetic biology. Each of these issues deserves thorough 
consideration and public participation. This raises wider 
issues of trust and confidence building between the sci-
entific community and the public, including the need to 
promote proper debate. It ultimately leads to issues of 
deliberative democracy, including questions about who 
draws the lines between what is allowed, acceptable, 
and what is not; and who overviews those who draw the 
lines. 

Social scientists have suggested that upstream engage-
ment could be productive for a development of science 
and technology consistent with societal expectations, 
concerns, and wishes. (227) Many scientists working in 
synthetic biology are already aware of the importance of 
public engagement, and to this end, they have engaged 
in activities such as debates, podcasts and blogs.

Public debate needs to be properly informed about the 
effective features and potentials of synthetic biology 
and this may raise difficulties of identifying, estimating 
and managing risks in an area where there are consider-
able uncertainties and knowledge gaps, and when the 
short-term and long-term risks may be different. Similar 
considerations apply to ‘hype’ benefits, where the public 
is confronted, with the assistance of media and science 
fiction writers,  with unrealistic scenarios on synthetic bi-
ology products (for example, synthetic biology hype with 
regard to the curability of all diseases or bio-remedy to 
environmental pollution of prospects for energy crisis). 
Non-documented hopes or fears communicated to the 
public distort the public debate on synthetic biology.

Recommendation No 21: The Group asks the EU and 
EU Member States to take actions to promote public 
debates and engagement amongst the stakeholders 
in order to identify main societal concerns in the dif-
ferent areas covered by synthetic biology.

Recommendation No 22: The Group recommends 
that journalists, editors, including science editors, and 
other stakeholders promote responsible reporting on 
synthetic biology. 

Recommendation No 23: In order to promote a com-
prehensive approach to new technologies by the me-
dia the Group asks the Commission to stimulate spe-
cific actions, such as, inter alia, creating fora, seminars 
and courses, addressing the implications of synthetic 
biology in the media.

4.7.  Research

It has been observed for quite some time that basic 
research, the fundament of all different applications 
in a given field, has been pushed to the background 
in research funding programmes. Even though basic 
research is not to be sharply separated from applied 
research, the former needs public funding, and this 
should be the policy of the European Union. 

A key novelty synthetic biology introduces in the sci-
entific method of modern biology is the possibility not 
only to use deductive approaches from observed phe-
nomena but synthesising heuristic tools that allow in 
themselves exploring basic biology phenomena. Basic 
research in synthetic biology is however not necessar-
ily connected to market and industrial interests and is 
therefore dependent on public financing. The Group 
is concerned that this may lead to a lack of adequate 
funding of EU basic research in a near future, and that 
this may jeopardise the role the EU research may play 
in global governance of synthetic biology.

In parallel, the ethical debate on synthetic biology ad-
dresses issues related to the ethical legitimacy of man-
ufacturing living organisms, similar to the debate on 
engineering life. Human intervention in nature, which 
includes the environment and other living organisms, 
also raises concerns over the ‘naturalness’ of interven-
tion and ‘manufacturing life’. (228) The Group therefore 

(227) http://www.bbsrc.ac.uk/organisation/policies/reviews/

scientific_areas/0806_synthetic_biology.pdf 

(228) John Harris, ‘Who’s Afraid of a Synthetic Human?’ The Times, 

55

10 | RECOMMENDATIONS

underlines the need of fi nancing EU interdisciplinary 
research projects on the relation between humans and 
nature, particularly with regard to questions concern-
ing the views towards life. 

Recommendation No 24: The Group invites the Com-
mission to support basic research in the fields of 
biology, chemistry, energy and materials science and 
engineering and applied research as identified in 
this Opinion. This should be refl ected in the R&D EU 
research Framework Programmes budget. A similar 
invitation is addressed to EU member states in their 
national R&D programmes. 

Recommendation No 25: The Group requests the EU 
to properly fi nance interdisciplinary research on the 
following aspects of synthetic biology: 

risk assessment and safety; 

- 
-  security uses of synthetic biology; 
-  ethical, legal and social implications 
-  governance; 
- 

science and society (including media and the public). 

This should be refl ected in the R&D EU research Frame-
work Programmes budget.  Similar request is ad-
dressed to EU MS in their national R&D programmes. 

Recommendation No 26: The Group notes that syn-
thetic biology could lead, in the future, to a paradigm 
shift in understanding concepts of life. It therefore calls 
on the Commission to initiate an open intercultural 
forum to address the issues, to include philosophical 
and religious input.

May 17, 2008. Colin Nickerson, ‘A Quest to Create Life Out of 
Synthetics,’ Boston Globe, April 2, 2008. Erik Parens, ‘Making 
Cells Like Computers,’ Boston Globe, February 18, 2008. 
Natalie Angier, ‘Pursuing Synthetic Life, Dazzled by Reality,’ 
New York Times, February 5, 2008.

y
g
o

l

o

i

b
c
i
t
e
h
t
n
y
s

f
o
s
c
i

h
t
E

56

 
 
 
57

groupe européen d’éthique
des sciences et des nouvelles
technologies auprès 
de la commission européenne

AVIS DU GROUPE EUROPéEN  
D’éTHIQUE DES SCIENCES  
ET DES NOUVELLES TECHNOLOGIES  
AUPRèS DE LA COMMISSION EUROPéENNE

Éthique  
de biologie synthétique

Référence: 

avis requis par le président Barroso 

Rapporteurs:  Rafael Capurro, Julian Kinderlerer,  

Paula Martinho da Silva et Pere Puigdomenech Rosell

Seul le texte original en anglais est authentique.

N°

25

 
RECOMMANDATIONS | 4

4. 

Recommandations

4.1.  Définir la terminologie et la portée de 

l’avis

Comme déjà décrit dans le premier chapitre de l’avis, la 
biologie synthétique représente un nouveau domaine 
de recherche qui résulte de la convergence de diffé-
rentes disciplines technologiques et scientifiques et 
qui ouvre la voie à une meilleure compréhension des 
systèmes biologiques, de leur complexité et des pro-
priétés émergentes qui découlent de l’interaction entre 
des approches complexes. Parallèlement, elle permet 
la production de bioproduits directement utilisables 
dans divers domaines, tels que les produits de bioré-
habilitation, les biocarburants, les matières premières 
ou les outils biomédicaux (vaccins, par exemple), ou de 
nouveaux agents de défense biologique. Le GEE recon-
naît qu’il est difficile de tracer une limite précise entre 
des pratiques déjà établies dans la recherche biologi-
que et la nouvelle approche de la biologie synthétique. 
Néanmoins, il existe une transition progressive entre la 
modification et la fabrication de systèmes biologiques, 
entre l’élaboration de systèmes simples et l’élaboration 
de systèmes complexes, ainsi qu’entre l’adaptation de 
systèmes biologiques naturels et l’élaboration (ou la 
conception) de systèmes biologiques partiellement ou 
totalement artificiels.

Il n’existe pas encore de définition internationalement 
acceptée de ce domaine de recherche. Cette situation 
pourrait provoquer une certaine confusion, s’agissant 
des cadres scientifiques et réglementaires à appliquer 
aux différentes utilisations de la biologie synthétique. 
Il est dès lors nécessaire qu’une définition de la biolo-
gie synthétique soit reconnue internationalement, en 
particulier si la recherche et les applications dans ce 
domaine doivent être réglementées.

Néanmoins, le GEE considère que la notion de «biologie 
synthétique» (1), recouvre au moins: 1) la conception 
de cellules ou d’organismes minimaux (2) (y compris 
de génomes minimaux); 2) l’identification et l’utilisa-
tion de «parties» biologiques (la boîte à outils); 3) la 
construction de systèmes biologiques partiellement 
ou totalement artificiels.

(1)  Cf. chapitre 1.3. du présent avis.

(2)  Le terme d’«organisme» recouvre ici des entités biologiques 
acellulaires, unicellulaires ou multicellulaires qu’il est possible 
de modifier ou d’améliorer. 

Ses applications potentielles dans les domaines de 
la biomédecine, des biomédicaments, de l’industrie 
chimique, de l’environnement et de l’énergie, de la 
production de matériaux intelligents et de biomaté-
riaux donnent lieu à des préoccupations spécifiques 
notamment, mais pas exclusivement, du point de vue 
de la sécurité et de la sûreté (3). En outre, le débat porte 
sur des aspects juridiques, de gouvernance, de dialo-
gue entre la science et la société, de propriété intellec-
tuelle et de discussions philosophiques sur le vivant (4)  
(cf. chapitres 3.1. et 3.2. du présent avis). Tout comme les 
autres nouvelles technologies, la biologie synthétique 
doit respecter le cadre de référence international en 
matière d’éthique et de droits de l’homme (cf. chapi-
tre 2.3. du présent avis); elle doit notamment respecter 
la dignité humaine, qui «n’est pas seulement un droit 
fondamental en soi, mais constitue la base même des 
droits fondamentaux» (5). 

Parmi les autres principes éthiques à prendre en consi-
dération figurent, notamment, les principes de sécurité, 
de durabilité, de justice, de précaution, de liberté de la 
recherche et de proportionnalité (6).

4.2.  Sécurité

S’agissant des questions éthiques soulevées par la 
biologie synthétique, il est fondamental d’exiger que 
la recherche et les applications dans ce domaine ne 
nuisent ni à la santé humaine ni à l’environnement. 
À cet égard, la sécurité constitue une condition préa-
lable à toute utilisation de la biologie synthétique.  

(3)  Cf. Andrew Balmer & Paul Martin, Synthetic Biology. Social and 
Ethical Challenges, mai 2008, http://www.bbsrc.ac.uk/publica-
tions/corporate/synthetic_biology.pdf.  

(4)  Cf. Markus Schmidt, Helge Togersen, Agomoni Ganguli-Mi-
tra, Alexander Kelle, Anna Deplazes, Nikola Biller-Andorno, 
«SYNBIOSAFE e-conference: online community discussion 
on the societal aspects of synthetic biology», in: Systems 
and Synthetic Biology (16 septembre 2008). Accessible en 
ligne à l’adresse suivante: http://www.zora.uzh.ch/3947/2/
Schmidt_m_torg.V.pdf
Paul Rabinow & Gaymon Bennett, From Bio-Ethics to Human 
Practice, Working Paper no 11, 2007 http://anthropos-lab.net/
wp/publications/2007/08/workingpaperno11.pdf.

(5)  Déclaration concernant les explications relatives à la Charte 

des droits fondamentaux.

(6)  D’après lequel (1) le but ou l’objectif de la recherche doit 
être important; (2) les méthodes utilisées doivent être  
nécessaires en vue d’atteindre ces objectifs; et (3) il n’existe 
pas d’autres méthodes moins controversées ou moins  
risquées qui pourraient être utilisées en vue d’atteindre ces 
objectifs.

61

 
4 | RECOMMANDATIONS

Nombre de questions relatives à la sécurité en ma-
tière de biologie synthétique ont déjà été abordées 
il y a trois décennies lors de la réunion sur l’ADN 
recombinant au centre de conférence Asilomar de 
Pacific Grove, en Californie, qui avait ouvert un dé-
bat sur l’éthique des technologies émergentes de 
l’époque basées sur l’ADN, axé principalement sur la 
sécurité de la transmission de gènes d’un organisme 
à un autre par un vecteur tel qu’un virus ou un plas-
mide. L’UE dispose aujourd’hui d’une législation en 
matière de biosécurité, y compris d’une législation 
visant à protéger la santé humaine et animale ainsi 
que l’environnement, ou les personnes exposées à 
des agents biologiques ou à d’autres agents dange-
reux. La question est de savoir si le cadre susmen-
tionné répond entièrement aux particularités de la 
biologie synthétique. 

Lorsqu’on l’aborde du point de vue de la sécurité, 
la biologie synthétique soulève un certain nombre 
de questions dont celle, notamment, de l’évaluation 
de la sécurité des organismes dont le génome est le 
produit de techniques utilisant de l’ADN recombinant 
et qui permettent de produire des systèmes combi-
nant des éléments provenant de sources multiples. 
Il subsiste des incertitudes quant à la façon d’évaluer 
ces constructions d’un point de vue de la biosécurité 
d’organismes pouvant contenir des gènes ou des pro-
téines qui n’ont jamais coexisté dans un organisme 
biologique ou contenant des fonctions biologiques 
nouvelles qui n’existent pas dans la nature.

Une autre question concerne les risques inconnus 
pour l’environnement et la santé publique découlant 
des interactions inattendues entre les microorganis-
mes synthétiques et l’environnement ou d’autres 
organismes. Le transfert de gènes horizontal et son 
incidence possible sur l’équilibre des écosystèmes, 
l’interaction de microorganismes synthétiques avec 
des substances naturelles ou encore l’évolution im-
prévue d’agents de biologie de synthèse représentent 
toute une série de risques pouvant découler d’une 
utilisation non contrôlée de ces agents biologiques 
de synthèse ou d’une présence imprévue de ces or-
ganismes dans l’environnement.

Les questions de biosécurité concernant la biologie 
synthétique touchent également les méthodes d’éva-
luation des risques qui existent dans l’UE dans le do-
maine de la biologie. Les méthodes d’évaluation des 
OGM sont fondées sur la comparaison de l’organisme 
modifié avec les organismes naturels dont il dérive, en 

considérant chaque trait individuel introduit (7). La 
biologie synthétique produira des organismes pos-
sédant de multiples traits provenant de multiples or-
ganismes. Il pourrait dès lors être difficile de prédire 
leurs propriétés. 

La biosécurité des produits issus de la biologie syn-
thétique fait l’objet d’intenses débats entre les scien-
tifiques et les décideurs. Certains scientifiques ont 
même proposé qu’en l’absence de données claires 
en matière de biosécurité, tous les protocoles de re-
cherche en biologie synthétique aient lieu dans des 
laboratoires de niveau P3 ou P4 en matière de bio-
sécurité, ce qui aurait des implications précises en 
ce qui concerne le développement de ce domaine 
scientifique.

Le GEE est d’avis que les considérations sur la biosécu-
rité constituent une condition indispensable à la pro-
motion et à la mise en œuvre d’un programme euro-
péen de recherche en matière de biologie synthétique, 
à la fois sur le plan national et international.

Recommandation n° 1: Le GEE recommande que toute 
utilisation de la biologie synthétique soit subordonnée 
aux questions spécifiques de sécurité définies dans le 
présent avis. Dès lors, le GEE demande:

1)   que la Commission lance une étude sur les procé-
dures actuelles d’évaluation des risques au sein de 
l’UE. Cette étude devrait a) faire une enquête sur les 
procédures pertinentes en matière de biosécurité, 
b) déceler les lacunes éventuelles dans la régle-
mentation actuelle sur la biosécurité afin d’évaluer 
efficacement les organismes et les produits nou-
veaux créés au moyen de la biologie synthétique, 
c) indiquer le mécanisme permettant de combler 
les lacunes décelées; 

2)  que la procédure d’évaluation des risques ainsi dé-
terminée soit ensuite mise en œuvre par les autori-
tés compétentes au sein de l’UE (par exemple la CE, 
l’EMEA et l’EFSA) et par les autorités nationales;

3)  que le financement de la recherche en biologie 
synthétique et la commercialisation de produits 
issus de la biologie synthétique dans l’UE soient 
subordonnés à ces conditions. 

(7)  Cf. les méthodes d’évaluation des risques telles que débattues 
dans l’avis du GEE sur les aspects éthiques de la nanoméde-
cine.

e
u
q
i
t
é
h
t
n
y
s

e

i

g
o

l

o

i

b
e
d
e
u
q

i

h
t
É

62

 
 
 
RECOMMANDATIONS | 4

Recommandation n° 2: Le GEE propose qu’une fois la 
réglementation susmentionnée en matière de biosé-
curité définie, la Commission lance un débat interna-
tional avec les parties concernées afin de favoriser une 
approche standardisée de la biosécurité en matière de 
biologie synthétique pour les tests financés par des 
fonds publics et privés. Les instruments de suivi de 
la mise en application de ces dispositions devraient 
être considérés comme faisant partie intégrante de la  
réglementation en matière de biosécurité (y compris 
des questions de fiabilité).

Recommandation n° 3: Le GEE invite la Commission 
à préparer un code de conduite pour la recherche sur 
les microorganismes synthétiques. Ce code devrait, 
par exemple, garantir que les organismes de biologie 
synthétique soient fabriqués de telle façon qu’ils ne 
puissent survivre de manière autonome s’ils étaient 
libérés accidentellement dans l’environnement.

4.2.1.  Applications environnementales 

Le GEE est conscient du fait que la biologie synthétique 
peut également avoir des applications environnemen-
tales. Il reconnaît le rôle joué par la recherche actuelle 
en matière de biologie synthétique, notamment pour 
réduire les polluants présents dans l’environnement 
(bioréhabilitation) tels que les métaux lourds, les pesti-
cides et les matériaux radioactifs. Il a connaissance des 
recherches actuelles visant à produire des agents de 
biologie synthétique capables de dégrader des pesti-
cides afin de réduire leur impact environnemental (8) 
ou visant à produire des biocapteurs pour les eaux 
polluées (9). Il déclare que l’objectif d’amélioration de 
la protection de l’environnement et de fabrication de 
nouveaux outils de détection est un objectif positif 
qui peut contribuer au bien-être humain et à la pro-
tection de l’environnement. Cependant, des questions 
spécifiques surgissent, du point de vue de la biosé-
curité, lorsque des applications environnementales 
de biologie synthétique sont envisagées. Dès lors, 
une évaluation appropriée en matière de sécurité et 
d’impact environnemental devrait être réalisée avant 

(8)  Cf. http://pbd.lbl.gov/synthbio/aims.htm.

(9)  La contamination de l’eau potable à l’arsenic est un véritable 
problème dans certains pays en développement comme le 
Bangladesh. Cf. Aleksic J., Bizzari F., Cai Y. et al. (2007), «Deve-
lopment of a novel biosensor for the detection of arsenic in 
drinking water», Synthetic Biology, IET 1, p. 87–90. 

toute approbation préalable à une dissémination en 
milieu ouvert.

Dans le domaine des applications environnementales, 
la fabrication de systèmes ou d’organismes biologiques 
antipollution doit être examinée en tenant compte des 
aspects de protection des travailleurs et des citoyens, 
de liberté des consommateurs, et de responsabilité, y 
compris celle due aux animaux, aux plantes et à l’envi-
ronnement en général. (10) 

Recommandation n° 4: Le GEE recommande que, préa-
lablement à la dissémination dans l’environnement d’un 
organisme fabriqué ou modifié par l’intermédiaire de la 
biologie synthétique, des études d’évaluation d’impact 
à long terme soient réalisées. Les données dégagées 
par ces études devraient ensuite être évaluées en tenant 
compte du principe de précaution (10) et des mesures 
prévues dans la législation européenne (directive rela-
tive à la dissémination volontaire d’organismes généti-
quement modifiés dans l’environnement). En l’absence 
d’évaluation favorable, la dissémination d’organismes 
fabriqués ou modifiés ne devrait pas être autorisée.

4.2.2.  Énergie et industrie chimique durable

Le GEE est conscient du fait que la biologie synthétique 
pourrait contribuer au développement d’une industrie 
chimique durable, en particulier à la production de mi-
croorganismes de biologie synthétique visant à rempla-
cer les agents et les méthodes actuellement utilisées 
par l’industrie chimique organique pour sa production 
de matières premières.

S’agissant de l’utilisation de la biologie synthétique à 
des fins énergétiques, le GEE a également connaissance 
du fait que la recherche en matière de biologie synthé-
tique vise actuellement à concevoir des bactéries desti-
nées à produire des composés organiques (11) amenés 
à remplacer le pétrole ou à produire de l’hydrogène à 
partir de différentes sources (12). 

(10)  Directive 2001/18/CE, directive 98/81/CE et cadre réglemen-

taire au chapitre 2.1. de l’avis.

(11)  Tels que des acides gras parfaitement adaptés à l’utilisation 
en tant que biodiesel ou d’autres composés à forte teneur 
énergétique.

(12)  Cf. aussi: LS9 (www.ls9.com), Amyris (www.amyris.com), OPX 
Biotechnologies (www.opxbiotechnologies.com), Solazyme 
(www.solazyme.com), Gevo (www.gevo.com).

63

4 | RECOMMANDATIONS

Le GEE reconnaît que ces applications gagneront en 
importance compte tenu de la diminution des réser-
ves de carburant fossile et de l’impact climatique de 
la combustion des carburants fossiles. Toutefois, il se 
préoccupe des implications possibles en matière de 
sécurité et propose dès lors ce qui suit:

Recommandation n° 5: Le GEE propose que l’utilisation 
de la biologie synthétique en tant que source d’éner-
gie de substitution pour les États membres de l’UE soit 
complémentaire au plan d’action de l’UE en matière 
d’énergie renouvelable, et que les essais de recherche 
au niveau international (UE - États-Unis, par exemple) 
soient promus et cofinancés afin de favoriser une stra-
tégie internationale intégrée.

Recommandation n° 6: Le GEE recommande que les 
autorités compétentes suivent de manière appropriée 
les procédures d’autorisation de la production de ma-
tériaux et de produits chimiques dérivés de la biologie 
synthétique, si cette production n’est pas identique à 
des substances équivalentes, en prenant en considé-
ration a) les facteurs d’évaluation des risques, b) la sé-
curité des travailleurs exposés aux agents chimiques 
provenant de la biologie synthétique et c) la protection 
de l’environnement. 

S’agissant de l’utilisation de la biologie synthétique 
pour les produits chimiques et les matériaux nouveaux, 
le GEE est conscient du fait que les produits chimiques 
non destinés aux denrées alimentaires ou aux aliments 
pour animaux qui sont dérivés d’organismes généti-
quement modifiés ne demandent pas un étiquetage 
spécifique les identifiant comme génétiquement mo-
difiés. Le GEE est conscient du fait que la quasi-totalité 
des produits de la biologie synthétique entrant dans 
la composition de denrées alimentaires ou d’aliments 
pour animaux qui contiennent ou sont des organismes 
modifiés ou dérivent de ces organismes devraient être 
étiquetés comme génétiquement modifiés. Toutefois, 
le GEE exprime ses préoccupations à propos d’utilisa-
tions possibles de la biologie synthétique dans l’indus-
trie cosmétique et textile.

4.2.3.  Biomédecine et production biopharmaceutique 

La biologie synthétique ouvre de nouvelles perspecti-
ves en matière d’applications médicales, telles que la 
conception et l’amélioration de biocapteurs, de médica-
ments, de thérapies, d’appareils et de cellules disposant 
de propriétés nouvelles qui pourraient être utilisées 
pour améliorer la santé humaine ou les méthodes théra-
peutiques. Des applications de la biologie synthétique 
sont prévues dans les domaines suivants: production 
de médicaments, mise au point de nouveaux vaccins, 
appareils médicaux tels que biocapteurs, diagnostics, 
synthèse de virus pour les thérapies génétiques et uti-
lisations potentielles dans la thérapie anticancéreuse.

Le GEE est conscient du fait que les utilisations médica-
les de la biologie synthétique en sont pour le moment 
au stade de la recherche fondamentale et que les ap-
plications cliniques de nouveaux médicaments et de 
nouvelles méthodes sont encore loin d’être disponibles 
pour les patients. 

Comme décrit au chapitre deux du présent avis, le GEE 
indique que les applications médicales de la biologie 
synthétique ne peuvent pas enfreindre le cadre des 
droits fondamentaux et de l’éthique précédemment 
établi et doivent être soumises à des dispositions stric-
tes en matière de biosécurité. Pour les produits actuel-
lement envisagés, le cadre réglementaire existant régit 
dans l’ensemble de manière appropriée l’utilisation de 
la biologie synthétique et doit être appliqué. (13)

Recommandation n° 8: Le GEE recommande que, outre 
l’application de cadres scientifiques et juridiques, des 
considérations éthiques spécifiques soient également 
prises en compte par les autorités compétentes (telles 
que l’EMEA(13)) lorsque paraîtront des médicaments et 
des produits médicaux résultant de protocoles fondés 
sur la biologie synthétique. Les données concernant 
les applications médicales de la biologie synthétique 
mises en pratique dans les États membres de l’UE 
ou résultant de financements de l’UE devraient être  
collectées par des organes compétents dans les pays 

Recommandation n° 7: Le GEE affirme que la protection 
des droits des consommateurs est un élément crucial à 
prendre en considération en ce qui concerne le marché 
intérieur de l’UE et insiste sur le fait que l’étiquetage de 
produits spécifiques issus de la biologie synthétique, 
tels les cosmétiques et les textiles, devrait être exploré. 

(13)  Comme l’exige la législation européenne, les produits mé-
dicaux provenant de la biologie synthétique seront évalués 
du point de vue de la sécurité. Les autorités compétentes 
des états membres et de l’UE (EMEA) devraient s’assurer que 
les considérations en matière de sécurité exprimées dans le 
présent avis soient prises en compte avant toute procédure 
d’autorisation d’essais cliniques et de recherche et toute pro-
cédure de commercialisation.

e
u
q
i
t
é
h
t
n
y
s

e

i

g
o

l

o

i

b
e
d
e
u
q

i

h
t
É

64

 
 
 
RECOMMANDATIONS | 4

où ces essais ont lieu et devraient être rendues dispo-
nibles au niveau international.

4.3.  Biosécurité, prévention du  

bioterrorisme et doubles usages

S’agissant de biosécurité, le GEE est conscient des uti-
lisations et abus possibles de la biologie synthétique 
ainsi que de la recherche actuelle dans l’UE et aux États-
Unis dans ce secteur spécifique. La biologie synthéti-
que peut permettre la conception de nouveaux outils 
pouvant être utilisés à des fins militaires, qu’il s’agisse 
de biomatériaux ou d’armes biologiques. L’analyse éthi-
que doit mettre en balance l’objectif de sécurité et le 
besoin de transparence:

•	

•	

•	

la	production	et	l’utilisation	possible	de	matériaux	
ou de systèmes provenant de la biologie synthé-
tique dans les politiques nationales de sécurité, y 
compris la production d’armes biologiques. Ces uti-
lisations doivent avoir lieu dans le respect des cadres 
réglementaires nationaux et internationaux actuels. 
La transparence et la diffusion d’informations peu-
vent favoriser les abus à des fins terroristes, mais une 
société ouverte doit trouver des façons de gérer le 
difficile équilibre entre le droit à l’information des 
citoyens et la nécessité d’assurer leur sécurité;

la	production	et	l’utilisation	possible	de	matériaux	
ou de systèmes provenant de la biologie synthéti-
que à des fins terroristes, en particulier la produc-
tion de systèmes biologiques qui présentent un fort 
potentiel de destruction. Il convient de s’attaquer à 
tout usage impropre des connaissances en biologie 
synthétique; 

la	production	d’organismes	synthétique	en	dehors	
des institutions reconnues. Étant donné que les 
matériaux et les procédures en matière de biologie 
synthétique sont à la disposition du grand public, la 
génétique libre constitue un autre scénario exigeant 
une gouvernance en matière de sécurité.  

Le GEE prend également note de la récente commu-
nication adoptée par la Commission européenne le  
24 juin 2009 (14), qui définit la nouvelle politique de l’UE 
dans le domaine chimique, biologique, radiologique ou 

nucléaire (CBRN). S’il considère cette initiative comme 
louable, elle n’est toutefois selon lui pas encore suffi-
sante dans l’optique d’une approche saine et démocrati-
que, d’un point de vue éthique, de la biosécurité au sein 
de l’UE et au delà. Le GEE se félicite de l’intégration des 
préoccupations éthiques dans la formation des scien-
tifiques spécialisés dans la biosécurité, y compris d’ac-
tions spécifiques visant à clarifier la dimension éthique 
des utilisations de la biologie synthétique en matière 
de biosécurité. 

S’agissant des applications de biologie synthétique, 
toutefois, des informations concernant la fabrication de 
virus de synthèse, par exemple, pourraient provoquer 
une nouvelle vague de bioterrorisme. Rares ont été les 
débats sur la manière de gérer ce risque. Il convient de 
protéger la santé des civils et des militaires, de garan-
tir une transparence aussi poussée que possible et de 
permettre la recherche uniquement dans le cadre d’un 
encadrement strict. Comme décrit au chapitre trois du 
présent avis, le GEE soutient que les applications de la 
biologie synthétique à des fins militaires et de sécu-
rité ne doivent pas enfreindre le cadre de l’éthique et 
des droits fondamentaux établi dans le présent avis. 
La tâche de prévention d’usages terroristes et/ou mal-
veillants de la biologie synthétique place les chercheurs 
comme les États démocratiques devant le dilemme 
moral du double usage. La dualité de certains objectifs, 
intentionnelle ou non, peut être prévue, mais pas dans 
tous les cas. Une façon de traiter le dilemme du double 
usage passe par les mécanismes de contrôle tels que 
le brevetage et l’enregistrement des outils utilisés par 
la biologie synthétique.

Parmi les exemples de mesures envisageables pour 
prévenir toute action militaire ou terroriste inaccep-
table figurent: 1) l’établissement, au niveau européen 
au moins, mais de préférence au niveau international, 
d’une base de données centralisée dans laquelle les 
autorités compétentes enregistreraient tous les synthé-
tiseurs d’ADN; 2) l’inscription dans le registre susmen-
tionné des départements ou groupes de recherche tra-
vaillant sur l’utilisation de la biologie synthétique dans 
les domaines de la biosécurité ou de la biodéfense; 3) la 
définition, au niveau des États membres et de l’UE, de 
critères de publication des données concernant les vi-
rus ou les agents toxiques hautement pathogènes (15)

(14)  COM(2009)  273  final;  SEC(2009)  874;  SEC(2009)  790;  

SEC(2009) 791

(15)  En matière d’organismes génétiquement modifiés, y com-
pris ceux produits grâce aux techniques de la biologie syn-
thétique, des réglementations sont en vigueur en Europe, 
qui exigent un enregistrement et/ou une approbation des  

65

4 | RECOMMANDATIONS

Il convient en outre d’envisager les questions éthiques 
soulevées par le risque de double usage sous un angle 
pédagogique. Il est crucial de responsabiliser les indivi-
dus et les institutions en suscitant le débat sur l’éthique 
de la biologie synthétique.

Recommandation n° 9: Le GEE recommande d’intégrer 
des dispositions sur la limitation ou l’interdiction de la 
recherche en biologie synthétique dans la convention 
sur l’interdiction de la mise au point, de la fabrication 
et du stockage des armes bactériologiques (biologi-
ques) ou à toxines et sur leur destruction. 

Recommandation n° 10: Le GEE demande à la Com-
mission de définir, en concertation avec lui, un cadre 
éthique et de sécurité complet en matière de biologie 
synthétique. 

Recommandation n° 11: Le GEE recommande que la 
Commission européenne

1)  garantisse que les bases de données sont accessi-

bles à tous leurs utilisateurs; 

2)  fournisse aux entreprises les systèmes juridiques 
leur permettant de faire rapport aux autorités 
compétentes lorsque ces entreprises sont chargées 
de synthétiser des séquences suspectes, tout en ga-
rantissant la confidentialité; 3) détermine la chaîne 
des responsabilités pour l’intégration de séquences 
particulières dans la (les) base(s) de données et leur 
identification comme potentiellement nocives. 

4.4.  Gouvernance

Le GEE préconise également que lorsqu’il est prévu 
d’utiliser une technologie dans l’UE, il convient d’en 
étudier soigneusement ses effets et de les soumettre 
à une évaluation d’impact qui inclue à la fois les ris-
ques et les profits des technologies nouvelles et ceux 
des technologies remplacées. Cette évaluation devrait 
prendre place dans le contexte de l’approche intégrée 
de la biologie synthétique qui tient compte des impli-
cations tant environnementales que sociales. Outre la 
gouvernance du risque technologique, il convient de 
mettre en place une stratégie plus large et mieux à 

infrastructures où ces organismes peuvent être cultivés et 
étudiés. Cf. également la page 40 du présent avis et l’article 7 
de la directive 98/81/CE du Conseil.

même, par rapport aux instruments actuels, de s’adap-
ter aux changements qui pourraient affecter l’environ-
nement, les sociétés, les économies de marché ou les 
politiques nationales. L’éthique de la biologie synthé-
tique devrait étudier au cas par cas les bénéfices et 
les dangers de cette technologie pour certains milieux 
écologiques ainsi que les risques et les bénéfices éven-
tuels pour l’ensemble de la biosphère. (16) 

Une utilisation responsable de la biologie synthétique 
devrait impliquer l’utilisation d’outils de gouvernance 
visant à encourager les avancées scientifiques et les 
applications de la recherche qui pourraient être bé-
néfiques à la santé humaine, ainsi qu’à contribuer aux 
économies d’énergie et à la réduction des effets néga-
tifs du changement climatique tout en prévenant les 
abus de la biologie synthétique, à savoir le bioterroris-
me, et en préservant la biosécurité et la biosûreté. Il ne 
s’agit pas d’une sinécure et cette tâche pose un certain 
nombre de questions auxquelles l’UE doit répondre.

a) Questions d’ordre général: comment les outils de 
gouvernance peuvent-ils 

–  encourager l’utilisation à des fins bénéfiques et 
prévenir les abus? Quand y a-t-il risque de double 
usage?  

–  encourager la transparence sans créer les condi-

tions favorables aux abus?  

–  protéger contre les abus sans introduire une cen-
sure non souhaitée des publications et autres?

b) Défis spécifiques de gouvernance: comment l’UE 
peut-elle utiliser les outils de gouvernance afin de  

•	

tenir	compte	du	fait	que	la	biologie	synthétique	
consiste en un grand nombre de domaines compre-
nant des niveaux et une densité de réglementation 
très variés et déceler les lacunes éventuelles dans la 
préservation de la biosécurité et de la biosûreté?

(16)  Cf. Markus Schmidt, Helge Togersen, Agomoni Ganguli-
Mitra, Alexander Kelle, Anna Deplazes, Nikola Biller-Andorno, 
«SYNBIOSAFE e-conference: online community discussion 
on the societal aspects of synthetic biology», in: Systems 
and Synthetic Biology (16 septembre 2008). Accessible en 
ligne à l’adresse suivante: http://www.zora.uzh.ch/3947/2/
Schmidt_m_torg.V.pdf
Paul Rabinow & Gaymon Bennett, From Bio-Ethics to Human 
Practice. Working Paper no 11, 2007 http://anthropos-lab.
net/wp/publications/2007/08/workingpaperno11.pdf.

e
u
q
i
t
é
h
t
n
y
s

e

i

g
o

l

o

i

b
e
d
e
u
q

i

h
t
É

66

 
 
 
 
RECOMMANDATIONS | 4

•	 déterminer	les	domaines	où	des	normes	juridiques	
non contraignantes offriront une protection suffi-
sante	et	ceux	où	une	législation	contraignante	est	
jugée nécessaire (cf. recommandation n° 2 sur la 
réglementation en matière de biosécurité et la re-
commandation n° 9 sur la convention sur les armes 
biologiques)?

•	 encourager	les	responsabilités	professionnelles	
pour les chercheurs individuels et les institutions 
(y compris les scientifiques qui ne sont pas néces-
sairement habitués à travailler avec des organismes 
vivants et les problèmes spécifiques que cela im-
plique) et compléter le code de conduite proposé 
dans la recommandation n° 3?

•	

jouer	un	rôle	dans	la	recherche	nécessaire	d’une	
gouvernance mondiale en matière de biologie syn-
thétique?  

Le GEE exprime ses préoccupations quant à l’actuel ca-
dre réglementaire fragmenté, qui pourrait ne pas être 
suffisant pour réglementer de manière appropriée les 
aspects actuels et à venir de la biologie synthétique. Il 
insiste également sur la nécessité d’examiner la mise 
en place d’un modèle approprié de gouvernance en 
matière de biologie synthétique (normes juridiques 
non contraignantes, codes de conduite, etc.), en tenant 
compte aussi des risques de délocalisation des essais 
de	recherche	dans	des	pays	où	la	réglementation	pour-
rait être moins contraignante que celle en vigueur dans 
l’UE. 

Recommandation n° 13: Le GEE recommande vive-
ment à la Commission de proposer un solide cadre 
de gouvernance pour la biologie synthétique et de 
le mettre en place au niveau de l’UE. La Commission 
devrait réviser la législation applicable à la biologie 
synthétique et évaluer sa pertinence par rapport aux 
questions soulevées par la biologie synthétique. Le 
cadre susmentionné devrait prendre en compte les 
parties prenantes concernées (scientifiques, indus-
tries, agents militaires, politiques et administratifs) et 
indiquer clairement leurs responsabilités. 

Recommandation n° 14: Les communautés scientifi-
ques concernées devraient être encouragées à établir 
des lignes directrices éthiques, de préférence au niveau 
mondial, qui pourraient faire office de points de repère 
et inciter les institutions scientifiques et les chercheurs 

individuels à évaluer l’incidence de leur travail, y com-
pris les conséquences d’abus éventuels (17).

Recommandation n° 15: Le GEE propose que l’UE 
soulève la question de la gouvernance de la biologie 
synthétique au sein de forums mondiaux consacrés 
à ce sujet.

4.5.  Propriété intellectuelle

4.5.1.   Brevetage et patrimoine commun   (17)

Les questions soulevées par le brevetage des méthodes 
et des matériaux biologiques font l’objet de vifs débats 
depuis quelque temps et sont maintenant à l’ordre du 
jour de discussions dans différentes disciplines. Le fait 
que les brevets remplissent une fonction de stimula-
tion de la recherche et de ses applications concrètes 
ainsi qu’une fonction de promotion de la diffusion au 
grand public de la base des applications peut être re-
mis en question par l’énorme quantité de demandes de 
brevets relatifs au matériel génétique et aux méthodes 
biologiques. Parallèlement, l’appropriation d’éléments 
d’organismes biologiques par des acteurs industriels 
spécifiques a également soulevé un certain nombre de 
questions éthiques. L’article 7 de la directive sur les bre-
vets concernant les inventions biotechnologiques dis-
pose que «le groupe européen d’éthique des sciences 
et des nouvelles technologies de la Commission évalue 
tous les aspects éthiques liés à la biotechnologie». C’est 
le seul article de la directive qui n’ait pas été appliqué 
dans la réglementation mettant en œuvre cette direc-
tive de l’Office européen des brevets ou des offices des 
brevets des différents États membres. Il est difficile à 
appliquer étant donné qu’il ne précise aucune action 
et qu’aucun autre article ne reprend sa teneur. Les dif-
férents offices nationaux des brevets se sont souvent 
plaints de ce que les clauses morales du droit européen 
des brevets sont difficiles à interpréter (allant même 
jusqu’à proposer qu’elles soient abordées par une autre 
législation). Le GEE propose que, lorsqu’une demande 
de brevet soulève une question d’ordre général dans 
le domaine de la biotechnologie (y compris la nano-
technologie et la biologie synthétique), les offices des 
brevets concernés demandent l’avis du GEE dans le do-
maine général concerné par le brevet déposé.

(17)  Cf. les principes éthiques du programme MOST de l’Unesco 
pour une recherche internationale et comparative des 
sciences sociales.

67

4 | RECOMMANDATIONS

S’agissant de la question du brevetage et du patrimoi-
ne commun, le GEE reconnaît la complexité du sujet, 
comme le signale déjà l’annexe I du présent avis. Le GEE 
souligne que les questions éthiques générales soule-
vées par les demandes de brevet doivent être traitées 
de manière adéquate dans le cadre du système de dé-
livrance des brevets. 

Recommandation n° 16: Le GEE propose que soient 
lancés des débats sur les façons les plus appropriées de 
garantir l’accès du public aux résultats de la biologie 
synthétique. Ces débats devraient également porter 
sur ce qui peut faire l’objet d’un brevet et sur ce qui 
devrait relever du domaine public.

Recommandation n° 17: Conformément à la directive 
européenne sur les brevets (98/44/CE), l’organe char-
gé d’évaluer les implications éthiques des brevets est 
le GEE. Ce dernier recommande vivement à l’Office 
européen des brevets et aux offices des brevets des 
différents États membres de tenir compte de l’arti-
cle 7 de la directive sur les brevets et de rapporter les 
questions éthiques controversées d’ordre général au 
GEE afin que celui-ci les examine. Ce point est parti-
culièrement important lorsqu’il s’agit de définir une 
classe d’inventions qui ne devrait pas être directement 
exploitée commercialement (18).

4.5.2.   Commerce et justice mondiale (18)

Le GEE est conscient de la dimension mondiale de la 
biologie synthétique et de ses applications et considère 
le développement économique et la croissance du bien-
être social comme un objectif positif de l’UE. La biologie 
synthétique peut contribuer à la prospérité socio-éco-
nomique de l’UE et au-delà. Le GEE se félicite de cette 
possibilité, pour autant que ce secteur technologique 
et le commerce de ses produits ne portent pas atteinte 

(18)  L’article 6, paragraphe 2, de la directive 98/44/CE fournit une 
liste indicative des procédés exclus du brevetage, à savoir: 
«a) les procédés de clonage des êtres humains; b) les pro-
cédés de modification de l’identité génétique germinale 
de l’être humain; c) les utilisations d’embryons humains à 
des fins industrielles ou commerciales; d) les procédés de 
modification de l’identité génétique des animaux de nature 
à provoquer chez eux des souffrances sans utilité médicale 
substantielle pour l’homme ou l’animal, ainsi que les ani-
maux issus de tels procédés.» L’article 7 dispose également 
que «le groupe européen d’éthique des sciences et des 
nouvelles technologies de la Commission évalue tous les 
aspects éthiques liés à la biotechnologie.»

aux principes de la Charte européenne des droits fon-
damentaux ni aux principales valeurs fondamentales 
de l’UE. C’est pourquoi le GEE se préoccupe des risques 
possibles d’une fracture technologique au sein de l’UE 
et entre les pays développés et moins développés.

Le GEE recommande l’intégration des valeurs fonda-
mentales de l’UE dans le commerce mondial des pro-
duits issus de la biologie synthétique. Tout comme dans 
ses avis précédents (tels que les avis 23 (19) et 24 (20)), 
il souligne la nécessité d’introduire des considérations 
éthiques dans le commerce mondial et dans les actions 
de l’Organisation mondiale du commerce.  

Il conviendrait dès lors de prendre des mesures visant à 
éviter l’accentuation de la fracture technologique. Si des 
essais impliquant des produits issus de la biologie syn-
thétique sont menés dans les pays en développement 
et émergents, il convient d’appliquer les mêmes normes 
éthiques que celles en vigueur au sein de l’UE (21). Les 
objectifs du millénaire pour le développement des Na-
tions unies devraient être mis en œuvre. (22)

Recommandation n° 18: Le GEE recommande que lors-
que la biologie synthétique fera l’objet de discussions 
au niveau international, y compris au sein de l’OMC, 
les questions éthiques associées à cette technologie (22) 
soient abordées. Ce point devrait être pris en considé-
ration lors des négociations du cycle de Doha.

Recommandation n° 19: Le GEE recommande vive-
ment que les normes européennes de biosécurité pour 
les produits issus de la biologie synthétique, telles que 
définies dans les recommandations n° 1, 2 et 5 du pré-
sent avis, soient adoptées au titre de normes minima-
les pour les importations et exportations européennes 
de produits issus de la biologie synthétique.  

Recommandation n° 20: Le GEE recommande que l’UE 
prenne des mesures spécifiques afin d’éviter de nouvel-
les fractures entre l’UE et les pays en développement 
et émergents, ou au sein des États membres de l’UE, 

(19)  http://ec.europa.eu/european_group_ethics/activities/

docs/opinion23_en.pdf

(20)  http://ec.europa.eu/european_group_ethics/docs/

opinion24_en.pdf

(21)  http://ec.europa.eu/european_group_ethics/docs/avis17_

en.pdf

(22)  Cf. chapitres 2.2.b et 2.2.c du présent avis.

e
u
q
i
t
é
h
t
n
y
s

e

i

g
o

l

o

i

b
e
d
e
u
q

i

h
t
É

68

 
 
 
RECOMMANDATIONS | 4

et afin de mettre en application les recommandations 
formulées dans le présent avis. De telles mesures de-
vraient être introduites dans les programmes scienti-
fiques bilatéraux et multilatéraux de l’UE et dans les 
politiques de l’UE concernant les pays en développe-
ment et émergents.

4.6.  Dialogue entre la science et la société 

civile

Comme développé dans le chapitre 3 du présent avis, la 
problématique éthique de la biologie synthétique est 
complexe et les questions conceptuelles mises au jour 
appellent à un dialogue efficace entre la science et la 
société civile. 

La perception de la biologie synthétique est influencée 
par des considérations sociales, culturelles et éthiques 
portant sur la manipulation de la vie, les implications 
économiques pour les régions développées et en dé-
veloppement, les questions relatives à la propriété et à 
la propriété intellectuelle, les préoccupations à propos 
de la dégradation de l’environnement et des risques 
d’utilisations militaires, etc. Les médias traditionnels et 
interactifs jouent un rôle important dans la représen-
tation que les gens se font des technologies nouvelles 
et émergentes, y compris de la biologie synthétique. 
Chacune de ces questions mérite une considération et 
une participation publique approfondies. Ce point sou-
lève plus largement la question de la confiance à établir 
entre la communauté scientifique et le grand public, y 
compris la nécessité de promouvoir un débat approprié. 
Enfin, cet aspect conduit à aborder des questions relati-
ves à la démocratie délibérative, y compris la question 
de savoir qui trace les limites entre ce qui est permis, 
acceptable, et ce qui ne l’est pas, et qui contrôle ceux 
qui tracent ces limites.

Les spécialistes des sciences sociales ont suggéré qu’un 
engagement en amont pourrait favoriser un dévelop-
pement scientifique et technologique qui soit cohérent 
avec les attentes, les préoccupations et les souhaits de 
la société (23). De nombreux scientifiques travaillant 
dans le domaine de la biologie synthétique sont déjà 
conscients de l’importance de l’engagement public et, 
dans cette optique, se sont impliqués dans des activités 
telles que des débats, des balados et des blogs.

(23)  http://www.bbsrc.ac.uk/organisation/policies/reviews/

scientific_areas/0806_synthetic_biology.pdf 

Le débat public doit être alimenté par des informations 
correctes sur les caractéristiques effectives et les po-
tentialités de la biologie synthétique, ce qui pourrait 
soulever des difficultés de définition, d’évaluation et de 
gestion	des	risques	dans	un	domaine	où	les	incertitudes	
et les lacunes des connaissances sont considérables et 
où	les	risques	à	court	et	long	terme	peuvent	être	dif-
férents. Des considérations similaires s’appliquent 
aux conséquences des «battages» auxquels le public 
est confronté, à travers les médias et les écrivains de 
science-fiction qui élaborent des scénarios irréalistes à 
propos de produits issus de la biologie synthétique (par 
exemple, le battage au sujet de la possibilité de guérir 
toutes les maladies ou de la bioréhabilitation pour lut-
ter contre la pollution de l’environnement, ou encore 
des perspectives dans le cadre de la crise énergétique). 
La diffusion au grand public d’espoirs ou de craintes 
nourris par des informations non documentées fausse 
le débat public sur la biologie synthétique.

Recommandation n° 21: Le GEE demande à l’UE et à 
ses États membres de prendre des mesures pour pro-
mouvoir les débats publics entre parties prenantes 
ainsi que leur participation afin de cerner les princi-
pales préoccupations de la société dans les différents 
domaines concernés par la biologie synthétique.

Recommandation n° 22: Le GEE recommande que les 
journalistes, les éditeurs, y compris les éditeurs de pu-
blications scientifiques, et les autres parties prenantes 
promeuvent une couverture responsable des sujets 
touchant à la biologie synthétique. 

Recommandation n° 23: Afin de promouvoir une ap-
proche exhaustive des nouvelles technologies par les 
médias, le GEE demande à la Commission de favori-
ser des actions spécifiques telles que, par exemple, la 
création de forums, de séminaires et de cours abor-
dant les implications de la biologie synthétique dans 
les médias.

4.7.  Recherche

Depuis un certain temps, on observe que la recherche 
fondamentale, à la base de toutes les différentes ap-
plications dans un domaine donné, a été reléguée au 
second plan dans les programmes de financement de 
la recherche. Même si la recherche fondamentale ne 
doit pas être rigoureusement séparée de la recherche 
appliquée, elle a besoin d’un financement public qui 
devrait s’inscrire au cœur de la politique de l’UE. 

69

disciplinaire portant sur les aspects suivants de la 
biologie synthétique: 

-  évaluation des risques et sécurité,
-  utilisations de la biologie synthétique à des fins de 

sécurité,
implications éthiques, juridiques et sociales,

- 
-  gouvernance;
- 

science et société (y compris les médias et le public).

Ce soutien devrait se refléter dans le budget alloué 
aux programmes-cadres de recherche et de dévelop-
pement de l’UE. Une invitation semblable est adressée 
aux États membres de l’UE à propos de leurs program-
mes de recherche et de développement nationaux. 

Recommandation n° 26: Le GEE note que la biologie 
synthétique pourrait entraîner, à l’avenir, un change-
ment de paradigme dans la compréhension du vivant. 
C’est pourquoi il invite la Commission à mettre sur pied 
un forum interculturel et ouvert où ces questions pour-
ront être abordées et qui accordera également une 
place aux aspects philosophiques et religieux.

4 | RECOMMANDATIONS

La biologie synthétique a introduit dans la méthode 
scientifique de la biologie moderne un élément nou-
veau capital: la possibilité non seulement de se servir 
de démarches déductives fondées sur des phénomènes 
observés, mais aussi de synthétiser des outils heuristi-
ques permettant en eux-mêmes d’explorer des phéno-
mènes biologiques de base. Cependant, la recherche 
fondamentale en biologie synthétique n’est pas néces-
sairement liée directement aux intérêts commerciaux 
et industriels et dépend dès lors des financements pu-
blics. Le GEE s’inquiète de ce que cette absence de lien 
direct n’entraîne un manque de financement adéquat 
de la recherche fondamentale dans un proche avenir et 
que cela ne compromette le rôle que la recherche euro-
péenne pourrait jouer dans la gouvernance mondiale 
de la biologie synthétique.

Parallèlement, le débat éthique à propos de la biologie 
synthétique aborde des questions relatives à la légi-
timité éthique de la fabrication d’organismes vivants, 
tout comme pour le débat sur l’ingénierie du vivant. 
L’intervention de l’homme dans la nature, qui comprend 
l’environnement et d’autres organismes vivants, sou-
lève également des questions à propos du «caractère 
naturel» de cette intervention et de la «fabrication du 
vivant» (24). Le GEE souligne dès lors la nécessité de 
financer au niveau de l’UE des projets de recherche 
interdisciplinaire sur la relation entre les humains et la 
nature, en particulier par rapport aux questions concer-
nant le vivant.

Recommandation n° 24: Le GEE invite la Commission à 
soutenir la recherche fondamentale dans les domaines 
de la biologie, de la chimie, de l’énergie et de la science 
et de l’ingénierie des matériaux, ainsi que la recherche 
appliquée, telles que définies dans le présent avis. Ce 
soutien devrait se refléter dans le budget alloué aux 
programmes-cadres de recherche et de développe-
ment de l’UE. Une invitation semblable est adressée 
aux États membres de l’UE à propos de leurs program-
mes de recherche et de développement nationaux.

Recommandation n° 25: Le GEE demande à l’UE de  
financer de manière appropriée la recherche inter-

(24)  John Harris, «Who’s Afraid of a Synthetic Human?», The Times, 
17 mai 2008. Colin Nickerson, «A Quest to Create Life Out of 
Synthetics», Boston Globe, 2 avril 2008. Erik Parens, «Making 
Cells Like Computers», Boston Globe, 18 février 2008. Natalie 
Angier, «Pursuing Synthetic Life, Dazzled by Reality», New 
York Times, 5 février 2008.

e
u
q
i
t
é
h
t
n
y
s

e

i

g
o

l

o

i

b
e
d
e
u
q

i

h
t
É

70

 
 
 
Europäische gruppe 
für Ethik in naturwissenschaften 
und neuen technologien 
bei der Europäischen Kommission

STELLUNGNAHME DER EUROPäISCHEN  
GRUPPE FüR ETHIK  
IN NATURWISSENSCHAFTEN  
UND NEUEN TECHNOLOGIEN  
BEI DER EUROPäISCHEN KOMMISSION

Ethik  
der synthetischen 
Biologie

Bezug: 

Ersuchen von Präsident Barroso 

Berichterstatter:  Rafael Capurro, Julian Kinderlerer,  

Paula Martinho da Silva und  

Pere Puigdomenech Rosell

Nur der Originaltext auf Englisch ist authentisch.

Nr.

25

 
 
EMPFEHLUNGEN | 4

4. 

Empfehlungen

4.1.  Definition der Terminologie und  
Umfang der Stellungnahme

Wie bereits im ersten Abschnitt der Stellungnahme 
beschrieben, ist synthetische Biologie ein neues For-
schungsfeld, das sich daraus ergibt, dass hier verschie-
dene technologische und wissenschaftliche Disziplinen 
zusammenlaufen und das für ein besseres Verständnis 
der biologischen Systeme, ihrer Vielschichtigkeit und 
der sich neu herausbildenden Eigenschaften sorgt, die 
sich aus der Wechselwirkung komplexer Wege erge-
ben. Zugleich bietet die synthetische Biologie die Mög-
lichkeit der Herstellung von biologischen Erzeugnissen, 
die unmittelbar in einer Vielzahl von Sektoren wie Bio-
Medikamente, Biokraftstoffe, Rohstoffe oder biome-
dizinische Werkzeuge, wie etwa Impfstoffe oder auch 
neue biologische Abwehrstoffe, zum Einsatz gelangen. 
Die Gruppe erkennt an, dass es schwierig ist, bereits 
eingeführte Praktiken in der biologischen Forschung 
und den neuen, der synthetischen Biologie zugrunde 
liegenden Ansatz genau gegeneinander abzugrenzen. 
Nichtsdestoweniger lässt sich ein schrittweiser Über-
gang von der Veränderung biologischer Systeme hin 
zu ihrer Entwicklung feststellen, von der Entwicklung 
einfacher Systeme hin zur Konstruktion komplexer 
Systeme und von der Anpassung natürlicher biologi-
scher Systeme hin zur Auslegung bzw. Konstruktion 
von teilweise oder komplett künstlichen biologischen 
Systemen. 

Bislang gibt es noch keine international vereinbarte 
Definition dieses Forschungsbereichs, was im Hinblick 
auf den wissenschaftlichen Rahmen und das Regelwerk 
für die unterschiedliche Nutzung der synthetischen 
Biologie Verwirrung stiften könnte. Eine international 
anerkannte Definition der synthetischen Biologie ist 
daher insbesondere dann erforderlich, wenn die For-
schung und die Anwendungen in diesem Bereich einer 
Regelung bedürfen. 

Der Begriff „synthetische Biologie“ umfasst nach dem 
Verständnis der Gruppe (1) mindestens folgende As-
pekte: 1.) das Design von Minimalzellen bzw. -orga-
nismen (2) (einschließlich Minimalgenome), 2.) die 

(1)  Siehe Abschnitt 1.3 der Stellungnahme. 

(2)  Unter dem Begriff „Organismus“ werden in diesem Zusam-
menhang azellulare, einzellige oder mehrzellige biologische 
Einheiten verstanden, die verstärkt oder verändert werden 
können. 

Beschreibung und Verwendung von „bioparts“ (Werk-
zeugkasten) und 3.) die Konstruktion von teilweise oder 
komplett künstlichen biologischen Systemen.

Ein spezielles Anliegen sind die potenziellen Anwen-
dungen in den Bereichen Biomedizin, Biopharmaka, 
chemische Industrie, Umwelt und Energie, die Erzeu-
gung von intelligenten Materialien und von Biomate-
rialien, und zwar insbesondere (wenngleich nicht aus-
schließlich) unter dem Aspekt der Sicherheit (safety) 
und des Ausschlusses eines möglichen Missbrauchs 
(security). (3) Darüber hinaus erstreckt sich die Debatte 
auf Aspekte der Gerechtigkeit, der „Governance“, der 
Wissenschaft, des gesellschaftlichen Dialogs und des 
geistigen Eigentums sowie auf philosophische Diskus-
sionen über das Leben (4) (siehe Abschnitte 3.1 und 3.2). 
Im Hinblick auf weitere neue Technologien muss die 
synthetische Biologie im Einklang mit dem internati-
onalen Rahmen für Ethik und Menschenrechte (siehe 
Abschnitt 2.3 dieser Stellungnahme) und insbesondere 
mit dem Gebot der Achtung der Würde des Menschen 
stehen, die nicht nur als Grundrecht an sich verstanden 
wird, sondern „das eigentliche Fundament der Grund-
rechte“ bildet (5). 

Weitere ethische Grundsätze, die in diesem Zusam-
menhang berücksichtigt werden müssen, sind unter 
anderem der Sicherheitsgrundsatz, der Grundsatz der 
Nachhaltigkeit, das Prinzip der Gerechtigkeit, das Vorsor-
geprinzip, das Prinzip der Freiheit der Forschung sowie der 
Grundsatz der Verhältnismäßigkeit (6).

(3)  Siehe Andrew Balmer & Paul Martin: Synthetic Biology. Social 
and Ethical Challenges. Mai 2008. http://www.bbsrc.ac.uk/
publications/corporate/synthetic_biology.pdf .    

(4)  Siehe Markus Schmidt, Helge Togersen, Agomoni Ganguli-
Mitra, Alexander Kelle, Anna Deplazes, Nikola Biller-Andorno: 
SYNBIOSAFE e-conference: online community discussion on 
the societal aspects der synthetischen Biologie. In: Systems 
and Synthetic Biology 16. September (2008). Online: http://
www.zora.uzh.ch/3947/2/Schmidt_m_torg.V.pdf. 
Paul Rabinow & Gaymon Bennett: From Bio-Ethics to Human 
Practice. Working Paper # 11, 2007 http://anthropos-lab.net/
wp/publications/2007/08/workingpaperno11.pdf. 

(5)  Erklärung zu den Erläuterungen zur Charta der Grundrechte.

(6)  Demzufolge  (1) müssen Ziel oder Zweck der Forschung von 
Belang sein; (2) müssen die angewandten Methoden für die 
Erreichung der Zielvorgaben erforderlich sein; und (3) gibt 
es keine anderen, weniger umstrittenen oder gefährlichen 
Methoden, die zur Erreichung desselben Ziels angewandt 
werden könnten.

75

 
4 | EMPFEHLUNGEN

4.2.  Sicherheit

Im Umgang mit ethischen Fragen, die von der syn-
thetischen Biologie aufgeworfen werden, lautet ein 
grundsätzliches Postulat, dass in der Forschung eben-
so wie im Hinblick auf die Anwendungsmöglichkeiten  
die menschliche Gesundheit ebenso wenig gefähr-
det werden darf wie die Umwelt. Diesbezüglich ist 
Sicherheit eine Grundvoraussetzung für die Nutzung 
der synthetischen Biologie in jedweder Hinsicht. Viele 
sicherheitsrelevante Fragen in Bezug auf die syntheti-
sche Biologie wurden bereits vor dreißig Jahren auf der 
Sitzung zum Thema rekombinante DNA im Asilomar 
Conference Centre in Pacific Grove, Kalifornien, dis-
kutiert, was eine Debatte über die ethischen Aspekte 
der neu entstehenden Technologien auf der Grundlage 
von DNA auslöste, in deren Mittelpunkt insbesonde-
re die Sicherheit des Transfers von Genen von einem 
Organismus zu einem anderen über einen Vektor wie 
etwa ein Virus oder ein Plasmid stand. Derzeit gibt es in 
der EU Rechtsvorschriften zur biologischen Sicherheit 
einschließlich von Rechtsvorschriften zum Schutz der 
Gesundheit von Mensch und Tier oder von Menschen, 
die biologischen Stoffen und anderen Gefahrstoffen 
ausgesetzt sind. Die Frage lautet, ob der vorstehend 
beschriebene Rahmen den besonderen Merkmalen der 
synthetischen Biologie tatsächlich uneingeschränkt ge-
recht wird. 

Betrachtet man die Frage unter sicherheitsrelevanten 
Aspekten, so ergeben sich aus der synthetischen Bio-
logie eine Reihe von Fragen, unter anderem, wie die 
Sicherheit von Organismen bewertet werden kann, die 
ein Genom beinhalten, das anhand von rekombinanten 
DNA-Verfahren gewonnen wurde, und die Erzeugung 
von Systemen ermöglichen, bei denen Bestandteile 
aus einer Vielzahl von Quellen miteinander kombiniert 
werden. Wie solche Konstruktionen für die biologische 
Sicherheit von Organismen bewertet werden sollen, 
die möglicherweise Gene oder Proteine enthalten, die 
noch niemals zusammen in einem biologischen Or-
ganismus existiert haben, oder die neu konstruierte 
biologische Funktionen umfassen, die in der Natur gar 
nicht vorkommen, ist nach wie vor unklar. 

Anlass zur Besorgnis bieten aber auch die unbekannten 
Risiken für die Umwelt und die öffentliche Gesundheit, 
die durch unerwartete Wechselwirkungen zwischen 
synthetischen Mikroorganismen und der Umwelt oder 
anderen in der Umwelt vorkommenden Organismen 
ausgelöst werden. Ein horizontaler Gentransfer und 
dessen potenzielle Auswirkungen auf das Gleichge-
wicht der Ökosysteme oder auch die Wechselwirkung 

zwischen synthetischen Mikroorganismen und in der 
Natur vorkommenden Stoffen oder auch die unvor-
hergesehene Entwicklung synthetischer biologischer 
Substanzen sind allesamt Risiken, die sich aus einer un-
kontrollierten Nutzung von Stoffen der synthetischen 
Biologie oder aus dem unbeabsichtigten Vorkommen 
von Organismen in der Umwelt ergeben können. 

Die Bedenken im Zusammenhang mit der Biosicherheit 
wirken sich auch auf die Methoden der Risikobewer-
tung aus, die in der EU im Zusammenhang mit der Bio-
logie entwickelt wurden. Die Methoden zur Bewertung 
genetisch veränderter Organismen (GVO) beruhen auf 
einem Vergleich des veränderten Organismus mit den 
natürlichen Organismen, die ihnen als „Vorbilder“ die-
nen, wobei jedes einzelne der eingebrachten Merkmale 
genau geprüft wird (7). Die synthetische Biologie wird 
Organismen hervorbringen, die sich durch eine Vielfalt 
von Merkmalen von vielen verschiedenen Organismen 
auszeichnen und deren Eigenschaften sich daher nur 
schwer vorhersagen lassen. 

Die Biosicherheit von Erzeugnissen der synthetischen 
Biologie ist ein Thema, das von Wissenschaftlern und 
Entscheidungsträgern heftig diskutiert wird. Einige 
Wissenschaftler haben sogar vorgeschlagen, alle For-
schungsprotokolle der synthetischen Biologie von 
Labors der Biosicherheitsstufe P3 oder P4 erstellen zu 
lassen, solange keine eindeutigen Daten zur Biosicher-
heit vorliegen, was mit klaren Folgen für die weitere 
Entwicklung dieses Gebiets der Wissenschaft verbun-
den ist.  

Die Gruppe ist der Auffassung, dass Überlegungen 
zur Biosicherheit unabdingbare Voraussetzungen für 
die Förderung und Umsetzung eines EU-Forschungs-
programms im Bereich der synthetischen Biologie auf 
nationaler wie internationaler Ebene sind.

Empfehlung Nr. 1: Die Gruppe empfiehlt, dass der 
Einsatz der synthetischen Biologie von bestimmten 
Sicherheitsfragen abhängig gemacht wird, die in die-
ser Stellungnahme näher ausgeführt werden. Daher 
ersucht die Gruppe 

(7)  Siehe Methoden zur Risikobewertung, die in der Stellungnah-
me der Europäischen Gruppe für Ethik der Naturwissenschaf-
ten und der Neuen Technologien (EGE) zu ethischen Aspekten 
der Nanomedizin diskutiert werden.

e

i

g
o

l

o

i

B
n
e
h
c
s
i
t
e
h
t
n
y
s

r
e
d
k

i

h
t
E

76

 
 
 
EMPFEHLUNGEN | 4

1)  die Kommission, eine Studie zu den derzeit be-
stehenden Verfahren zur Risikobewertung in der 
EU zu veranlassen. Die Studie sollte (a) eine Erhe-
bung wichtiger Biosicherheitsverfahren durchfüh-
ren, (b) mögliche Lücken in der derzeit geltenden 
Verordnung über Biosicherheit für eine effiziente 
Bewertung von im Rahmen der synthetischen Bio-
logie entwickelten Organismen und neuartigen 
Produkten aufdecken; (c) die Mechanismen zur 
Schließung der aufgedeckten Lücken aufzeigen.

2)   Das beschriebene Verfahren zur Risikobewertung 
sollte anschließend von den zuständigen Behörden 
in der EU (z. B. Europäische Kommission, EMEA und 
EFSA) und  den nationalen Behörden durchgeführt 
werden.

3)   Die Finanzierung der Forschung im Bereich der 
synthetischen Biologie und die Vermarktung von 
Produkten der synthetischen Biologie in der EU 
sollten an diese Bedingung geknüpft werden. 

Empfehlung Nr. 2: Die Gruppe schlägt vor, dass die 
Kommission nach der Definition der vorstehend ge-
nannten Vorschriften für die Biosicherheit eine inter-
nationale Debatte  mit den entsprechenden Ansprech-
partnern anstößt, damit ein einheitliches Konzept im 
Bereich der Biosicherheit der synthetischen Biologie für 
öffentlich und privat finanzierte Versuche gefördert 
wird. Instrumente zur Überwachung der Umsetzung 
dieser Vorschriften sollten als fester Bestandteil der 
Vorschriften zur Biosicherheit konzipiert werden (ein-
schließlich von Haftungsfragen). 

Empfehlung Nr. 3: Die Gruppe setzt sich dafür ein, 
dass die Kommission einen Verhaltenskodex für die 
Forschung im Bereich synthetischer Mikroorganismen 
erstellt.  Dieser Kodex sollte beispielsweise gewähr-
leisten, dass Organismen der synthetischen Biologie 
so hergestellt werden, dass sie im Fall einer unbeab-
sichtigten Freisetzung in die Natur nicht selbständig 
überleben können.

von Umweltschadstoffen (biologische Sanierung) bei-
tragen kann, etwa von Schwermetallen, Pestiziden 
und radioaktiven Stoffen. Die Gruppe ist sich dessen 
bewusst, dass die derzeitige Forschung Stoffe der syn-
thetischen Biologie herstellen kann, die in der Lage 
sind, Pestizide abzubauen, um die dadurch verursachte 
Umweltbelastung zu verringern (8), oder auch Biosen-
soren für  verunreinigtes Wasser (9). Die Gruppe erklärt, 
dass die stetige Verbesserung des Umweltschutzes und 
die Herstellung neuer Werkzeuge zur Erkennung von 
Umweltbelastungen ein positives Ziel sind und zur 
Steigerung des Wohlergehens der Menschen und zur 
Verbesserung des Umweltschutzes beitragen können. 
Besondere Bedenken ergeben sich jedoch im Hinblick 
auf die Biosicherheit, wenn Anwendungen der synthe-
tischen Biologie im Bereich Umweltschutz geplant sind 
und daher zunächst die Sicherheit und Umweltverträg-
lichkeit angemessen bewertet werden müssen, bevor 
eine Genehmigung zur Freisetzung der Stoffe in die 
Umwelt erteilt wird.  

Bei den Anwendungsmöglichkeiten im Bereich Umwelt-
schutz muss die Erzeugung umweltschonender biolo-
gischer Systeme bzw. Organismen im Hinblick auf den 
Schutz von Arbeitnehmern und Bürgern, die Freiheit 
der Verbraucher und die Verantwortung einschließlich 
der Verantwortung für Tiere, Pflanzen und die Umwelt 
im Allgemeinen analysiert werden.        10

Empfehlung Nr. 4: Die Gruppe empfiehlt, dass vor der 
Freisetzung eines im Rahmen der synthetischen Bio-
logie hergestellten oder modifizierten Organismus 
in die Umwelt Langzeitstudien zur Umweltverträg-
lichkeit durchgeführt werden müssen. Die Daten aus 
diesen Studien sollten dann unter Berücksichtigung 
des Vorsorgeprinzips (10) und der in der EU-Rechtspre-
chung vorgesehenen Maßnahmen (Richtlinie über 
die absichtliche Freisetzung genetisch veränderter 
Organismen in die Umwelt) bewertet werden. Fällt 
die Bewertung negativ aus, sollte keine Genehmigung 
zur Freisetzung von hergestellten oder modifizierten 
Organismen erteilt werden.  

4.2.1.  Anwendungsmöglichkeiten im Bereich  

(8)  Siehe http://pbd.lbl.gov/synthbio/aims.htm.

Umweltschutz

Die Gruppe ist sich dessen bewusst, dass es für die syn-
thetische Biologie auch potenzielle Anwendungsmög-
lichkeiten im Bereich Umweltschutz gibt. Die Gruppe 
erkennt an, dass die derzeitige Forschung im Bereich 
der synthetischen Biologie beispielsweise zum Abbau 

(9) 

In den sich entwickelnden Teilen der Welt wie z. B. Bangla-
desch stellt die Kontamination des Trinkwassers durch Arsen 
ein großes Problem dar. Siehe: Aleksic J, Bizzari F, Cai Y et al. 
(2007) Development of a novel biosensor for the detection of 
arsenic in drinking water Synthetic Biology, IET 1: 87–90. 

(10)  2001/18/EG, 98/81/EG und Regelungsrahmen in Abschnitt 2.1 

der Stellungnahme.

77

4 | EMPFEHLUNGEN

4.2.2.  Energie und nachhaltige chemische Industrie

Die Gruppe ist sich dessen bewusst, dass die synthe-
tische Biologie einen Beitrag zur Entwicklung einer 
nachhaltigen chemischen Industrie leisten könnte, 
vornehmlich zur Herstellung von Mikroorganismen 
im Rahmen der synthetischen Biologie mit dem Ziel, 
Wirkstoffe und Methoden zu ersetzen, die derzeit von 
der organischen chemischen Industrie für die Herstel-
lung von Rohstoffen eingesetzt werden.

Was die Anwendungsmöglichkeiten der synthetischen 
Biologie zu Energiezwecken anbetrifft, ist sich die Grup-
pe ebenfalls bewusst, dass das Ziel der Forschung auf 
dem Gebiet der synthetischen Biologie darin besteht, 
Bakterien zu entwickeln, die organische Verbindun-
ge  (11) zur Substitution von Erdöl produzieren, und 
die Konstruktion von Bakterien zu erforschen, die den 
Brennstoff Wasserstoff aus alternativen Quellen her-
stellen (12). 

Die Gruppe erkennt an, dass diese Möglichkeiten durch 
die immer knapper werdenden fossilen Energiereser-
ven, die derzeit die Rohstoffe liefern, und durch die 
Auswirkungen der Verbrennung fossiler Kraftstoffe auf 
das Klima zunehmend an Bedeutung gewinnen. Die 
Gruppe hat allerdings Bedenken bezüglich der mögli-
chen Auswirkungen für die Sicherheit und unterbreitet 
daher folgende Vorschläge:

Empfehlung Nr. 5: Die Gruppe schlägt den Einsatz der 
synthetischen Biologie für die alternative Energieversor-
gung in den Mitgliedstaaten ergänzend zum EU-Plan 
zum Ausbau erneuerbarer Energien und die Förderung 
und Kofinanzierung internationaler Forschungsversu-
che (z. B. EU-USA) im Hinblick auf die Förderung eines 
integrierten internationalen Konzepts vor.

Empfehlung Nr. 6: Die Gruppe empfiehlt, dass die zu-
ständigen Behörden die Genehmigungsverfahren für 
die Herstellung von Chemikalien und Stoffen aus der 
synthetischen Biologie, sofern diese nicht mit entspre-
chenden Stoffen identisch sind, streng überwachen 
und dabei (a) Faktoren der Risikobewertung und (b) der 

(11)  Wie z. B. Fettsäuren, die sich optimal für den Einsatz als Bio-
diesel eignen, oder andere energiereiche Verbindungen.

(12)  Siehe auch: LS9 (www.ls9.com), Amyris (www.amyris.com), 
OPX Biotecnologies (www.opxbiotechnologies.com), Sola-
zyme (www.solazyme.com), Gevo (www.gevo.com). 

Sicherheit der Arbeitnehmer, die den im Rahmen der 
synthetischen Biologie erzeugten Chemikalien aus-
gesetzt sind,  sowie (c) dem Umweltschutz Rechnung 
tragen. 

Was den Einsatz der synthetischen Biologie für chemi-
sche Produkte und neuartige Materialien  anbetrifft, so ist 
sich die Gruppe dessen bewusst, dass chemische Pro-
dukte auf Basis genetisch veränderter Organismen, die 
nicht als Lebens- oder Futtermittel gedacht sind, nicht 
speziell als genetisch verändert gekennzeichnet zu 
werden brauchen. Die Gruppe ist sich dessen bewusst, 
dass praktisch alle Produkte der synthetischen Biologie, 
die Organismen enthalten oder Organismen sind oder 
aus solchen Organismen in Lebens- oder Futtermitteln 
stammen, als genetisch verändert gekennzeichnet wer-
den müssen. Die Gruppe hat allerdings Bedenken in 
Bezug auf mögliche Anwendungen der synthetischen 
Biologie in der Kosmetik- und Textilindustrie.    

Empfehlung Nr. 7: Die Gruppe macht geltend, dass 
der Verbraucherschutz ein Schlüsselfaktor auf dem 
EU-Markt ist, dem Rechnung getragen werden muss, 
und betont, dass die Kennzeichnung spezifischer Pro-
dukte der synthetischen Biologie, wie Kosmetika und 
Textilien, untersucht werden sollte. 

4.2.3.  Biomedizinische und biopharmazeutische  

Herstellung 

Die  synthetische  Biologie  bietet  auch  potenzielle 
Anwendungsmöglichkeiten in der Medizin, etwa zur 
Verbesserung und Entwicklung von Biosensoren, Me-
dikamenten, Therapien, Geräten und Zellen mit neuen 
Eigenschaften, die zur Verbesserung der menschlichen 
Gesundheit oder therapeutischer Modelle genutzt wer-
den können. Es wird erwartet, dass die synthetische 
Biologie auch in den Bereichen Arzneimittelherstel-
lung, Entwicklung neuer Impfstoffe, medizinischer 
Geräte wie Biosensoren, Diagnostika, die Synthese 
von Viren für Gentherapien sowie potenziell auch im 
Bereich der Krebstherapien Anwendung findet. 

Die Gruppe ist sich bewusst, dass sich die Anwendung 
der synthetischen Biologie im medizinischen Bereich 
derzeit noch im Stadium der Grundlagenforschung  
befindet  und  dass  klinische  Anwendungen  neuer  
Medikamente und Methoden noch lange nicht für Pa-
tienten zur Verfügung stehen.

e

i

g
o

l

o

i

B
n
e
h
c
s
i
t
e
h
t
n
y
s

r
e
d
k

i

h
t
E

78

 
 
 
EMPFEHLUNGEN | 4

Wie in Abschnitt 2 dieser Stellungnahme beschrieben, 
macht die Gruppe geltend, dass medizinische Anwen-
dungen der synthetischen Biologie nicht gegen die 
Grundrechte und den an früherer Stelle bereits ge-
nannten Rahmen für Ethik verstoßen dürfen und an 
die Einhaltung strenger Vorschriften im Bereich der  
Biosicherheit geknüpft werden müssen. Für die derzeit 
geplanten Produkte ist der bereits bestehende Rege-
lungsrahmen für eine Regulierung der Nutzung der 
synthetischen Biologie im Allgemeinen angemessen 
und muss umgesetzt werden.   (13)

Empfehlung Nr. 8: Die Gruppe empfiehlt, dass die 
zuständigen Behörden (z. B. die EMEA (13)) neben 
der Anwendung wissenschaftlicher und rechtlicher 
Rahmen im Fall von aus den Protokollen der synthe-
tischen Biologie hervorgegangenen Medikamenten 
und medizinischen Erzeugnissen spezifische ethische 
Überlegungen anstellen. Daten über medizinische 
Anwendungen der synthetischen Biologie in den EU-
Mitgliedstaaten bzw. Daten aus EU-Finanzierungen 
sollten von den zuständigen Einrichtungen in den Län-
dern erhoben werden, in denen Versuche stattfinden, 
und international zugänglich gemacht werden.

4.3.  Biosicherheit, Prävention von  

Bioterrorismus und Doppelverwendung 

Die  EGE  ist  sich  der  möglichen  Nutzung  bzw.  des 
möglichen Missbrauchs der synthetischen Biologie 
in  Bezug  auf  die  Biosicherheit  und  die  derzeitige 
Forschung in diesem speziellen Bereich, die in der EU 
und den USA betrieben wird, bewusst. Die synthetische 
Biologie  kann  die  Entwicklung  neuer  Werkzeuge 
ermöglichen,  die  für  militärische  Zwecke  von 
Biomaterialien bis hin zu biologischen Waffen reichen 
können. Bei einer Analyse der ethischen Aspekte muss 
auch für ein ausgewogenes Verhältnis zwischen der 
Sicherheit und der notwendigen Transparenz gesorgt 
werden:

(13)  Nach Maßgabe der EU-Rechtsvorschriften werden medi-
zinische Produkte der synthetischen Biologie unter sicher-
heitsrelevanten Aspekten bewertet. Die hierfür zuständigen 
Behörden in den Mitgliedstaaten und auf EU-Ebene (EMEA) 
sollten sicher sein, dass die in dieser Stellungnahme darge-
legten überlegungen zu sicherheitsrelevanten Aspekten 
auch tatsächlich angestellt werden, bevor sie die Geneh-
migung für klinische Versuchsverfahren und Forschungs-
versuche sowie für Marketingverfahren erteilen.

•	 Die	 Herstellung	 und	 potenzielle	 Verwendung	
von Materialien oder Systemen der synthetischen 
Biologie im Rahmen der nationalen Sicherheitspolitik 
einschließlich der Herstellung von biologischen 
Waf fen.  Solche  Anwendungsmöglichkeiten 
müssen im Einklang mit den derzeitigen nationalen 
und internationalen Regelungsrahmen stehen. 
Transparenz und die Herausgabe von Informationen 
können zu Missbrauch zu terroristischen Zwecken 
führen – doch offene Gesellschaften müssen Mittel 
und Wege finden, um mit diesem nur schwer zu 
erzielenden Gleichgewicht zwischen dem Recht 
der Bürger auf Unterrichtung einerseits und dem 
notwendigen Schutz ihrer Sicherheit andererseits 
umzugehen. 

•	 Die	 Herstellung	 und	 potenzielle	 Nutzung	 von	
Materialien  oder  Systemen  der  synthetischen 
Biologie für terroristische Zwecke, an erster Stelle 
die  Herstellung  biologischer  Systeme,  die  ein 
großes zerstörerisches Potenzial aufweisen können. 
Der Missbrauch jeder Art von Kenntnissen der 
synthetischen Biologie muss bekämpft werden. 

•	 Die	 Herstellung	 synthetischer	 Organismen	
außerhalb  der  anerkannten  Einrichtungen.  Da 
Stoffe und Verfahren der synthetischen Biologie 
öffentlich  zugänglich  sind,  ist  Biohacking  ein 
weiteres Szenario, das im Hinblick auf die Sicherheit 
kontrolliert und gesteuert werden muss.  

Die  EGE  ist  sich  auch  der  erst  vor  kurzem,  d.  h. 
am  24.  Juni  2009  angenommenen  Mitteilung  der 
Kommission (14), bewusst, in der die neue EU-Politik im 
Bereich der chemischen, biologischen, radiologischen 
oder nuklearen Stoffe oder Wirkstoffe (CBRN) definiert 
wird. Nach Auffassung der Gruppe ist diese Initiative 
zwar wertvoll, jedoch für einen ethisch vertretbaren und 
demokratischen Ansatz im Bereich der Biosicherheit 
in der EU und darüber hinaus noch nicht ausreichend. 
Die  Gruppe  begrüßt  die  Verankerung  ethischer 
Aspekte in die Studienpläne von Wissenschaftlern im 
Bereich der Biosicherheit einschließlich spezifischer 
Maßnahmen,  die  die  ethische  Dimension  der 
Anwendungsmöglichkeiten der synthetischen Biologie 
für die Biosicherheit besser erläutern können. 

Bei Anwendungen der synthetischen Biologie könnten 
Informationen beispielsweise über die Herstellung 

(14)  KOM(2009) 273 endgültig; SEK(2009) 874; SEK(2009) 790; 

SEK(2009) 791.

79

4 | EMPFEHLUNGEN

synthetischer Viren eine neue Welle des Bioterrorismus 
auslösen. Wie mit diesem Problem umzugehen ist, wurde 
bislang noch nicht eingehend diskutiert. Die Gesundheit 
von Soldaten und Zivilisten muss geschützt, Transparenz 
sollte  möglichst  aufrechterhalten,  und  Forschung 
kann nur bei einer strengen Überwachung zugelassen 
werden. Wie in Abschnitt 3 dieser Stellungnahme näher 
ausgeführt, macht die Gruppe geltend, dass die Sicherheit 
und die militärischen Anwendungen der synthetischen 
Biologie  nicht  gegen  die  Grundrechte  und  den  in 
dieser Stellungnahme dargelegten Rahmen für Ethik 
verstoßen dürfen. Die Aufgabe, terroristische und/oder 
böswillige Anwendungen der synthetischen Biologie zu 
verhindern, ist für Forscher und demokratische Staaten 
gleichermaßen  mit  dem  moralischen  Dilemma  der 
Doppelverwendung verbunden. Manche beabsichtigten 
und unbeabsichtigten Doppelverwendungen lassen sich 
vorhersehen, andere wiederum nicht. Eine Möglichkeit, 
mit  dem  Dilemma  der  Doppelverwendung  besser 
umzugehen, besteht darin, auf Kontrollmechanismen 
zurückzugreifen, etwa die Zulassung und Registrierung 
der im Rahmen der synthetischen Biologie eingesetzten 
Werkzeuge. 

Als Beispiel für mögliche Maßnahmen zur Verhinderung 
nicht  hinnehmbarer  militärischer  Aktionen  oder 
Terrorakte können u. a. Folgende angeführt werden: 
1) eine zentrale Datenbank, die zumindest auf EU-
Ebene oder nach Möglichkeit sogar auf internationaler 
Ebene eingerichtet wird, in der alle DNA-Synthesizer 
von den zuständigen Behörden registriert werden; 
2) Forschungsabteilungen oder Forschergruppen, die 
die synthetische Biologie im Bereich der Biosicherheit 
und  Bioverteidigung  anwenden,  sollten  in  dem 
genannten  Register erfasst werden; 3) auf Ebene 
der Mitgliedstaaten und der EU sollten Kriterien für 
die  Veröffentlichung  von  Daten  über  hochgradig 
pathogene  Viren  oder  toxische  Stoffe  definiert 
werden. (15)

Darüber hinaus gibt es aber auch ethische Bedenken, 
weil das Potenzial der Doppelverwendung auch im 
Rahmen der Ausbildung behandelt werden sollte. 
Die  Förderung  des  Verantwortungsbewusstseins 
von  Menschen  und  Institutionen  im  Rahmen 

(15)  Für genetisch veränderte Organismen einschließlich von 
Organismen, die mithilfe der Verfahren der synthetischen 
Biologie hergestellt werden, gibt es Verordnungen in Europa, 
die eine Registrierung und/oder Genehmigung der Einrich-
tungen vorschreiben, in denen diese Organismen gezüchtet 
und untersucht werden dürfen. Siehe hierzu auch S. 40 dieser 
Stellungnahme sowie Art. 7 98/81/EG.

einer  Diskussion  über  die  ethischen  Aspekte  der 
synthetischen Biologie ist eine Frage von zentraler 
Bedeutung.

Empfehlung Nr. 9: Die Gruppe empfiehlt, dass das 
Übereinkommen über das Verbot der Entwicklung, 
Herstellung und Lagerung bakteriologischer (biolo-
gischer) Waffen und von Toxinwaffen sowie über die 
Vernichtung solcher Waffen auch Bestimmungen zur 
Beschränkung bzw. zum Verbot der Forschung im Be-
reich der synthetischen Biologie enthalten sollte.  

Empfehlung Nr. 10: Die Gruppe ersucht die Kommissi-
on, im Einvernehmen mit der EGE einen umfassenden 
Rahmen für Ethik und Sicherheit im Bereich der syn-
thetischen Biologie festzulegen. 

Empfehlung Nr. 11: Die Gruppe empfiehlt, dass die 
Europäische Kommission 1) dafür Sorge trägt, dass 
allen Nutzern Datenbanken zur Verfügung stehen; 
2) den Unternehmen Rechtssysteme bereitstellt, da-
mit sie den zuständigen Behörden Bericht erstatten, 
sobald sie gebeten werden, verdächtige Sequenzen 
unter gleichzeitiger Einhaltung des Datenschutzes zu 
synthetisieren; 3) die Kette der Zuständigkeiten ermit-
telt, wenn es darum geht, bestimmte Sequenzen in 
die Datenbank(en) einzugeben und sie als potenziell 
schädlich einzustufen. 

4.4.  Regulierung („Governance“)

Die Gruppe tritt außerdem dafür ein, dass die Aus-
wirkungen einer Technologie, deren mögliche An-
wendung in der EU in Betracht gezogen wird, anhand 
einer Folgenabschätzung sorgfältig untersucht und 
bewertet werden. Diese Folgenabschätzung sollte 
sich sowohl auf die Risiken als auch die Vorteile der 
neuen Technologien und die Risiken und Vorteile der 
dadurch ersetzten Technologien erstrecken. Sie sollte 
im Rahmen des integrierten Ansatzes für den Bereich 
der synthetischen Biologie erfolgen, der Umwelt- und 
sozialen Auswirkungen Rechnung trägt. Neben einer 
technischen Risikosteuerung muss ein breiter angeleg-
ter Ansatz entwickelt werden, der besser als die derzeit 
verfügbaren Instrumente in der Lage ist, sich an mögli-
che Veränderungen in der Umwelt, in der Gesellschaft, 
in der Marktwirtschaft oder in der nationalen Politik 
anzupassen. Die Ethik der synthetischen Biologie sollte 
sich mit einer Untersuchung der Vorzüge und Risiken 
dieser Technologie bei bestimmten ökologischen 
Konstellationen von Fall zu Fall sowie mit potenziel-

e

i

g
o

l

o

i

B
n
e
h
c
s
i
t
e
h
t
n
y
s

r
e
d
k

i

h
t
E

80

 
 
 
EMPFEHLUNGEN | 4

len Risiken und Vorteilen für die gesamte Biosphäre 
befassen (16).

Ein verantwortungsvoller Umgang mit der syntheti-
schen Biologie würde auch den Einsatz von Regulie-
rungswerkzeugen voraussetzen, um den wissenschaft-
lichen Fortschritt sowie Anwendungsmöglichkeiten 
der Forschung zu fördern, die der menschlichen Ge-
sundheit zugute kommen können; ein solcher verant-
wortungsbewusster Umgang würde helfen, Energie 
zu sparen und die negativen Auswirkungen des Klima-
wandels zu verringern und zugleich vor Missbrauch, 
d. h. Bioterrorismus, schützen sowie zur Biosicherheit 
beitragen. Diese Aufgabe ist keinesfalls einfach und 
stellt die EU vor eine ganze Reihe von Dilemmata.

a) Allgemeine Dilemmata: Wie können Regulierungs-
werkzeuge

–  einen nutzbringenden Einsatz fördern und Miss-
brauch verhindern, wenn eine Doppelverwendung 
möglich ist?  

–  Transparenz fördern, ohne das Risiko eines Miss-

brauchs einzugehen?  

–  vor Missbrauch schützen, ohne zu einer ungewoll-
ten Zensur bei der Veröffentlichung usw. zu füh-
ren?

b) Spezifische Herausforderungen an die Regulierung: 
Wie kann die EU Regulierungswerkzeuge einsetzen, 
um 

•	 der	Tatsache	Rechnung	zu	tragen,	dass	die	synthe-
tische Biologie eine Vielzahl von Bereichen um-
fasst, die in völlig unterschiedlichem Maß und in 
unterschiedlicher Ausprägung reguliert sind und 
in denen mögliche Lücken klaffen, was die Gewähr-
leistung der Biosicherheit und den Ausschluss eines 
möglichen Missbrauchs anbetrifft?

(16)  Siehe Markus Schmidt, Helge Togersen, Agomoni Ganguli-
Mitra, Alexander Kelle, Anna Deplazes, Nikola Biller-Andorno: 
SYNBIOSAFE e-conference: online community discussion on 
the societal aspects der synthetischen Biologie. In: Systems 
and Synthetic Biology, 16. September (2008). Online: http://
www.zora.uzh.ch/3947/2/Schmidt_m_torg.V.pdf .
Paul Rabinow & Gaymon Bennett: From Bio-Ethics to Human 
Practice. Working Paper # 11, 2007 http://anthropos-lab.net/
wp/publications/2007/08/workingpaperno11.pdf .

•	 Bereiche	zu	ermitteln,	in	denen	das	nicht	zwin-
gende Recht („soft law“) für ausreichenden Schutz 
sorgt, und Bereiche, in denen ein normativ festge-
legtes Recht („hard law“) für notwendig erachtet 
wird (siehe Empfehlung 2 zu den Vorschriften für 
die Biosicherheit und Empfehlung 9 zum Überein-
kommen über biologische Waffen)?

•	 einzelne	Forscher	und	Einrichtungen	(einschließ-
lich von Wissenschaftlern, die nicht unbedingt mit 
lebenden Organismen arbeiten und mit den damit 
verbundenen spezifischen Probleme konfrontiert 
sind) anzuhalten, professionell Verantwortung zu 
übernehmen und den in Empfehlung Nr. 3 vorge-
schlagenen Verhaltenskodex zu ergänzen? 

•	

im	Hinblick	auf	die	notwendige	weltweite	Regu-
lierung im Bereich der synthetischen Biologie eine 
Rolle zu spielen?  

Die Gruppe äußert Bedenken hinsichtlich des beste-
henden bruchstückhaften Regelungsrahmens, der 
möglicherweise für eine entsprechende Regulierung 
der derzeitigen und sich neu herausbildenden Aspekte 
der synthetischen Biologie nicht ausreichend ist. Außer-
dem hebt sie die Notwendigkeit hervor, ein geeignetes 
Modell der Governance im Bereich der synthetischen 
Biologie zu untersuchen (nicht zwingendes Recht, Ver-
haltenskodizes usw.), wobei auch potenziellen Risiken 
der Auslagerung von Forschungsversuchen in Länder 
Rechnung zu tragen ist, in denen sich die Regulierung 
im Vergleich zum Vorschlag für die EU möglicherweise 
weniger streng gestaltet.

Empfehlung Nr. 13: Die Gruppe ersucht die Kommmissi-
on dringend, einen soliden Rahmen für die Regulierung 
im Bereich der synthetischen Biologie vorzuschlagen 
und diesen in der EU einzurichten. Die Kommission sollte 
die für die synthetische Biologie anwendbaren Rechts-
vorschriften einer Überprüfung unterziehen und prüfen, 
ob diese auch geeignet sind, Antworten auf die durch 
die synthetische Biologie aufgeworfenen Fragen zu ge-
ben. Der vorstehend dargelegte Rahmen sollte sich an 
die entsprechenden Interessengruppen (Wissenschaft-
ler, Industrie, Vertreter des Militärs sowie Vertreter von 
Politik und Verwaltung) wenden und deren Verantwor-
tungsbereiche und Aufgaben klar darlegen. 

Empfehlung Nr. 14: Die entsprechenden Wissenschafts-
gemeinden sollten dazu angehalten werden, ethische 
Leitlinien, vorzugsweise weltweit, einzuführen, die als 

81

 
4 | EMPFEHLUNGEN

„Wegweiser“ fungieren und wissenschaftliche Einrich-
tungen und einzelne Forscher dazu bringen sollen, die 
Auswirkungen ihrer Arbeit einschließlich der Folgen  
eines Missbrauchs (17) zu bewerten.

Empfehlung Nr. 15: Die EGE schlägt vor, dass die EU die 
Frage der Governance im Bereich der synthetischen 
Biologie auf den entsprechenden globalen Foren an-
spricht.

4.5.  Geistiges Eigentum   (17)

4.5.1.   Patentierung und gemeinsames Erbe

Die im Zusammenhang mit der Patentierung biolo-
gischer Methoden und Stoffe aufgeworfenen Fragen 
waren eine gewisse Zeit lang Gegenstand heftiger De-
batten und werden jetzt in verschiedenen Disziplinen 
erörtert. Die Funktion von Patenten, Anreize für die For-
schung und deren Anwendungen zu bieten und eine 
Veröffentlichung der Grundlage dieser Anwendungen 
zu fördern, könnte durch die enorm hohe Zahl von 
Patentanmeldungen in Verbindung mit genetischem 
Material und biologischen Methoden aufs Spiel gesetzt 
werden. Zugleich hat die Verwendung von Bestand-
teilen biologischer Organismen durch bestimmte in-
dustrielle Akteure auch dazu geführt, dass zunehmend 
Fragen nach den ethischen Aspekten gestellt werden. 
In Artikel 7 der Richtlinie über die Patentierung biotech-
nologischer Erfindungen heißt es: „Die Europäische 
Gruppe für Ethik der Naturwissenschaften und Neuen 
Technologien der Kommission bewertet alle ethischen 
Aspekte im Zusammenhang mit der Biotechnologie“. 
Dies ist der einzige Artikel in dieser Richtlinie, der nicht 
in Durchführungsbestimmungen zur Richtlinie des EPA 
bzw. der Patentämter in den Mitgliedstaten umgesetzt 
wurde. Er ist deshalb so schwierig umzusetzen, weil 
darin keine konkreten Maßnahmen beschrieben sind 
und auch in keinem der anderen Artikel darauf einge-
gangen wird. Die Patentämter klagen häufig darüber, 
dass sich die Auslegung der Bestimmungen des Euro-
päischen Patentrechts zu den guten Sitten schwierig 
gestaltet (oder diese Bestimmungen sogar im Rahmen 
anderer Rechtsvorschriften aufgegriffen werden soll-
ten). Die Gruppe schlägt vor, dass dann, wenn im Rah-
men einer bestimmten Patentanmeldung im Bereich 
der Biotechnologie (einschließlich Nanontechnologie 

(17)  Siehe Unesco MOST Ethische Leitlinien für eine international 

vergleichbare sozialwissenschaftliche Forschung.

und synthetische Biologie) eine allgemeine Frage auf-
geworfen wird, die entsprechenden Patentämter die 
EGE in dem in der Anmeldung bezeichneten allgemei-
nen Bereich um Rat ersuchen sollen.

Im Hinblick auf die Frage der Patentierung und des ge-
meinsamen Erbes erkennt die Gruppe an, dass es sich 
hierbei um ein vielschichtiges Thema handelt, wie bereits 
in Anhang I dieser Stellungnahme ausgeführt wurde.  
Die Gruppe hebt hervor, dass allgemeine ethische Fra-
gen im Zusammenhang mit Patentanmeldungen ent-
sprechend im Rahmen des Systems der Patenterteilung 
geklärt werden sollten.   (18)

Empfehlung Nr. 16: Die EGE schlägt vor, dass Debatten 
über die am besten geeigneten Möglichkeiten ange-
stoßen werden, um den Zugang der Öffentlichkeit zu 
den Ergebnissen der synthetischen Biologie zu gewähr-
leisten. Diese Debatten sollten sich auch auf die Frage 
erstrecken, was Gegenstand des Patents sein kann und 
was im Rahmen eines offenen Zugangs zur Verfügung 
gestellt werden sollte.

Empfehlung Nr. 17: Die EU-Patentrichtlinie (98/44/EG) 
definiert die EGE als das Gremium, das die ethischen 
Auswirkungen in Verbindung mit Patenten einer Be-
wertung unterzieht. Die Gruppe ersucht das Euro-
päische Patentamt und die nationalen Patentämter 
dringend, Artikel 7 der Patentrichtlinie Rechnung zu 
tragen und kontroverse ethische Fragen von allgemei-
ner Bedeutung der EGE zur Prüfung vorzulegen. Dies 
ist dann besonders wichtig, wenn eine Gruppe von 
Erfindungen definiert werden muss, die nicht unmit-
telbar gewerblich verwertet werden sollten (18).

(18)  Artikel 6 Absatz 2 der Richtlinie 98/44/EG enthält eine Liste 
von Beispielen, die von der Patentierbarkeit ausgenommen 
sind, und zwar „(a) Verfahren zum Klonen von menschlichen 
Lebewesen; (b) Verfahren zur Veränderung der genetischen 
Identität der Keimbahn des menschlichen Lebewesens;  
(c) die Verwendung von  menschlichen Embryonen zu 
industriellen oder kommerziellen Zwecken; (d) Verfahren 
zur Veränderung der genetischen Identität von Tieren, 
die geeignet sind, Leiden dieser Tiere ohne wesentlichen 
medizinischen Nutzen für den Menschen oder das Tier zu 
verursachen, sowie die mit Hilfe solcher Verfahren erzeug-
ten Tiere.“ In Artikel 7 der Richtlinie heißt es weiter: „Die 
Europäische Gruppe für Ethik der Naturwissenschaften 
und der Neuen Technologien der Kommission bewertet 
alle ethischen Aspekte im Zusammenhang mit der Bio-
technologie.“

e

i

g
o

l

o

i

B
n
e
h
c
s
i
t
e
h
t
n
y
s

r
e
d
k

i

h
t
E

82

 
 
 
EMPFEHLUNGEN | 4

4.5.2.   Handel und globale Gerechtigkeit

Die Gruppe ist sich der globalen Dimension der synthe-
tischen Biologie und ihrer Anwendungsmöglichkeiten 
bewusst und sieht die wirtschaftliche Entwicklung und 
die Zunahme der sozialen Wohlfahrt als ein positives 
Ziel der EU an. Die synthetische Biologie kann zum so-
zioökonomischen Wohlstand der EU und darüber hin-
aus beitragen. Die Gruppe begrüßt diese Möglichkeit, 
soweit die Grundsätze der EU-Charta der Grundrechte 
und die wichtigsten Grundwerte der EU von diesem 
Technologiesektor und vom Handel mit seinen Pro-
dukten nicht negativ beeinflusst werden. Daher hat die 
EGE Bedenken hinsichtlich der möglichen Risiken einer 
technologischen Kluft innerhalb der EU sowie zwischen 
entwickelten und weniger entwickelten Ländern.  

Die EGE empfiehlt, die Grundwerte der EU in den glo-
balen Handel mit Produkten der synthetischen Biolo-
gie einzubinden. Wie in früheren Stellungnahmen (z. B. 
Stellungnahme 23 (19) und Stellungnahme 24 (20)) betont 
die Gruppe die Notwendigkeit, ethische Betrachtungen 
in den globalen Handel und in die politischen Aktionen 
der Welthandelsorganisation einzubinden. 

Im Anschluss daran sollten Maßnahmen ergriffen wer-
den, um eine technologische Kluft größeren Ausmaßes 
zu verhindern. Wenn in Entwicklungs- und Schwellen-
ländern Versuche mit Produkten der synthetischen 
Biologie durchgeführt werden, müssen dieselben ethi-
schen Standards wie in der EU angewandt werden (21). 
Die Millenniumsziele der Vereinten Nationen sollten 
umgesetzt werden.   (22)

Empfehlung Nr. 18: Die EGE empfiehlt, dass bei Dis-
kussionen über die synthetische Biologie auf interna-
tionaler Ebene einschließlich der WTO auch ethische 
Fragen in Verbindung mit der Technologie angespro-
chen werden sollten (22). Dies sollte bei der Doha- 
Verhandlungsrunde berücksichtigt werden.

(19)  http://ec.europa.eu/european_group_ethics/activities/

docs/opinion23_en.pdf

(20)  http://ec.europa.eu/european_group_ethics/docs/

opinion24_en.pdf

(21)  http://ec.europa.eu/european_group_ethics/docs/avis17_

de.pdf.

(22)  Siehe Abschnitte 2.2.b und 2.2.c dieser Stellungnahme.

Empfehlung Nr. 19: Die EGE bittet dringend darum, 
dass die EU-Standards im Bereich Biosicherheit für Pro-
dukte der synthetischen Biologie, die in den Empfeh-
lungen Nr. 1, 2 und 5 dieser Stellungnahme beschrie-
ben sind, als Mindeststandards für Aus- und Einfuhren 
von Produkten der synthetischen Biologie aus der EU 
bzw. in die EU  übernommen werden.  

Empfehlung Nr. 20: Die Gruppe empfiehlt der EU, 
spezifische Maßnahmen zu ergreifen, um zu verhin-
dern, dass neue Lücken zwischen der EU und den 
Entwicklungs- und Schwellenländern bzw. innerhalb 
der EU-Mitgliedstaten aufklaffen, und die in dieser 
Stellungnahme ausgesprochenen Empfehlungen zu 
verwirklichen. Maßnahmen dieser Art sollten in den 
bilateralen und multilateralen Wissenschaftsprogram-
me der EU und in der EU-Politik für Entwicklungs- und 
Schwellenländer verankert werden.

4.6.  Wissenschaftlicher und gesellschaftlicher 

Dialog

Wie in Abschnitt 3 dieser Stellungnahme ausführlich 
dargelegt, sind die ethischen Aspekte der syntheti-
schen Biologie komplex, und die aufgeworfenen kon-
zeptuellen Fragen müssen im Rahmen eines wirksamen 
wissenschaftlichen und gesellschaftlichen Dialogs er-
örtert werden. 

Die Art der Wahrnehmung der synthetischen Biologie 
wird von sozialen, kulturellen und ethischen Erwägungen 
über die Manipulation von Leben, von den wirtschaft-
lichen Auswirkungen auf entwickelte und in Entwick-
lung befindliche Regionen, von Fragen in Verbindung 
mit Eigentum und geistigem Eigentum, von Bedenken 
hinsichtlich einer Zerstörung der Umwelt und poten-
zieller militärischer Anwendungen usw. beeinflusst. Die 
herkömmlichen und interaktiven Medien spielen eine 
wichtig Rolle, wenn es darum geht, die Meinungen der 
Menschen zu neuen und aufstrebenden Technologien 
einschließlich der synthetischen Biologie zu prägen. Jede 
dieser Fragen bedarf einer gründlichen Betrachtung 
und der Beteiligung der Öffentlichkeit. Damit werden 
weiter gefasste Fragen der Vertrauensbildung zwischen 
der Wissenschaftsgemeinschaft und der Öffentlichkeit 
einschließlich der Notwendigkeit, eine angemessene 
Debatte zu fördern, aufgeworfen. Und schließlich führt 
dies zu Fragen der beratenden Demokratie einschließlich 
von Fragen wie zum Beispiel, wer die Trennlinien zieht 
zwischen dem, was erlaubt und akzeptabel ist und was 
nicht; und wer überblickt, wer diese Trennlinien zieht. 

83

4 | EMPFEHLUNGEN

Sozialwissenschaftler haben vorgeschlagen, dass eine 
Verpflichtung im Vorfeld der wissenschaftlichen und 
technologischen Entwicklung im Einklang mit gesell-
schaftlichen Erwartungen, Bedenken und Wünschen 
förderlich sein könnte. (23) Viele Wissenschaftler, die im 
Bereich der synthetischen Biologie tätig sind, sind sich 
bereits der Bedeutung einer öffentlichen Verpflichtung 
bewusst und haben sich zu diesem Zweck an Aktivitä-
ten wie Debatten, Podcasts und Blogs beteiligt.

In die öffentliche Debatte müssen sachdienliche und an-
gemessene Informationen über die tatsächlichen Merk-
male und Potenziale der synthetischen Biologie einge-
bracht werden, was Schwierigkeiten bei der Ermittlung, 
Einschätzung und Steuerung von Risiken in einem Be-
reich mit sich bringen könnte, der von erheblicher Un-
sicherheit und von großen Wissenslücken geprägt ist, 
vor allem, wenn damit kurz- und langfristig unterschied-
liche Risiken verbunden sind. Ähnliche Überlegungen 
sind in Bezug auf die Vorteile angebracht, die in den 
Medien hochgejubelt werden, wobei die Öffentlich-
keit auch durch die Beiträge von Medien- und Science- 
Fiction-Autoren mit unrealistischen Szenarien zu Pro-
dukten der synthetischen Biologie konfrontiert wird 
(zum Beispiel der Medienrummel um die synthetische 
Biologie im Hinblick auf die Heilbarkeit aller Krankhei-
ten, auf biologische Abhilfemaßnahmen zur Bekämp-
fung der Umweltverschmutzung oder auf die Wahr-
scheinlichkeit einer Energiekrise). Hoffnungen oder 
Befürchtungen, die der Öffentlichkeit ohne entspre-
chende Nachweise kommuniziert werden, verzerren die 
öffentliche Debatte über die synthetische Biologie.

Empfehlung Nr. 21: Die Gruppe ersucht die EU und die 
EU-Mitgliedstaaten, Maßnahmen zur Förderung öffent-
licher Debatten und zur Verpflichtung der Interessen-
gruppen zu ergreifen, um die wichtigsten gesellschaft-
lichen Anliegen in den einzelnen Bereichen, auf die sich 
die synthetische Biologie bezieht, aufzuzeigen.

Empfehlung Nr. 22: Die Gruppe empfiehlt, dass Journa-
listen, Redakteure einschließlich Wissenschaftsredak-
teure und andere Akteure eine verantwortungsvolle Be-
richterstattung über die synthetische Biologie fördern. 

(23)  http://www.bbsrc.ac.uk/organisation/policies/reviews/

scientific_areas/0806_synthetic_biology.pdf.

e

i

g
o

l

o

i

B
n
e
h
c
s
i
t
e
h
t
n
y
s

r
e
d
k

i

h
t
E

84

Empfehlung Nr. 23: Zur Förderung eines umfassenden 
Ansatzes im Bereich der neuen Technologien durch die 
Medien bittet die Gruppe die Kommission, spezifische 
Maßnahmen zu initiieren, u. a. die Einrichtung und 
Durchführung von Foren, Seminaren und Kursen, die 
sich mit den Auswirkungen der synthetischen Biologie 
in den Medien befassen.

4.7. 

Forschung

Seit geraumer Zeit ist zu beobachten, dass die Grundla-
genforschung, die das Fundament aller Anwendungen 
in einem bestimmten Forschungsfeld darstellt, in Pro-
grammen der Forschungsförderung in den Hintergrund 
gedrängt wird. Auch wenn sich die Grundlagenfor-
schung nicht scharf von der angewandten Forschung 
abgrenzen lässt, ist Erstere auf öffentliche Gelder ange-
wiesen, und dies sollte auch die Politik der Europäischen 
Union sein. 

Ein äußerst wichtiges Novum, das mit der syntheti-
schen Biologie in die wissenschaftliche Methodik der 
modernen Biologie eingebracht wird, ist die Möglich-
keit, nicht nur deduktive Methoden bei beobachteten 
Phänomenen anzuwenden, sondern auch heuristische 
Werkzeuge zu synthetisieren, die an sich schon die Un-
tersuchung grundlegender Phänomene der Biologie 
ermöglichen. Die Grundlagenforschung im Bereich der 
synthetischen Biologie ist jedoch nicht unbedingt an 
Interessen des Marktes und der Industrie gekoppelt und 
ist daher auf öffentliche Gelder angewiesen. Die Gruppe 
ist besorgt, dass dies in naher Zukunft zu einem Man-
gel an angemessener Finanzierung der Grundlagenfor-
schung in der EU führen und die Rolle der EU-Forschung 
im Zusammenhang mit der weltweiten Regulierung der 
synthetischen Biologie gefährden könnte.

Parallel dazu befasst sich die ethische Debatte über 
die synthetische Biologie mit Themen in Verbindung 
mit der ethischen Legitimität der Herstellung lebender 
Organismen, ähnlich wie die Debatte über die Mani-
pulation des Lebens. Das Eingreifen des Menschen in 
die Natur einschließlich der Umwelt und anderer leben-
der Organismen wirft Fragen zur „Natürlichkeit“ des  

 
 
 
Eingreifens und zur „Herstellung von Leben“ auf (24)  
Daher unterstreicht die Gruppe die Notwendigkeit, in-
terdisziplinäre EU-Forschungsprojekte über die Bezie-
hung zwischen Mensch und Natur zu finanzieren, ins-
besondere in Bezug auf Fragen nach den Vorstellungen 
vom Leben.  

Empfehlung Nr. 24: Die Gruppe bittet die Kommission, 
die Grundlagenforschung in den Bereichen Biologie, 
Chemie, Energie, Materialwissenschaften und Werk-
stofftechnik sowie die angewandte Forschung im Sin-
ne dieser Stellungnahme zu fördern. Dies sollte sich 
im Budget für die EU-Forschungsrahmenprogramme 
niederschlagen. Ein ähnlicher Antrag wird an die  
EU-Mitgliedstaaten in Bezug auf ihre nationalen FuE-
Programme gerichtet.

Empfehlung Nr. 25: Die Gruppe ersucht die EU, die in-
terdisziplinäre Forschung zu folgenden Aspekten der 
synthetischen Biologie in angemessenem Rahmen zu 
finanzieren: 

-  Risikobewertung und Sicherheit; 
-  Anwendungen  der  synthetischen  Biologie  im  

Bereich Sicherheit; 
ethische, rechtliche und soziale Auswirkungen  

- 
-  Governance; 
-  Wissenschaft und Gesellschaft (einschließlich  

Medien und Öffentlichkeit). 

Dies sollte sich im Budget der EU-Forschungsrahmen-
programme niederschlagen. Ein ähnlicher Antrag wird 
an die EU-Mitgliedstaaten in Bezug auf ihre nationa-
len FuE-Programme gerichtet.

Empfehlung Nr. 26: Die Gruppe nimmt zur Kenntnis, 
dass die synthetische Biologie in Zukunft zu einem Pa-
radigmenwechsel im Zusammenhang mit den Vorstel-
lungen vom Leben führen könnte. Sie ersucht daher 
die Kommission, ein offenes interkulturelles Forum 
zu initiieren, das sich mit diesen Fragen befasst, ein-
schließlich philosophischer und religiöser Beiträge. 

(24)  John Harris, „Who’s Afraid of a Synthetic Human?“ The Times, 
17. Mai 2008. Colin Nickerson, „A Quest to Create Life Out of 
Synthetics,“ Boston Globe, 2. April 2008. Erik Parens, „Making 
Cells Like Computers,“ Boston Globe, 18. Februar 2008. 
Natalie Angier, „Pursuing Synthetic Life, Dazzled by Reality,“ 
New York Times, 5. Februar 2008.

EMPFEHLUNGEN | 4

85

ANNEXES

Annex I: The Patent System, Biotechnology and Synthetic Biology

Julian Kinderlerer and Djims Milius
Intellectual Property Law Research Unit,
Faculty of Law, University of Cape Town

1. 

INTRODUCTION

A very detailed examination of the patent system, including an introduction to patent law in Europe 
and in the United States and an examination of many cases that involve the patenting of life forms, 
was produced for the EGE by Geertrui van Overwalle in 2002 (1). There is therefore no attempt to 
provide the detailed examination of the patent system in this current paper.

2. 

INNOVATION

‘The last half of the 19th century and the first years of the 20th century saw the development of 
technologies that would create the basis of wealth generation by means of major new industries – 
principally petrochemical, automotive, aviation and electronics. These developments helped create 
the modern world.’ (2). During the latter part of the 20th Century and the beginning of this century 
electronics and biotechnology have been leading the revolution in providing ever-increasing so-
phistication to our lives. Amongst the new technologies are those involving the manipulation 
(and commercialization) of biology. The range of applications to which new uses of biology are 
becoming available is extensive, reaching far beyond the provision of medicines, food and fibre. 
Synthetic biology provides a new set of tools for using biology, and may either be for the purpose 
of pure research with an intention to understand the manner in which living systems have devel-
oped including their interactions, or for producing new processes or products. An argument has 
developed as to whether all or some of the fruits of synthetic biology should be patentable, for 
the commercial benefit of those that ‘invent’ the processes or products.

The ‘bioeconomy’ is primarily growing in developed countries.  The United States originated 40.6% 
of biotechnology patents in 2005, with the European Union at 25.1% and Japan at 17%. Brazil, 
China, India, Indonesia, the Russian Federation and South Africa combined provided 2.7% of the 
total patents in biotechnology (3).  Developing countries may not have the infrastructure to support 
the use of modern technologies and hence lack the capacity to innovate in areas (like biotech-
nology) where infrastructure is essential. The same problem exists for nanotechnology (US 41.8,  
EU 25.4, Japan 16.7). 

It is believed that for the ‘bioeconomy’ to grow, Intellectual Property, primarily in the form of pat-
ents, will play an important role – this includes the manner in which they are recognised, traded 
and managed. IP will have an impact on where the bioeconomy will flourish, the form it takes and 
to whom the principal benefits will accrue. (4)

(1)  EGE (2002) Study on the patenting of inventions related to human stem cell research. Luxembourg Office 

for Official Publications of the European Communities. ISBN 92-894-1987-3

(2)  The Royal Academy of Engineering (May 2009) ‘Synthetic Biology: scope, applications and implications’ 

ISBN: 1-903496-44-6

(3)  OECD (2008) Compendium of Patent Statistics 

(4)  Herder M and Gold ER ‘Intellectual Property Issues in Biotechnology: Health and Industry’ Report prepared 
for the OECD International Futures project on the Bioeconomy to 2030: Designing a Policy Agenda (OECD, 
2008)

87

ANNEXES

88

Many argue that patenting is an essential part of the protection of scientific endeavour. A recent 
paper on ‘Inventing Biological Organisms: A Reader of Selected Articles’ states the case succinctly: 
‘The ability to patent biological inventions is central to protecting scientists’ work… What can be 
patented, for how long, and the extent of global protection are critical issues. However, patenting 
biological organisms, particularly human genes and other human parts, is controversial. Economists 
question whether patenting is the quickest and best way to diffuse new knowledge throughout 
the marketplace. Some bioethicists question whether genetic information is the common herit-
age of mankind, making gene patenting inappropriate’ (5). The debate about gene patenting has 
been dealt with in detail in the previous EGE paper (footnote 1). The concern has shifted to the 
role of the patent system as technology moves towards a ‘knowledge economy’. It has always been 
assumed that there is an important balance between private and public interests in the manner 
in which the patent system has been designed – limited rights for a limited time. This balance 
has shifted towards the private interest, particularly when examined from the perspective of the 
developing world.  (6)

There is an assumption within governments and judicial reasoning that IP rights (Patent rights in 
particular) ‘are crucial if not absolutely necessary to foster innovation’ (7) ‘Should some biological 
inventions be kept in the public domain and not be patentable? Would this slow or speed the devel-
opment of socially important products? Conversely, does patenting new biotechnology products 
(agricultural seeds that are resistant to pesticides, for example) accelerate the development of 
products that have high social utility?’ Gold has argued that the evidence for assumptions about 
patents having a positive effect on innovation is relatively weak. (8)

Gold explains:

‘More recent work has… cast doubt on this conclusion. The international economics literature 
considers cross-country differences in patent systems and the implications of these differences for 
economic behavior. The link between patents and innovation in the multi-country (open economy) 
is less clear.

Even within a closed economy, patents on initial innovations may deter later discoveries that build 
on patented innovations. There are also structural reasons to believe that one can never know, in 
fact, whether patents actually encourage or discourage innovation. First, […] while patent law 
takes a ‘one-size-fits-all’ approach to innovation, the markets for different products and knowledge 
assets differ significantly from one another. Second, the empirical study of the effects of patents 
on innovation suffers from the lack of control. Given that innovation is driven by many factors 
(including access to capital, access to skilled managers, first mover advantage, curiosity, etc.), cross-
jurisdictional comparisons are difficult. Since countries rarely radically change their patent systems 
without changing fundamental aspects of their economies, single jurisdiction controls are usually 
lacking. Several studies that examine changes within a single jurisdiction – the semi-conductor 
industry in the US between the 1970s and 1980s and the strengthening of the Japanese patent 
system in the 1980s – indicate that patents either reduced innovation or had no effect. Third, 
[…] industry rarely relies solely on a single patent to secure its inventions. Normally, firms use a  

(5)  California Research Bureau (1998) http://www.library.ca.gov/crb/98/reader/reader01.pdf

(6)  Walker, Simon. 2001. The TRIPS Agreement, Sustainable Development and the Public Interest: Discussion 
Paper. IUCN, Gland, Switzerland and Cambridge, UK and CIEL, Geneva, Switzerland ISBN 2-8317-0604-1

(7)  Herder M and Gold ER ‘Intellectual Property Issues in Biotechnology: Health and Industry’ Report prepared 
for the OECD International Futures project on the Bioeconomy to 2030: Designing a Policy Agenda (OECD, 
2008) page 5

(8)  E. Richard Gold et al., ‘The Unexamined Assumptions of Intellectual Property: Adopting an evaluative Ap-

proach to Patenting Biotechnological Innovation’ (2004) 18 Public Affairs Quarterly 299

ANNEXES

combination of patents, trade secrets, and even trademarks to protect their innovations. In addi-
tion, firms also use other mechanisms such as complementary asset management (by forming 
alliances) and innovation lead-time to gain advantage over competitors.

All of these intellectual property management mechanisms make it difficult, if not impossible, to 
isolate the effect of patents on innovation.’ (9) The vast majority of drugs produced (and patented) 
by the pharmaceutical companies never reach commercialization, as they fail during the various 
processes, including trials on patients, to meet the criteria for an effective drug. These patents 
would then count as not ‘used’ although they may be kept to ensure that when other companies 
produce similar products they can be relied on to block anything that might be competitively 
efficacious.

A distinction between pure science, not for commercial gain and technology has become blurred 
during the last 20 years. The goal of biological research during the first part of the 20th century was 
primarily to understand the mechanisms of biology; products were spin-off results of the research. 
Pressure from government and industry during the latter part of the 20th century moved the goal 
of research towards a conscious search for commercial products from the information available 
from biological research. Very often commercialization now occurs before a full understanding 
of the biology has been achieved. On 27 April 2009 President Obama spoke at a meeting of the 
National Academy of Science in New York. He addressed the relationship between primary basic 
research and technology:

‘The fact is an investigation into a particular physical, chemical, or biological process might 
not pay off for a year, or a decade, or at all. And when it does, the rewards are often broadly 
shared, enjoyed by those who bore its costs but also by those who did not.

And that’s why the private sector generally under-invests in basic science, and why the 
public sector must invest in this kind of research – because while the risks may be large, so 
are the rewards for our economy and our society.’

This paper does not attempt to address the rationale for using the patent system to allow the bio-
economy to grow, rather it asks the question what discoveries and inventions should be capable 
of being patented, and hence available directly for commercial exploitation, and which of these 
should not be (if any). It has been argued that some discoveries or inventions should be consid-
ered as the common heritage of mankind, and this argument is developed and considered later 
in this paper. Perhaps common heritage is not a necessary concept, rather that these would be in 
the common ownership – to the benefit of all. There is a general appreciation in Europe that there 
are some discoveries or inventions that should never result in commercialisation for profit. For 
example, processes the use of which offend human dignity such as the production of chimeras 
from germ-cells, or totipotent cells from plants and animals; process for cloning a human being, 
modified germ-line cells etc. Article 6, paragraph 2 of Directive 98/44/EC on the legal protection of 
biotechnological inventions provides a non-exclusive list of those products and processes consid-
ered to be not patentable due to their commercial exploitation being contrary to morality or ordre 
public. This may provide a conceptual framework for other inventions that may be unpatentable, 
but there are no criteria provided.

Article 7 of the Directive provides ‘[t]he Commission’s European Group on Ethics in Science and 
New Technologies evaluates all ethical aspects of biotechnology.’ It gives no advice on how to 
implement the Article, which is the only one not implemented by any of the European Patent 
Offices in their rules.

(9) 

ibid

89

ANNEXES

It may be that ‘inventions’ in biology in general and in synthetic biology in particular should be 
placed in one of three categories:

a.  That which is common to all humankind, and should not be patentable or directly exploited 

for commercial gain.

b.  That which, for a variety of reasons, should be placed in the public domain for all to use and 
exploit (the ‘commons’). It may be that the process or product is so expensive to produce or 
require a vast range of expertise not available to any one organisation, or that the placing of 
the information in the public domain enables open standards that allow for the effective com-
mercialisation and use of a number of products that use the technology or product.

c.  That which may, at the inventor’s discretion, be protected through an intellectual property 

rights system to encourage innovation.

3. 

THE PATENT SYSTEM

Most nations of the world are party to the World Trade Organisation. As part of their agreement to 
join the organisation, they agreed and in general ratified all the component treaties of the General 
Agreements on Tariffs and Trade (GATT). The last successful round of trade negotiations culminated 
in all ratifying Member States endorsing all agreements in the WTO package under the so-called 
‘single undertaking’. No opting out of individual treaties (over 17 in total) was allowed as they 
were to be ratified all at once. One of these is the TRIPS Agreement (Agreement on Trade-Related 
Aspects of Intellectual Property Rights). TRIPS provides for each country to institute a minimum 
set of laws protecting intellectual property, so that where inventors so wish they may protect that 
which they have created or invented in any jurisdiction. Countries may not discriminate between 
domestic and international ‘creations’. (10)

It is patently obvious that a business has a competitive advantage if it develops, maintains and 
exploits its assets appropriately. These have to include its intellectual property where it has an 
advantage over its competitors if it has information which it has not shared (secrecy) or where it 
has asserted rights that permit it to assure that others cannot use or copy without permission.  A 
relatively new concept is that the portfolio of intellectual property constitutes a currency that is 
negotiable for use in (commercial or research?) interactions with others. Patents may then be used 
as such, without the intention to use them in advancing technology.  

A patent is a limited ‘negative’ national right given to an inventor for a short period of time (usu-
ally 20 years from date of filing) in exchange for a publication of a full specification that allows 
anyone reading the patent to replicate the invention. In practice descriptions are often published 
a (relatively) long time after application, and due to careful patent drafting can be difficult to 
replicate.  The patent specifies a set of claims by the inventor that permits the exclusion of others 
from making, using, offering for sale, selling, or importing that which is claimed, but only in the 
jurisdiction to which it applies. This relatively old system has worked extremely well for inventions 
in many fields in engineering, including modern electric and electronic engineering.  The patent 
system is thought to be extremely important in the pharmaceutical industry, where the companies 
argue that it has enabled the expensive innovation of modern drugs and devices. Gold quotes 
studies conducted by Levin et al. and Cohen et al. over the last twenty years to have shown that 

(10)  TRIPS Article 27.1 provides that ‘…patents shall be available and patent rights enjoyable without discrimi-
nation as to the place of invention, the field of technology and whether products are imported or locally 
produced.’

90

ANNEXES

R&D managers in pharmaceutical companies attributed significantly more importance to patent 
rights relative to their counterparts in other sectors. (11), (12) 

In the last few years there appears to have been a ‘‘patent gold gush,’ in which ‘inventions long 
thought unpatentable —everything from gene sequences of unknown function to one-step pur-
chasing over the Internet— are now being claimed as property.’ These developments are of particu-
lar concern because they tend to allow patents on subject matter that is both further ‘upstream’ in 
the innovation process and further afield from traditional industrial products and processes than 
has ever before been the case. (13) Does this expansion of the patent system encourage or discour-
age innovation and is the incentive really necessary to achieve innovation? The Canadian Supreme 
Court, in deciding against permitting the patenting of an altered mouse, stated succinctly that 
‘The massive private sector investment in biotechnological research is exactly the sort of research 
and innovation that the Patent Act was intended to promote. Healthcare is the major beneficiary 
of biotechnology. At the same time, vast amounts of money must be found to finance biomedical 
research. The Patent Act embodies the public policy that those who directly benefit from an inven-
tion should be asked, through the patent system, to pay for it, at least in part.’  (14)

The diagram below indicates the range of patent applications in all fields in 2008 at WIPO (Patent 
Cooperation Treaty applications) (15). It indicates that traditional applications still predominate, 
although applications for pharmaceuticals and biotechnology are increasing. The largest propor-
tions of PCT applications related to the medical technology (12%), computer technology (8.5%) and 
pharmaceuticals (7.9%) sectors. Between 2003 and 2005 medicine and biotechnology accounted 
for 14.8% of nanotechnology filings. (16)

(11)  Richard D. Levin et al., ’Appropriating the Returns from Industrial Research and Development’ (1987) Brook-

ings Papers on Economic Activity 783

(12)  W. Cohen et al., ‘Appropriability Conditions and Why Firms Patent and Why They Do Not in the American 

Manufacturing Sector’ Working Paper (Pittsburgh: Carnegie-Mellon University 1997).

(13)  McManis C ‘Re-Engineering Patent Law: The Challenge of New Technologies’ Washington University Journal 

of Law and Policy http://law.wustl.edu/journal/2/p1mcmanis.pdf

(14)  Harvard College v. Canada (Commissioner of Patents), [2002] 4 S.C.R. 45, 2002 SCC 76

(15)  WIPO - The International Patent System in 2008 http://www.wipo.int/pct/en/activity/pct_2008.html

(16)  OECD Compendium of Patent Statistics 2008

91

ANNEXES

The numbers in the diagram are the percentage of the total for each sector. The numbers in the 
chemistry segment can be broken down further:

There is, however, a question as to whether the system is effi  cient in 2 areas:

a.  Modern technologies, specifi cally biotechnologies, personalised medicine and biologics 

where a specifi cation that allows specifi c claims to be made may be diffi  cult.

b.  The ability to replicate an invention from its specifi cation requires a basic infrastructure to 
be in place in the country in which a copy is to be used for further innovation. The system 
therefore favours economies that are advanced enough to replicate an invention and hence 
allow for innovation. The US patent offi  ce alludes to this as follows: 

‘The patentee is not required to disclose all possible uses, but promoting the 
subsequent discovery of other uses is one of the benefi ts of the patent system. 
When patents for genes are treated the same as for other chemicals, progress is 
promoted because the original inventor has the possibility to recoup research 
costs, because others are motivated to invent around the original patent, and 
because a new chemical is made available as a basis for future research. Other 
inventors who develop new and non-obvious methods of using the patented 
compound have the opportunity to patent those methods.’

In most jurisdictions, as defi ned in the TRIPS Agreement patents may only be granted if they 
meet specifi c criteria. They must be new, involve an inventive step and be of industrial applica-
tion.

i. 

‘An invention shall be considered to be new if it does not form part of the state of the 
art’ (17), which includes that which has been communicated to the ‘public’ by oral or written 
means.

(17)  European Patent Convention, Article 54

92

ANNEXES

ii. 

‘An invention shall be considered as involving an inventive step if, having regard to the state 
of the art, it is not obvious to a person skilled in the art.’ (18) There has been controversy 
over whether uses for genes are not obvious to scientists ‘skilled in the art’. The meaning of 
invention may be different in different jurisdictions. For example, the distinction between 
inventions and discoveries is not entirely clear. In the United States an inventor may patent 
a discovery if the invention satisfies the statutory requirements. The US Constitution (Arti-
cle 1 (8)) provides for Congress to have the obligation ‘To promote the Progress of Science 
and useful Arts by securing for limited Times to Authors and Inventors the exclusive Right 
to their respective Writings and Discoveries’ 35USC 101 provides for patents for those who 
‘invent or discover’.

iii.  ‘An invention shall be considered as susceptible of industrial application if it can be made 
or used in any kind of industry, including agriculture.’ (19) If a patent application specifies 
only the DNA or RNA structure without specifying a utility for a particular sequence, the 
claimed invention is not patentable in the US or under the European Patent Convention. 
Under US law, if an invention discloses a ‘specific substantial and credible utility for the 
claimed isolated and purified gene, the isolated and purified gene composition may be 
patentable.’ (20) US Patent law stipulates that ‘a patent must be granted when at least one 
specific, substantial and credible utility has been disclosed, and the application satisfies the 
other statutory requirements.’ Similar rulings have been made in Europe. 

iv.  ‘Biotechnological inventions’ in Europe are inventions which concern a product consisting 
of or containing biological material or a process by means of which biological material is 
produced, processed or used. (21) They are patentable if they are

(a)  biological material which is isolated from its natural environment or produced by means 

of a technical process even if it previously occurred in nature;

(b)  plants or animals if the technical feasibility of the invention is not confined to a particular 

plant or animal variety;

(c)  a microbiological or other technical process, or a product obtained by means of such a 

process other than a plant or animal variety. (22)

v. 

‘Synthetic DNA preparations are eligible for patents in the US because their purified state 
is different from the naturally occurring compound.’20 In an early patent for adrenaline, the 
court explained that compounds isolated from nature are patentable: ‘even if it were merely 
an extracted product without change, there is no rule that such products are not patentable’. 
(is there therefore (in the US) no conceptual difference between a synthesized purified DNA 
preparation and one found in the state of nature and which is subsequently purified? Are 
they hence interchangeable as end products for the purpose of patenting etc, and should 
we therefore not go any further in distinguishing between them in terms of origin of initial 
creation?) The same condition applies in Europe.

(18)  European Patent Convention, Article 56

(19)  European Patent Convention, Article 57

(20)  USPTO (2001) Utility Examination Guidelines Federal Register (2001) Vol 66 Page 1093.

(21)  European Patent Convention, Rule 26(2)

(22)  European Patent Convention, Rule 27

93

ANNEXES

94

vi.  A patent on a gene covers the isolated and purified gene but does not cover the gene as it 

occurs in nature.

vii.  The US has no clauses that require a decision on whether a product or process is not patent-
able when its commercial exploitation may be contrary to morality or ordre public. European 
patent law does have these clauses, and the biotechnology directive (23) specifies a non-
exclusive list of inventions that are not patentable:

a.  processes for cloning human beings;

b.  processes for modifying the germ line genetic identity of human beings;

c.  uses of human embryos for industrial or commercial purposes

d.  processes for modifying the genetic identity of animals which are likely to cause them 
suffering without any substantial medical benefit to man or animal, and also animals 
resulting from such processes.

4. 

GENOMES & PATENTS

An enormous amount of data has been generated in determining the sequences of the ge-
nomes of living systems. At the time of collection of the data for the human genome project 
the US National Institutes of Health claimed ownership of the data, triggering many to attempt 
to patent DNA sequences (initially even where a use could not have been known).  Many sci-
entists were concerned with this approach – not only because of a lack of utility of the naked 
DNA sequences in question. (24) 

Many international organizations asserted that the human genome (and by extension other 
genomes) are ‘the common heritage of mankind’. These include the Human Genome Organiza-
tion (HUGO) Ethics Committee (2000) (25), the Council on Responsible Genetics (CRG 2000)(26), 
and the International Federation of Gynaecology and Obstetrics (1997)(27). The Parliamentary 
Assembly of the Council of Europe (Council of Europe 2001) asserted that it was ‘of the opinion 
that the results of this grandiose research effort – in which the United States has the lead over 
Europe – must be made available to all, genetic information being a common human heritage, 
as set out in Article 1 of the Universal Declaration on the Human Genome and Human Rights, 
adopted at UNESCO in Paris on 11 November 1997. The Assembly in particular refers in this 
context to the Council of Europe Convention for the Protection of Human Rights and Dignity 
of the Human Being with regard to the Application of Biology and Medicine – Convention on 
Human Rights and Biomedicine (ETS No. 164) as well as its own Recommendations 1425 (1999) 
on biotechnology and intellectual property and 1468 (2000) on biotechnologies’, (28) as well 

(23)  DIRECTIVE 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection 

of biotechnological inventions

(24)  HUGO Statement on the Patenting of DNA Sequences and Rebecca S. Eisenberg & Robert P. Merges, Opinion 
Letter as to the Patentability of Certain Inventions Associated with the Identification of Partial CDNA Sequences, 
23 AIPLA Q.J. 1 (1995)

(25)  Human Genome Organization Ethics Committee, 2000. Genetic benefit sharing. Science, 290 (5489), 49.

(26)  CRG, 2000. The genetic bill of rights. Council for Responsible Genetics CRG, Cambridge. [http://www.

gene-watch.org/programs/bill-of-rights/bill-of-rights-text.html]

(27)  International Federation of Gynecology and Obstetrics, 1997. Patenting human genes. http://www.figo.org/]

(28)  Council of Europe, 2001. Recommendation 1512: Protection of the human genome. [http://assembly.coe.int/

Documents/AdoptedText/ta01/EREC1512.htm]

ANNEXES

as that of UNESCO in its Universal Declaration on the Human Genome and Human Rights (29). 
UNESCO’s Declaration states that, ‘The human genome underlies that fundamental unity of all 
members of the human family...in a symbolic sense, it (the human genome) is the heritage of 
humanity...The human genome in its natural state shall not give rise to financial gain.’

What exactly is the ‘common heritage of mankind’? Bartha Knoppers has described it as that 
which ‘argues against private appropriation in favor of sharing, administration in the common 
interest, benefits and burdens equitably distributed, equitable access, peaceful use and pres-
ervation for future generations’ (30)

When the US Patent Office considered its guidelines for utility patents in 2001 it addressed the 
question of whether there should be patents on genes ‘as the nature of the human genome is at 
the core of what it means to be human, and no person should be able to own/control something 
so basic.’ They decided that ‘patents do not confer ownership of genes, genetic information 
or sequences. The patent system promotes progress by securing a complete disclosure of an 
invention to the public, in exchange for the inventor’s legal right to exclude other people from 
making, using, offering for sale, selling, or importing the composition for a limited time. That 
is, a patent owner can stop infringing activity by others for a limited time.’20

Jasper Bovenberg has argued that we should not simply focus on the criteria for patentability 
when examining whether the claim of ownership should be entertained. In focussing on util-
ity, novelty, non-obviousness and even the requirement to ensure disclosure of a patented 
object, we detract from the question of whether or not such sequences should be patentable 
at all. (31)

The United Nations has endorsed the UNESCO Universal Declaration ‘stating, in a symbolic 
sense, that the human genome is the heritage of humanity. The Declaration stipulates that 
the human genome, in its natural state, shall not give rise to financial gains and that an inter-
national framework be established to make the benefits of research on the genome available 
to all.’ (32)

Bovenberg argues that the prohibition on financial gain is that the common heritage principle 
bars private appropriation. In addition, there is a need to apply this concept in practice. He ad-
dresses the first through the medium of the arguments of Grotius in relation to the legal status 
of the sea.  Is the genome the property of an individual, res nullius, the property of nobody, 
res communis – common property, or res publicae – public property.  In his arguments Grotius 
traced the origin of these terms, and hence the use to which each of these could be put. Gro-
tius reached two conclusions from these definitions of property. ‘[F]irst, that which cannot be 
occupied, or which never has been occupied, cannot be the property of anyone, because all 
property has arisen from occupation.’ Second, ‘all that which has been so constituted by nature 
that although serving some one person it still suffices for the common use of all other persons, 
is today and ought in perpetuity to remain in the same condition as when it was first created by 
nature.’ Based on these conclusions, Grotius then listed many objects that by nature were open 

(29)  UNESCO, 1997. Universal declaration on the human genome and human rights., Geneva. [http://www.

unesco.org/shs/human_rights/hrbc.htm]

(30)  quoted in De Jonge, B and Korthals M (2006), ‘vicissitudes of benefit sharing of crop genetic resources: 

Downstream and upstream’ Developing World Bioethics 6 144-157

(31)  Bovenberg JA (2006) ‘Mining The Common Heritage of our Dna: Lessons learned from Grotius and Pardo’ 

Duke Law & Technology Review 8

(32)  Universal Declaration on the Human Genome and Human Rights, UNESCO Gen. Conf. Res. 29 C/Res.16, re-
printed in Records of the General Conference, UNESCO, 29th Sess., 29 C/Resolution 19, at 41 (1997) (adopted 
by the UN General Assembly, G.A. res. 152, U.N. GAOR, 53rd Sess., U.N. Doc. A/RES/53/152 (1999)

95

ANNEXES

to the use of all; the water, the sun, the air and the waves. All of these were not susceptible to 
occupation, and their common use was destined for all. (33) This argument is not sufficient, how-
ever, for although the ‘sea’ is res omnium communes, that which is in the sea, including minerals 
and fish, can be owned by an individual. This argument, when applied to the genome, provides 
that the genome itself is common property but derived inventions or discoveries could in theory 
be owned. In relation to synthetic biology, it is conceivable that the genome and much of that 
which is used to produce a synthetic product is common to all, but the product itself could be 
owned, and therefore patentable. The use of genes to produce pharmaceuticals or probes for 
disease remains a commercial activity, therefore patentable if the criteria are met.

Grotius’ argument about the sea and its contents could conceivably be extended to owner-
ship of all that falls within the high and low water marks. Many countries provide for common 
ownership of land within these borders, with rights similar to those on common land.

Resnik (34) has argued very differently. In his article, The human genome: common resource but not 
common heritage, he states that ‘[T]hose who oppose proprietary control of DNA have voiced 
a variety of objections to the patenting of DNA sequences, including the claim that patenting 
DNA violates human dignity, the assertion that patenting DNA violates the sacredness of nature, 
and the hypothesis that patenting DNA will have adverse effects on the progress of science, 
medicine and agriculture’. The article quoted does not address these issues directly, but rather 
the idea that the human genome is the common heritage of mankind – to which Resnik takes 
exception. The article reminds the reader that ‘The common-heritage idea has influenced ethical 
and policy debates concerning the commercialization of the human genome’ for some time, and 
that this needs to be considered carefully. He argues that the ‘main ethical and policy rationale 
for granting patents is utilitarian: patents promote scientific and technological progress by giv-
ing financial incentives to inventors, investors and entrepreneurs’ The argument is reiterated 
that ‘[u]nder a theory known as the patent ‘bargain’, the government grants an inventor a private 
right in exchange for public disclosure of information in the patent application.’ (35)  

Resnik’s primary argument is that

‘A moment’s reflection on the nature of DNA is sufficient to show that there are some signifi-
cant problems with regarding the human genome as mankind’s common heritage. The first 
problem is that there is not a single, identifiable thing (or set of things) that constitute(s) the 
human genome. There is a significant amount of genetic variation among members of the spe-
cies Homo sapiens. Although human beings share most of their DNA, there are thousands of 
single-nucleotide polymorphisms (SNPs), which vary from person to person (Venter et al. 2001). 
Human beings also exhibit a great deal of variation in haplotypes (or patterns of sequence vari-
ation). The second problem is that there is not a single, identifiable set of people who inherit 
the human genome. Human beings share 98.5% of the DNA with chimpanzees, 95% with other 
primates, a great percentage of their DNA with other species, including fruit flies and yeast 
(Venter et al. 2001). So, only 1.5% of the human genome is actually ‘our’ common heritage; the 

(33)  Bovenberg JA (2006) ‘Mining The Common Heritage of our DNA: Lessons learned from Grotius and Pardo’ 

Duke Law & Technology Review 8 paragraph 12

(34)  http://library.wur.nl/frontis/ethics/13_resnik.pdf

(35)  Miller, A.R. and Davis, M.H., 2000. Intellectual property: patents, trademarks, and copyright in a nutshell. 

West Group, St. Paul.

96

ANNEXES

other 98.5% of the genome is the heritage of other species. (36) Should we say that the human 
genome is also the common heritage of the chimpanzees, the primates, all mammals, or even 
yeast? Does it make sense to say that non-human species can have property interests? (37) The 
third problem is that we cannot identify the persons or set of persons who have bequeathed 
our DNA to us. Did our ancestors ever intend to bequeath their DNA to all of humanity? These 
three problems show that is does not make much sense to regard the human genome as liter-
ally our common heritage. The common heritage idea may have symbolic importance, but 
it is an empirical fiction.’ (38) In essence Resnik argues ‘the human genome is not literally our 
common heritage. (39) If the human genome were literally our common heritage, the patenting 
of human DNA would be morally unacceptable because it would require the consent of every 
human being, a practical impossibility. (40) Even though the human genome is not literally our 
common heritage, it is still a very important common resource, and we have moral duties of 
stewardship and justice vis-à-vis the human genome. Our duties of stewardship include duties 
to refrain from harming the human genome but not duties to benefit the genome actively, 
because the idea of ‘benefiting’ or ‘improving’ the genome has clear eugenics implication. Our 
duties of justice imply obligations to share benefits fairly in genetics research and development. 
…. Finally, global benefit sharing may occur as products and services developed by companies 
become less expensive and more widely available. Short-term problems with access to genetic 
technology can be justified on the grounds that the system that allows such inequities, i.e. 
the patent system, promotes the interests of all members of society, especially the worst-off 
members, in the long run.’ This argument runs counter to Lincoln’s Gettysburg address, where 
he declared that “government of the people, by the people, for the people’ is the essence of US 
democracy, yet there is no requirement for a referendum on every issue voted on by congress 
or decided by the President of the USA.  Another counter-argument could be that as steward-
ship of the human genome does not necessarily involve active intentional improvement (other 
than through deliberate or capricious selective gene breeding, i.e., in the pairing and matching 
of sexual partners), it shall be made clear that the human genome can only be subject to the 

(36)  Substantively, it would appear that Resnik is questioning that there is such a thing as the human genome 
at all. If in agreement, one would need to ask then what it is that teams of scientists all over the world have 
spent billions of dollars and years sequencing; was the project misguided from the start, or is knowing the 
basis of human chemical life composition not an important research question? As President Clinton said at 
the conclusion and publication of the public sequencing effort in June 2000: ‘Today we are learning the 
language in which God created life’, of course it is understood that he meant human life. 

(37)  The debate in fact might be broader than that. Again, given the huge sums and money and most often 
the collaborative research effort put toward sequencing the genome of living organisms, including that 
of humans, should there not be a social return regardless? Is the ownership/property discursive paradigm 
the most appropriate analytical and practical tool for the promotion of further innovation to increase 
knowledge on our species and ensure its survival onto an unseen future?

(38)  Juengst, E.T., 1998. Should we treat the human germ-line as a global human resource? In: Agius, E. and 
Busuttil, S. eds. Germ-line intervention and our responsibilities to future generations. Kluwer Academic 
Press, Dordrecht, 85-102.

(39)  A contrary view might suggest that there would seem to be some aspects in which the human genome 
can be understood as that which is common to humanity proper, or which forms part of its chemical (DNA) 
constitutive essence in parts, and including re-arrangement in a distinct chromosomal number—barring 
some viable anomalies.  This enforces the boundaries of species. If what we take to constitute humanity in 
essence therefore is commonly inherited from progenitors to offspring in an unalterable chain of procrea-
tion (i.e.,  that no human child born of nature can fall off the species if his/her parents are ‘human’ from the 
start with respect to their genome), than it would not be far-fetched to posit that whatever the outcome 
of genetic permutation of sexual reproduction in the phenotypic variety of humans, there is safety in the 
knowledge that the genome of constitutive humans is therefore the essential non-excludable common 
heritage of these. No one will lose membership in a lifetime.

(40)  There are socially negotiated, acceptable and perhaps political, shortcut mechanisms for getting consent 
on other types of research involving human subjects, and for the disposition of research results; why not 
for research on the human genome and the use of its outcomes?

97

ANNEXES

98

realm of mutational innovation which can be both fortuitous or debilitative to human health 
and condition, and ultimately to the human genome itself. What’s more, there is no  agreed 
global mechanism in place to ensure that the outcomes of research on the human genome 
are distributed equitably amongst all those who bear the essential minimum human genome 
sequence, i.e. Homo sapiens. 

These arguments permit a return to the original questions, but in a slightly different form. 

Is it only objects like the human genome that should be non-patentable as they are part of our 
common heritage? All the references to common ownership or heritage relate to human ma-
terial; can this be extended to non-human products or processes that use material other than 
human tissue? The International undertaking on plant genetic resources, agreed in 1983, was 
based on the ‘universally accepted principle that plant genetic resources are a heritage of mankind 
and consequently should be available without restriction’. This was modified in 1991 when the 
Food and Agriculture Organisation passed resolution 3/91 that asserted that the concept of 
‘heritage of mankind’ is subject to the sovereign rights of nations over their genetic resources (41) 
When the Convention on Biological Diversity was agreed in 1992, much of that which had been 
considered to be in common ownership was recognised (or reaffirmed) as within the sovereign 
rights of States. Article 15 addresses access to genetic resources and identifies these as sovereign 
rights. Decisions on their exploitation depend solely on the need to assure biological diversity, 
and do not presume their ‘integrity’ as a common resource. (would such an argument for the 
human genome be too premature or unrealistic given the Human Hap-Map project sequencing 
an ethnic diversity of genome sequences for differences etc?).

The United States Patent Office and the European Patent Office, after long deliberation have 
agreed that a mouse created for a particular purpose is patentable; the Canadian Supreme 
Court, in a divided judgement, found that under their patent law the mouse (the ‘Harvard 
Oncomouse’) could not be patented. The invention was titled transgenic animals, although it 
referred primarily to a mouse produced through the injection and incorporation of an oncogene 
into the embryo. The purpose was to provide for research into cancer.  The court held that under 
Canadian Patent Law, a ‘higher life form is not patentable because it is not a ‘manufacture’ or 
‘composition of matter’ within the meaning of ‘invention’’. The court stated firmly that it was 
irrelevant whether the court believed that higher life forms such as the oncomouse ought to 
be patentable, the only question being addressed related to the wording of the Patent Act and 
whether the words ‘manufacture’ and ‘composition of matter’, within the context of the Patent 
Act, are sufficiently broad to include higher life forms. An important question discussed by the 
court related to whether it is defensible to permit the patenting of lower life forms, including 
bacteria whilst denying patentability to higher forms, such as a mouse. Among the arguments 
for a distinction is that the specific exception for plants and animals in trade agreements dem-
onstrates that a distinction between higher and lower life forms is widely accepted as valid.

In Europe the Patent Office granted the Patent, stating: ‘In the case at hand three different 
interests are involved and require balancing: there is a basic interest of mankind to remedy 
widespread and dangerous diseases, on the other hand the environment has to be protected 
against the uncontrolled dissemination of unwanted genes and, moreover, cruelty to animals 
has to be avoided. The latter two aspects may well justify regarding an invention as immoral 
and therefore unacceptable unless the advantages, i.e. the benefit to mankind, outweigh the 
negative aspects.’ (42)

(41)  FAO (2000) Multilateral Trade Negotiations on agriculture a resource manual http://www.fao.org/ 

docrep/003/x7355e/X7355e06.htm

(42)  (Grant of European patent No. 0 169 762 (Onco-mouse/Harvard) (1992), OJ EPO 1992, 588, at pp. 591-92) 

ANNEXES

Case law in Europe, therefore, provides little evidence of any ability to decline granting of pat-
ents relating to higher life forms where other criteria are met; the only grounds would be where 
it is considered contrary to morality to exploit the ‘invention’ commercially. 

An argument could be made that the information in the genome of any life form is so vast that 
it is in the public interest that the sequence should be placed in the public domain in order 
to ensure that innovation occurs. A patent would disallow others from using the information 
contained in the patented material for up to 20 years, and it may be that the holder is incapable 
of deriving the maximum benefit from the material in that time.

Hence the categories identified earlier may be confirmed as follows:

a.  That which is common to all humankind, and should not be patentable or directly ex-

ploited for commercial gain.
This should include the human genome and large projects such as the hap-map project (43) 
that address discoveries in the human genome. This would include artificial chromosomes 
introduced into human cells and would be justified under article 53(a) of the European 
Patent Convention (inventions for which the commercial exploitation would be contrary 
to morality). The International treaty on Plant Genetic Resources attempts to return some 
of that which was removed from the common heritage of mankind in the CBD to some 
crops (64) to permit free access to their genetic resources, arguing that ‘[n]o country is self-
sufficient in plant genetic resources; all depend on genetic diversity in crops from other 
countries and regions. International cooperation and open exchange of genetic resources 
are therefore essential for food security’.

b.  That which, for a variety of reasons, should be placed in the public domain for all to use 
and exploit (the ‘commons’). It may be that the process or product is so expensive to 
produce or require a vast range of expertise not available to any one organisation, or 
that the placing of the information in the public domain enables open standards that 
allow for the effective commercialisation and use of a number of products that use the 
technology or product.
This exclusion should address pre-competitive inventions, where the cost would be too 
great for a single organisation to bear. In addition, consideration of the compact between 
the private and public interest should be brought to bear. Where the range of information 
is so great as to make it impossible for a single organisation to develop and use during the 
lifetime of a patent, the basic information should be placed in the public domain or made 
available at minimum cost to others to use. This would ensure that information is not held 
so as to restrict innovation.

As synthetic biology may involve the development of building blocks which could be as-
sembled into a living organism, the development of open-standards that permit interaction 
between systems developed by the engineers needs to be explored. 

c.  That which may, at the inventor’s discretion, be protected through an intellectual prop-

erty rights system to encourage innovation.
Inventors should be mindful of the choices that they may be able to make. They could 
choose to patent the invention, or could choose to place some or all of the information 
in the public domain or using some form of open licence. Importantly, where a choice is 

(43)  See the HapMap website at http://www.hapmap.org/hapmappopulations.html.en. The HapMap is a catalog 
of common genetic variants that occur in human beings. It describes what these variants are, where they 
occur in our DNA, and how they are distributed among people within populations and among populations 
in different parts of the world. 

99

ANNEXES

made to patent, it should be remembered that although the rules relating to patents are 
almost universal, the patents themselves are national, and an inventor could choose the 
jurisdictions in which protection is sought. It may be that in order to encourage innovation 
in developing countries, inventors should be encouraged to choose not to patent their in-
ventions in these countries. As the information regarding the invention (process or product) 
is disclosed in a patent application, an inventor could choose to use some sort of licence in 
countries where patent protection is not sought.

Patenting in biotechnology would have to serve some goal of utility (as a sub-category of 
equity served in purpose) in the distribution of the benefits, and perhaps also necessarily 
of the costs, of advanced research in biotechnology.  Excluding one area of research from 
commercial ownership through the patent system does not mean that the benefits need 
necessarily have no return.  Returns can bear social value for forming infrastructure for fur-
ther development in research capacity or in real actual economic terms in the long run.

A second problem arises when dealing with Synthetic Biology – concern that unscrupulous 
individuals may attempt to use published information to synthesise dangerous DNA sequences. 
Due to the cost and analytical sophistication needed for synthesis, there are relatively few 
companies that synthesise long sequences of DNA. There have been suggestions that these 
companies screen all sequences for toxicity or infectivity before processing an order. That im-
plies that databases of toxic or infective DNA sequences are available. These databases would 
of necessity fall within the ambit of the Database Directive (44). Regulation should ensure that all 
necessary information is readily available to these companies to permit the required searches. 
If the copyright protection provided for databases restricts access to the information necessary 
Article 6(2)(c) (45) or Article 9(c) (46) should be invoked to ensure that these companies are able 
to track possible dangerous sequences before synthesis.

(44)  Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection 

of databases

(45)  Article 6: Exceptions to restricted acts

2. Member States shall have the option of providing for limitations on the rights set out in Article 5 in the 
following cases:
(c) where there is use for the purposes of public security of for the purposes of an administrative or judicial 
procedure;

(46)  Article 9 : Exceptions to the sui generis right 
  Member States may stipulate that lawful users of a database which is made available to the public in 
whatever manner may, without the authorization of its maker, extract or re-utilize a substantial part of its 
contents:
(c) in the case of extraction and/or re-utilization for the purposes of public security or an administrative 
or judicial procedure.

100

 
 
 
ANNEXES

101

Address 

European Commission
Berl 8/285 - B-1049 Brussels
Fax: (32-2) 299 45 65 
Email: BEPA-ETHICS-GROUP@ec.europa.eu 

EGE Secretariat

Maurizio Salvi
European Commission 
Head of the EGE Secretariat

Berl 8/282 - B-1049-Bruxelles
Tel: (32-2) 299 11 79
E-mail: maurizio.salvi@ec.europa.eu

Maja Prelog
European Commission 
EGE Secretariat

Berl 08/285 - B-1049 Bruxelles
Tel: (32-2) 296 66 39
E-mail: maja.prelog@ec.europa.eu

Kim Hoang Le
European Commission 
EGE Secretariat

Berl 8/285 - B-1049 Brussels
Tel: (32-2) 299 92 28
E-mail: Kim-Hoang.LE@ec.europa.eu 

European Commission

Ethics of synthetic biology

Luxembourg: Publications Office of the European Union

2010 — 104 pp. — 21 x 29.7 cm

ISBN 978-92-79-13829-4 
doi: 10.2796/10789

How to obtain EU publications

Publications for sale:

•	 via	EU	Bookshop	(http://bookshop.europa.eu);
•	
from	your	bookseller	by	quoting	the	title,	the	publisher	and/or	ISBN	number;
•	 by	contacting	one	of	our	sales	agents	directly.	You	can	obtain	their	contact	 
details	on	the	Internet	(http://bookshop.europa.eu)	or	by	sending	a	fax	 
to	+352	2929-42758.

Free publications:

•	 via	EU	Bookshop	(http://bookshop.europa.eu);
•	 at	the	European	Commission’s	representations	or	delegations.	You	can	obtain	
their	contact	details	on	the	Internet	(http://ec.europa.eu/)	or	by	sending	a	fax	 
to	+352	2929-42758.

K
A
A
J
0
9
0
2
5
3
A
C

E
t
h
i
c
s
o
f

s
y
n
t
h
e
t
i
c
b
o
o
g
y

l

i

Ethics of 
synthetic biology

Opinion No

BRUSSELS, 17 NOVEMBER 2009

 
 
 
